0001193125-22-282645.txt : 20221110 0001193125-22-282645.hdr.sgml : 20221110 20221110162027 ACCESSION NUMBER: 0001193125-22-282645 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 56 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221110 DATE AS OF CHANGE: 20221110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ESGEN Acquisition Corp CENTRAL INDEX KEY: 0001865506 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 981601409 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40927 FILM NUMBER: 221377556 BUSINESS ADDRESS: STREET 1: 5956 SHERRY LANE, SUITE 1400 CITY: DALLAS STATE: TX ZIP: 75225 BUSINESS PHONE: 214-987-6100 MAIL ADDRESS: STREET 1: 5956 SHERRY LANE, SUITE 1400 CITY: DALLAS STATE: TX ZIP: 75225 10-Q 1 d374880d10q.htm 10-Q 10-Q
Table of Contents
false0001865506--12-31Q3falseOn April 27, 2021, the Sponsor paid $25,000, or approximately $0.004 per share, to cover certain offering costs in consideration for 5,750,000 Class B ordinary shares, par value $0.0001. In September 2021, certain shareholders surrendered, for no consideration, an aggregate of 1,437,500 Class B ordinary shares, leaving 5,750,000 Founder Shares outstanding. In October 2021, a share dividend was issued which resulted in 6,900,000 Founder Shares outstanding; of which 900,000 were subject to surrender if the underwriter had not exercised their full over-allotment option. The underwriters exercised their over-allotment option in full on October 21, 2021. All share values and related amounts have been retroactively restated to reflect the dividend.Assumes the Private Placement Warrants were transferred on September 30, 2022. 0001865506 2022-09-30 0001865506 2021-12-31 0001865506 2022-07-01 2022-09-30 0001865506 2021-07-01 2021-09-30 0001865506 2022-01-01 2022-09-30 0001865506 2021-04-19 2021-09-30 0001865506 2021-10-22 0001865506 2021-04-19 2021-12-31 0001865506 2022-01-01 2022-03-31 0001865506 2022-04-01 2022-06-30 0001865506 2021-04-27 0001865506 2021-04-27 2021-04-27 0001865506 2022-01-01 2022-06-30 0001865506 2022-06-30 0001865506 2021-06-30 0001865506 2021-04-18 0001865506 2021-09-30 0001865506 2022-03-31 0001865506 esac:SponsorMember esac:PrivatePlacementWarrantsMember us-gaap:PrivatePlacementMember 2022-09-30 0001865506 us-gaap:PrivatePlacementMember esac:PrivatePlacementWarrantsMember 2022-09-30 0001865506 us-gaap:CommonClassBMember 2022-09-30 0001865506 us-gaap:CommonClassAMember 2022-09-30 0001865506 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2022-09-30 0001865506 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:CommonClassAMember us-gaap:OverAllotmentOptionMember 2022-09-30 0001865506 us-gaap:IPOMember esac:PublicWarrantsMember 2022-09-30 0001865506 us-gaap:IPOMember 2022-09-30 0001865506 esac:RedemptionOfWarrantPricePerShareEqualsOrExceeds18.00Member 2022-09-30 0001865506 esac:RedemptionOfWarrantPricePerShareEqualsOrExceeds10.00Member 2022-09-30 0001865506 esac:WorkingCapitalLoansWarrantMember 2022-09-30 0001865506 us-gaap:PrivatePlacementMember 2022-09-30 0001865506 us-gaap:CommonClassAMember esac:PrivatePlacementWarrantsMember us-gaap:PrivatePlacementMember 2022-09-30 0001865506 esac:PromissoryNoteWithRelatedPartyMember 2022-09-30 0001865506 us-gaap:CommonClassAMember us-gaap:IPOMember 2022-09-30 0001865506 esac:FounderSharesMember esac:SponsorMember us-gaap:CommonClassBMember 2022-09-30 0001865506 esac:PublicWarrantsMember us-gaap:CommonClassAMember 2022-09-30 0001865506 esac:AdditionalAmountOwedToRelatedPartyMember 2022-09-30 0001865506 esac:PublicWarrantsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001865506 esac:PublicWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001865506 us-gaap:FairValueMeasurementsRecurringMember esac:PrivatePlacementWarrantsMember 2022-09-30 0001865506 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2022-09-30 0001865506 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001865506 us-gaap:MeasurementInputExercisePriceMember 2021-12-31 0001865506 us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001865506 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001865506 us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001865506 us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001865506 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001865506 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001865506 us-gaap:CommonClassAMember 2021-12-31 0001865506 us-gaap:CommonClassBMember 2021-12-31 0001865506 esac:PromissoryNoteWithRelatedPartyMember 2021-12-31 0001865506 us-gaap:IPOMember us-gaap:CommonClassAMember 2021-12-31 0001865506 us-gaap:FairValueMeasurementsRecurringMember esac:PublicWarrantsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001865506 us-gaap:FairValueMeasurementsRecurringMember esac:PublicWarrantsMember 2021-12-31 0001865506 us-gaap:FairValueMeasurementsRecurringMember esac:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001865506 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001865506 esac:PrivatePlacementWarrantsMember 2022-07-01 2022-09-30 0001865506 esac:PublicWarrantsMember 2022-07-01 2022-09-30 0001865506 us-gaap:CommonClassAMember 2022-07-01 2022-09-30 0001865506 us-gaap:CommonClassBMember 2022-07-01 2022-09-30 0001865506 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-07-01 2022-09-30 0001865506 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001865506 us-gaap:CommonClassAMember 2021-07-01 2021-09-30 0001865506 us-gaap:CommonClassBMember 2021-07-01 2021-09-30 0001865506 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001865506 us-gaap:OverAllotmentOptionMember 2022-01-01 2022-09-30 0001865506 us-gaap:CommonClassAMember 2022-01-01 2022-09-30 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2022-01-01 2022-09-30 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:PrivatePlacementMember 2022-01-01 2022-09-30 0001865506 esac:SponsorMember us-gaap:CommonClassAMember 2022-01-01 2022-09-30 0001865506 us-gaap:CommonClassBMember 2022-01-01 2022-09-30 0001865506 us-gaap:IPOMember esac:PublicWarrantsMember us-gaap:CommonClassAMember 2022-01-01 2022-09-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001865506 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001865506 esac:FounderSharesMember 2022-01-01 2022-09-30 0001865506 esac:SponsorMember 2022-01-01 2022-09-30 0001865506 esac:RedemptionOfWarrantPricePerShareEqualsOrExceeds18.00Member 2022-01-01 2022-09-30 0001865506 esac:RedemptionOfWarrantPricePerShareEqualsOrExceeds10.00Member 2022-01-01 2022-09-30 0001865506 esac:UnitsEachConsistingOfOneShareOfClassCommonStockAndOneHalfOfOneWarrantMember 2022-01-01 2022-09-30 0001865506 esac:WarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceMember 2022-01-01 2022-09-30 0001865506 us-gaap:CommonClassAMember 2021-04-19 2021-09-30 0001865506 us-gaap:CommonClassBMember 2021-04-19 2021-09-30 0001865506 us-gaap:RetainedEarningsMember 2021-04-19 2021-09-30 0001865506 us-gaap:IPOMember 2021-10-22 2021-10-22 0001865506 us-gaap:IPOMember esac:PublicWarrantsMember us-gaap:CommonClassAMember 2021-10-22 2021-10-22 0001865506 esac:PrivateWarrantsMember 2021-10-22 0001865506 esac:PublicWarrantsMember 2021-10-22 0001865506 us-gaap:IPOMember 2021-10-22 0001865506 us-gaap:OverAllotmentOptionMember 2021-10-22 0001865506 us-gaap:IPOMember esac:PrivatePlacementWarrantsMember 2021-10-22 0001865506 us-gaap:CommonClassAMember esac:PublicWarrantsMember us-gaap:IPOMember 2021-10-22 0001865506 esac:PrivatePlacementWarrantsMember 2021-04-19 2021-12-31 0001865506 esac:PublicWarrantsMember 2021-04-19 2021-12-31 0001865506 us-gaap:RetainedEarningsMember 2021-04-19 2021-12-31 0001865506 us-gaap:CommonClassBMember esac:SponsorMember esac:FounderSharesMember 2021-04-27 2021-04-27 0001865506 esac:PromissoryNoteWithRelatedPartyMember 2021-04-27 0001865506 esac:FounderSharesMember esac:SponsorMember us-gaap:CommonClassBMember 2021-04-27 0001865506 us-gaap:CommonClassBMember esac:FounderSharesMember 2021-04-27 0001865506 esac:FounderSharesMember 2021-04-27 0001865506 esac:FounderSharesMember esac:SponsorMember us-gaap:CommonClassBMember 2021-09-10 2021-09-10 0001865506 us-gaap:CommonClassBMember esac:FounderSharesMember 2021-09-27 2021-09-27 0001865506 esac:FounderSharesMember us-gaap:CommonClassBMember 2021-09-27 0001865506 esac:PrivatePlacementWarrantsMember 2022-01-01 2022-03-31 0001865506 esac:PrivatePlacementWarrantsMember 2022-04-01 2022-06-30 0001865506 us-gaap:CommonClassAMember 2022-11-10 0001865506 us-gaap:CommonClassBMember 2022-11-10 0001865506 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-06-30 0001865506 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2022-06-30 0001865506 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001865506 us-gaap:RetainedEarningsMember 2022-06-30 0001865506 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-09-30 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-09-30 0001865506 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001865506 us-gaap:RetainedEarningsMember 2022-09-30 0001865506 esac:PrivatePlacementWarrantsMember 2022-09-30 0001865506 esac:PublicWarrantsMember 2022-09-30 0001865506 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2021-06-30 0001865506 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2021-06-30 0001865506 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001865506 us-gaap:RetainedEarningsMember 2021-06-30 0001865506 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2021-09-30 0001865506 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2021-09-30 0001865506 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001865506 us-gaap:RetainedEarningsMember 2021-09-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-12-31 0001865506 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001865506 us-gaap:RetainedEarningsMember 2021-12-31 0001865506 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2021-04-18 0001865506 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2021-04-18 0001865506 us-gaap:AdditionalPaidInCapitalMember 2021-04-18 0001865506 us-gaap:RetainedEarningsMember 2021-04-18 0001865506 esac:PrivatePlacementWarrantsMember 2021-04-18 0001865506 esac:PublicWarrantsMember 2021-04-18 0001865506 esac:PrivatePlacementWarrantsMember 2021-12-31 0001865506 esac:PrivatePlacementWarrantsMember 2022-03-31 0001865506 esac:PrivatePlacementWarrantsMember 2022-06-30 iso4217:USD xbrli:shares xbrli:pure utr:Day utr:Year utr:Month iso4217:USD xbrli:shares utr:D utr:Y
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 10-Q
 
 
Quarterly Report
Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended September 30, 2022
 
 
ESGEN Acquisition Corporation
(Exact name of registrant as specified in its charter)
 
 
 
Cayman Islands
 
001-40927
 
98-1601409
(State or other jurisdiction of
incorporation or organization)
 
(Commission File Number)
 
(I.R.S. Employer
Identification Number)
5956 Sherry Lane
Suite 1400
Dallas, Texas 75225
(Address of principal executive offices, including zip code)
(214)987-6100
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
 
 
 
Title of each class
 
Trading Symbol(s)
 
Name of each exchange
on which registered
Units, each consisting of one Class A ordinary share, $0.0001 par value, and
one-half
of one redeemable warrant
 
ESACU
 
The Nasdaq Stock Market LLC
Class A ordinary shares included as part of the units
 
ESAC
 
The Nasdaq Stock Market LLC
Warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
 
ESACW
 
The Nasdaq Stock Market LLC
 
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☐    No  ☒
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in
Rule 12b-2ofthe
Exchange Act.
 
Large accelerated filer      Accelerated filer  
       
Non-accelerated
filer
     Smaller reporting company  
       
         Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  
Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2ofthe
Exchange Act):    Yes      No  ☐
As of November 10, 2022
, 27,600,000 Class A ordinary shares, par value $0.0001, and 6,900,000 Class B ordinary shares, par value $0.0001, were issued and outstanding.
 
 
 


Table of Contents

Table of Contents

ESGEN ACQUISITION CORPORATION

FORM 10-QFOR THE QUARTER ENDED SEPTEMBER 30, 2022

TABLE OF CONTENTS

 

     Page  

PART 1 – FINANCIAL INFORMATION

  

Item 1. Financial Statements (Unaudited)

     1  

Condensed Balance Sheets as of September 30, 2022 and December 31, 2021

     1  

Condensed Statements of Operations for the three and nine months ended September 30, 2022, for the three months ended September 30, 2021 and for the period from April 19, 2021 (inception) through September 30, 2021

     2  

Condensed Statements of Changes in Shareholder’s (Deficit) Equity for the three and nine months ended September 30, 2022, for the three months ended September 30, 2021 and for the period from April 19, 2021 (inception) through September 30, 2021

     3  

Condensed Statements of Cash Flows for the nine months ended September 30, 2022 and for the period from April 19, 2021 (inception) through September 30, 2021

     4  

Notes to Condensed Financial Statements

     5  

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

     20  

Item 3. Quantitative and Qualitative Disclosures about Market Risk

     25  

Item 4. Control and Procedures

     26  

PART II – OTHER INFORMATION

     26  

Item 1. Legal Proceedings

     26  

Item 1A. Risk Factors

     26  

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

     26  

Item 3. Defaults Upon Senior Securities

     28  

Item 4. Mine Safety Disclosures

     28  

Item 5. Other Information

     28  

Item 6. Exhibits

     29  

SIGNATURES

     30  

 

 

i


Table of Contents
0.50
PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.
ESGEN ACQUISITION CORPORATION
CONDENSED BALANCE SHEETS
(UNAUDITED)
 
 
  
September 30,
2022
 
 
December 31,
2021
 
ASSETS
                
Cash
   $ 890,273     $ 1,323,903  
Prepaid expenses—current
     174,257       550,434  
    
 
 
   
 
 
 
Total current assets
     1,064,530       1,874,337  
Prepaid expenses,
non-current
     —         26,081  
Marketable securities held in trust account
     283,154,827       281,522,137  
    
 
 
   
 
 
 
Total Assets
  
$
284,219,357
   
$
283,422,555
 
    
 
 
   
 
 
 
Liabilities, Redeemable Ordinary Shares and Shareholders’ Deficit
                
Current liabilities
                
Accounts payable and accrued expenses
   $ 1,089,536     $ 411,416  
Due to related party
     114,193       24,193  
Promissory note – related party
     171,346       171,346  
    
 
 
   
 
 
 
Total current liabilities
  
 
1,375,075
 
 
 
606,955
 
Warrant liabilities
     2,367,600       13,976,160  
Deferred underwriter’s discount
     9,660,000       9,660,000  
    
 
 
   
 
 
 
Total liabilities
     13,402,675       24,243,115  
    
 
 
   
 
 
 
Commitments and Contingencies (Note 7)
                
Class A ordinary shares subject to possible redemption, 27,600,000 shares at redemption value
     283,154,827       281,520,000  
    
 
 
   
 
 
 
Shareholders’ Deficit:
                
Preferred share, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding
                  
Class A ordinary share, $0.0001 par value; 250,000,000 shares authorized; none issued or outstanding (excluding 27,600,000 shares subject to possible redemption)
                  
Class B ordinary share, $0.0001 par value; 25,000,000 shares authorized; 6,900,000 shares issued and outstanding
     690       690  
Additional
paid-in
capital
                  
Accumulated deficit
     (12,338,835     (22,341,250
    
 
 
   
 
 
 
Total shareholders’ deficit
    
(12,338,145
)
 
    (22,340,560
    
 
 
   
 
 
 
Total Liabilities, Redeemable Ordinary Shares and Shareholders’ Deficit
  
$
284,219,357
 
 
$
283,422,555
 
    
 
 
   
 
 
 
The accompanying notes are an integral part of these unaudited condensed financial statements.
 
 
1

ESGEN ACQUISITION CORPORATION
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)
 
    
Three Months Ended
September 30,
   
Nine
Months Ended
September 30,
   
For the Period
from April 19,
2021 (Inception)
through
September 30,
 
    
2022
   
2021
   
2022
   
2021
 
Legal and professional fees
   $ 145,588     $ —       $ 937,110     $ —    
Insurance
     133,302               395,559          
Other operating costs
     20,385               181,339          
Formation and operating costs
              1,690                15,393  
Operating cost—related party
     30,000                90,000       —    
    
 
 
   
 
 
   
 
 
   
 
 
 
Loss from operations
  
 
(329,275
 
 
(1,690
 
 
(1,604,008
 
 
(15,393
Other income:
                                
Interest income on marketable securities held in Trust Account
     1,245,745                1,632,690       —    
Change in fair value of warrant liabilities
     3,345,600                11,608,560       —    
    
 
 
   
 
 
   
 
 
   
 
 
 
Total other income
     4,591,345                13,241,250           
    
 
 
   
 
 
   
 
 
   
 
 
 
Net income (loss)
  
$
4,262,070
 
 
$
(1,690
 
$
 11,637,242
 
 
$
(15,393
    
 
 
   
 
 
   
 
 
   
 
 
 
                                  
Basic and diluted weighted average shares outstanding of Class A ordinary shares
     27,600,000                27,600,000       —    
    
 
 
   
 
 
   
 
 
   
 
 
 
Basic and diluted net income per share, Class A
  
 
0.13
 
 
 
  
 
 
 
0.35
 
 
 
—  
 
    
 
 
   
 
 
   
 
 
   
 
 
 
Basic and diluted weighted average shares outstanding of Class B ordinary shares (1)
     6,900,000       6,900,000       6,900,000       6,900,000  
    
 
 
   
 
 
   
 
 
   
 
 
 
Basic and diluted net income (loss) per share, Class B
  
 
0.09
 
 
 
(0.00
 
 
0.29
 
 
 
(0.00
    
 
 
   
 
 
   
 
 
   
 
 
 
 
(1)
On April 27, 2021, the Sponsor paid $25,000, or approximately $0.004 per share, to cover certain offering costs in consideration for 5,750,000 Class B ordinary shares, par value $0.0001. In September 2021, certain shareholders surrendered, for no consideration, an aggregate of 1,437,500 Class B ordinary shares, leaving 5,750,000 Founder Shares outstanding. In October 2021, a share dividend was issued which resulted in 6,900,000 Founder Shares outstanding; of which 900,000
were subject to surrender if the underwriter had not exercised their full over-allotment option. The underwriters exercised their over-allotment option in full on October 21, 2021. All share values and related amounts have been retroactively restated to reflect the dividend. 
The accompanying notes are an integral part of these unaudited condensed financial statements.
 
 
2

ESGEN ACQUISITION CORPORATION
CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDER’S (DEFICIT) EQUITY
(UNAUDITED)
FOR THE THREE SEPTEMBER 30, 2022
 
    
Class A
Ordinary share subject to
possible redemption
         
Class B
Ordinary share
    
Additional
Paid-in
    
Accumulated
   
Total
Shareholders’
 
    
Shares
    
Amount
         
Shares
    
Amount
    
Capital
    
Deficit
   
Deficit
 
Balance as of June 30, 2022
  
 
27,600,000
 
  
$
281,909,082
 
       
 
6,900,000
 
  
$
690
 
  
$
  
 
  
$
(15,355,160
 
$
(15,354,470
Accretion of ordinary share subject to possible redemption
     —          1,245,745             —          —          —          (1,245,745     (1,245,745
Net income
     —          —               —          —          —          4,262,070       4,262,070  
    
 
 
    
 
 
         
 
 
    
 
 
    
 
 
    
 
 
   
 
 
 
                                                                    
Balance as of September 30, 2022
  
 
27,600,000
 
  
$
283,154,827
 
       
 
6,900,000
 
  
$
690
 
  
$
  
 
  
$
(12,338,835
 
$
(12,338,145
    
 
 
    
 
 
         
 
 
    
 
 
    
 
 
    
 
 
   
 
 
 
 
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022
 
             
    
Class A
Ordinary share subject to
possible redemption
         
Class B
Ordinary share
    
Additional
Paid-in
    
Accumulated
   
Total
Shareholders’
 
    
Shares
    
Amount
         
Shares
    
Amount
    
Capital
    
Deficit
   
Deficit
 
Balance as of December 31, 2021
  
 
27,600,000
 
  
$
281,520,000
 
       
 
6,900,000
 
  
$
690
 
  
$
  
 
  
$
(22,341,250
 
$
(22,340,560
Accretion of ordinary share subject to possible redemption
     —          1,634,827             —          —          —          (1,634,827     (1,634,827
Net income
     —          —               —          —          —          11,637,242       11,637,242  
    
 
 
    
 
 
         
 
 
    
 
 
    
 
 
    
 
 
   
 
 
 
                                                                    
Balance as of September 30, 2022
  
 
27,600,000
 
  
$
283,154,827
 
       
 
6,900,000
 
  
$
690
 
  
$
  
 
  
$
(12,338,835
 
$
(12,338,145
    
 
 
    
 
 
         
 
 
    
 
 
    
 
 
    
 
 
   
 
 
 
 
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2021
 
             
    
Class A
Ordinary share subject to
possible redemption
         
Class B
Ordinary share
    
Additional
Paid-in
    
Accumulated
   
Total
Shareholders’
 
    
Shares
    
Amount
         
Shares (1)
    
Amount
    
Capital
    
Deficit
   
Equity
 
Balance as of June 30, 2021
  
 
  
 
  
$
  
 
       
 
6,900,000
 
  
$
690
 
  
$
24,310
 
  
$
(13,703
 
$
11,297
 
Net loss
     —          —               —          —          —          (1,690     (1,690
    
 
 
    
 
 
         
 
 
    
 
 
    
 
 
    
 
 
   
 
 
 
Balance as of September 30, 2021
  
 
  
 
  
$
  
 
       
 
6,900,000
 
  
$
690
 
  
$
24,310
 
  
$
(15,393
 
$
9,607
 
    
 
 
    
 
 
         
 
 
    
 
 
    
 
 
    
 
 
   
 
 
 
 
FOR THE PERIOD FROM APRIL 19, 2021 (INCEPTION) THROUGH SEPTEMBER 30, 2021
 
    
Class A
Ordinary share subject to
possible redemption
         
Class B
Ordinary share
    
Additional
Paid-in
    
Accumulated
   
Total
Shareholders’
 
    
Shares
    
Amount
         
Shares (1)
    
Amount
    
Capital
    
Deficit
   
Equity
 
Balance as of April 19, 2021 (inception)
  
 
  
 
  
$
  
 
       
 
6,900,000
 
  
$
690
 
  
$
24,310
 
  
$
  
 
 
$
25,000
 
Net loss
     —          —               —          —          —          (15,393     (15,393
    
 
 
    
 
 
         
 
 
    
 
 
    
 
 
    
 
 
   
 
 
 
Balance as of September 30, 2021
  
 
  
 
  
$
  
 
       
 
6,900,000
 
  
$
690
 
  
$
24,310
 
  
$
(15,393
 
$
9,607
 
    
 
 
    
 
 
         
 
 
    
 
 
    
 
 
    
 
 
   
 
 
 
 
(1)
On April 27, 2021, the Sponsor paid $25,000, or approximately $0.004 per share, to cover certain offering costs in consideration for 5,750,000 Class B ordinary shares, par value $0.0001. In September 2021, certain shareholders surrendered, for no consideration, an aggregate of 1,437,500 Class B ordinary shares, leaving 5,750,000 Founder Shares outstanding. In October 2021, a share dividend was issued which resulted in 6,900,000 Founder Shares outstanding; of which 900,000 were subject to surrender if the underwriter had not exercised their full
over-allotment option. The underwriters exercised their over-allotment option in full on October 21, 2021. All share values and related amounts have been retroactively restated to reflect the dividend. 
The accompanying notes are an integral part of these unaudited condensed financial statements.
 
3

ESGEN ACQUISITION CORPORATION
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
 
    
Nine Months

Ended

September 30,
2022
   
For the

Period from

April 19, 2021

(Inception)

through

September 30,
2021
 
Cash flows from operating activities:
                
Net income (loss)
   $ 11,637,242     $ (15,393
Adjustments to reconcile net income (loss) to net cash used in operating activities:
                
Formation costs paid by Sponsor
             11,693  
Interest earned on cash held in Trust Account
     (1,632,690     —    
Change in fair value of warrant liabilities
     (11,608,560     —    
Changes in current assets and liabilities:
                
Prepaid expenses
     402,258       —    
Accrued expenses
     678,120       3,700  
Due to related party
     90,000       —    
    
 
 
   
 
 
 
Net cash used in operating activities
     (433,630     —    
    
 
 
   
 
 
 
Net change in cash
     (433,630     —    
Cash, beginning of the period
     1,323,903       —    
    
 
 
   
 
 
 
Cash, end of the period
   $ 890,273     $ —    
    
 
 
   
 
 
 
Supplemental disclosure of cash flow information:
                
Change in value of Class A ordinary shares subject to possible redemption
   $ 1,634,827     $ —    
    
 
 
   
 
 
 
Deferred offering costs paid by Sponsor in exchange for issuance of Class B ordinary shares
   $ —       $ 25,000  
    
 
 
   
 
 
 
Deferred offering costs paid by Sponsor under the promissory note
   $ —       $ 243,913  
    
 
 
   
 
 
 
Deferred offering costs included in accrued offerings costs
   $ —       $ 462,712  
    
 
 
   
 
 
 
The accompanying notes are an integral part of these unaudited condensed financial statements.
 
 
4

ESGEN ACQUISITION CORPORATION
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
Note 1 — Organization and Business Operation
ESGEN Acquisition Corporation (the “Company”) was incorporated as a Cayman Islands exempted company on April 19, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (the “Business Combination”). The Company has not selected any Business Combination target. The Company will not be limited to a particular industry or geographic region in its identification and acquisition of a target company.
As of September 30, 2022, the Company had not commenced any operations. All activity for the period from April 19, 2021 (inception) through September 30, 2022, relates to the Company’s formation and the initial public offering (“Public Offering” or “IPO”) described below and since the closing of the IPO, the search for a prospective initial business combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate
non-operating
income in the form of interest income on cash and cash equivalents from the proceeds derived from the Public Offering (as defined below). The Company has selected December 31 as its fiscal year end.
The Company’s sponsor is ESGEN LLC, a Delaware limited liability company (the “Sponsor”).
The registration statement for the Company’s IPO was declared effective on October 19, 2021 (the “Effective Date”). On October 22, 2021, the Company consummated its IPO of 27,600,000 units (the “Units” and, with respect to the ordinary shares included in the Units being offered, the “Public Shares”) at $10.00 per Unit (which included the full exercise of the underwriters’ over-allotment option), which is discussed in Note 3 and the sale of 14,040,000 warrants (the “Private Placement Warrants”) each exercisable to purchase one Class A ordinary share at $11.50 per share, at a price of $1.00 per Private Placement Warrant in a private placement to the Sponsor that closed simultaneously with the Public Offering.
Transaction costs amounted to $16,138,202 consisting of $5,520,000 of underwriting commissions, $9,660,000 of deferred underwriting commissions and $958,202 of other cash offering costs. Of this amount, $15,428,121 was charged to shareholder’s deficit and $710,081 was allocated to the warrants and expensed.
The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (as defined below) (excluding the deferred underwriting commissions and taxes payable on the interest earned on the Trust Account) at the time of signing a definitive agreement in connection with the initial Business Combination. However, the Company will complete the initial Business Combination only if the post-Business Combination company in which its public shareholders own shares will own or acquire 50% or more of the outstanding voting securities of the target or is otherwise not required to register as an investment company under the Investment Company Act (the “Investment Company Act”). There is no assurance that the Company will be able to complete a Business Combination successfully.
Following the closing of the IPO on October 22, 2021, $281,520,000 ($10.20 per Unit) from the net proceeds sold in the IPO, including proceeds of the sale of the Private Placement Warrants, was deposited in a trust account (“Trust Account”) and will only be invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule2a-7promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations.
Except with respect to interest or other income earned on the funds held in the Trust Account that may be released to the Company to pay its income taxes, if any, the amended and restated memorandum and articles of association, as discussed below and subject to the requirements of law and regulation, will provide that the proceeds from the Public Offering and the sale of the Private Placement Warrants held in the Trust Account will not be released from the Trust Account (1) to the Company, until the completion of the initial Business Combination, or (2) to the public shareholders, until the earliest of (a) the completion of the initial Business Combination, and then only in connection with those Class A ordinary shares that such shareholders properly elected to redeem, subject to the limitations described herein, (b) the redemption of any public shares properly tendered in connection with a shareholder vote to amend the amended and restated memorandum and articles of association (A) to modify the substance or timing of the Company’s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the public shares if the Company does not complete its initial Business Combination within 15 months (unless otherwise extended as described in the prospectus relating to the IPO) from the closing of this offering (the “Combination Period”) or (B) with respect to any other
 
5

provision relating to the rights of holders of the Class A ordinary shares, and (c) the redemption of the public shares if the Company has not consummated the Business Combination within Combination Period, subject to applicable law. Public shareholders who redeem their Class A ordinary shares in connection with a shareholder vote described in clause (b) in the preceding sentence shall not be entitled to funds from the Trust Account upon the subsequent completion of an initial Business Combination or liquidation if the Company has not consummated an initial Business Combination within Combination Period, with respect to such Class A ordinary shares so redeemed.
The Company will provide its public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a proposed Business Combination or conduct a tender offer will be made by the Company, solely in its discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require the Company to seek shareholder approval under applicable law or stock exchange listing requirement.
The Company will provide its public shareholders with the opportunity to redeem all or a portion of their Class A ordinary shares upon the completion of its initial Business Combination at aper-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the initial Business Combination, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any, divided by the number of then-outstanding public shares, subject to the limitations described herein. The amount in the Trust Account is initially $10.20 per public share. The per share amount the Company will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters.
The ordinary shares subject to redemption were recorded at redemption value and classified as temporary equity upon the completion of the Public Offering, in accordance with Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination.
The Company will have 15 months (unless otherwise extended as described in the prospectus relating to the IPO) from the closing of the Public Offering to consummate the initial Business Combination. If the Company has not consummated the initial Business Combination within the Combination Period, the Company will: (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at aper-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any (less up to $100,000 of interest to pay winding up and dissolution expenses) divided by the number of the then-outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and its board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii), to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.
The Sponsor and each member of the management team have entered into an agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their Founder Shares; (ii) waive their redemption rights with respect to their Founder Shares and public shares in connection with a shareholder vote to approve an amendment to the Company’s amended and restated memorandum and articles of association (A) that would modify the substance or timing of the Company’s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the public shares if the Company does not complete its initial Business Combination within 15 months from the closing of the Public Offering (or up to 21 months if we extend the time to complete a business combination) or (B) with respect to any other provision relating to the rights of holders of the Company’s Class A ordinary shares and (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to consummate an initial business combination within Combination Period.
The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company (other than the Company’s independent registered public accounting firm), or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per public share due to reductions in the value of the Trust Account, in each case net of the interest that may be withdrawn to pay the Company’s income tax obligations, provided that such liability will not apply to any claims
 
6

by a third party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriters of the Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. However, the Company has not asked the Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believe that the sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure you that the Sponsor would be able to satisfy those obligations. None of the Company’s officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses.
COVID-19
Pandemic
In March 2020, the World Health Organization characterized the outbreak of the novel strain of coronavirus, specifically identified as
COVID-19,
as a global pandemic. This has resulted in governments enacting emergency measures to combat the spread of the virus. These measures, which include the implementation of travel bans, self-imposed quarantine periods and social distancing, have caused material disruption to business, resulting in a global economic slowdown. Equity markets have experienced significant volatility and weakness and the governments and central banks have reacted with significant monetary and fiscal interventions designed to stabilize economic conditions.
The current challenging economic climate may lead to adverse changes in cash flows, working capital levels and/or debt balances, which may also have a direct impact on the Company’s operating results and financial position in the future. The ultimate duration and magnitude of the impact and the efficacy of government interventions on the economy and the financial effect on the Company is not known at this time. The extent of such impact will depend on future developments, which are highly uncertain and not in the Company’s control, including new information which may emerge concerning the spread and severity of
COVID-19
and actions taken to address its impact, among others. The repercussions of this health crisis could have a material adverse effect on the Company’s business, financial condition, liquidity and operating results.
In response to
COVID-19,
the Company has implemented working practices to address potential impacts to its operations, employees and customers, and will take further measures in the future if and as required. At present, we do not believe there has been any appreciable impact on the Company specifically associated with
COVID-19.
Liquidity and Capital Resources
The Company’s liquidity needs prior to the consummation of the Public Offering had been satisfied through a payment from the Sponsor of $25,000 to cover certain offering costs in consideration for the Founder Shares and the loan under an unsecured promissory note from the Sponsor of $262,268 (See Note 5). Subsequent to the consummation of the Public Offering, the Company expects that it will need additional capital to satisfy its liquidity needs beyond the net proceeds from the consummation of the Public Offering and the proceeds held outside of the Trust Account for paying existing accounts payable, identifying and evaluating prospective business combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the initial Business Combination. In order to finance transaction costs in connection with a Business Combination, the Sponsor, an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans. As of September 30,2022, there were no amounts outstanding under any Working Capital Loans.
Going Concern
As of September 30, 2022, the Company had $890,273 in cash held outside of the Trust Account and owes $1,089,536 in accrued offering costs and expenses and an additional $285,539 to related parties. The Company anticipates that the cash held outside of the Trust Account as of September 30, 2022 will not be sufficient to allow the Company to operate for at least the next 12 months from the issuance of the financial statements, assuming that a Business Combination is not consummated during that time. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans.
In connection with the Company’s assessment of going concern considerations in accordance with ASC
Subtopic205-40,
“Presentation of Financial Statements – Going Concern”, the Company has until January 22, 2023 (unless extended) to consummate a Business Combination. If a Business Combination is not consummated by this date and an extension not obtained, there will be a mandatory liquidation and subsequent dissolution of the Company. Although the Company intends to consummate a Business Combination on or before January 22, 2023, it is uncertain whether the Company will be able to consummate a Business Combination by this time. Management has determined that the mandatory liquidation, should a Business Combination not occur, and an extension is not obtained, as well as the potential for us to have insufficient funds available to operate our business prior to a Business Combination, raises substantial doubt about the Company’s ability to continue as a going concern.
Risks and Uncertainties
Management is currently evaluating the impact of theCOVID-19pandemic and has concluded that while it is reasonably possible that the pandemic could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
 
7

Note 2 — Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to
Form 10-Q
and Article 8 of Regulation
S-X
of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.
The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on
Form 10-K,
which contains the initial audited financial statements and notes thereto for the period from April 19, 2021 (inception) to December 31, 2021, as filed with the SEC on April 1, 2022. The interim results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the period ending December 31, 2022 or for any future interim periods.
The Company has until January 22, 2023 (or July 22, 2023 if fully extended) to complete a Business Combination.
 
8

Emerging Growth Company Status
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents
The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company has $890,273 and $1,323,903 in cash and cash equivalents as of September 30, 2022 and December 31, 2021, respectively.
Marketable Securities Held in Trust Account
Following the closing of the Public Offering on October 22, 2021, an amount of $281,520,000 from the net proceeds of the sale of the Units in the Public Offering and the sale of the Private Placement Warrants were placed in the Trust Account and may be invested only in U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule2a-7under the Investment Company Act which invest only in direct U.S. government treasury obligations. The Trust Account is intended as a holding place for funds pending the earliest to occur of: (i) the completion of the initial Business Combination; (ii) the redemption of any public shares properly submitted in connection with a shareholder vote to amend the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to redeem 100% of the public shares if the Company does not complete the initial Business Combination within 15 months (unless otherwise extended as described in the prospectus relating to the IPO) from the closing of the Public Offering or (B) with respect to any other provision relating to shareholders’ rights or
pre-initial
Business Combination activity; or (iii) absent an initial Business Combination within 15 months (unless otherwise extended) from the closing of the Public Offering, the return of the funds held in the Trust Account to the public shareholders as part of redemption of the public shares.
Offering Costs Associated with Initial Public Offering
The Company complies with the requirements of
ASC340-10-S99-1and
SEC Staff Accounting Bulletin Topic 5A—“Expenses of Offering”. Offering costs consist of legal, accounting, underwriting and other costs incurred through the balance sheet date that are related to the Public Offering. Offering costs are charged against the carrying value of the ordinary shares or the statement of operations based on the relative value of the ordinary shares and the Public Warrants to the proceeds received from the Units sold upon the completion of the Public Offering. Offering costs amounted to $16,138,202 and of this, $15,428,121 was charged to temporary equity and $710,081 was deemed allocable to the warrants and charged to expense upon the completion of the IPO.
Fair Value of Financial Instruments
The fair value of the Company’s assets and liabilities, which qualify as financial instruments under FASB ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheets, primarily due to its short-term nature.
 
9

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The Company’s financial instruments are classified as either Level 1, Level 2 or Level 3. These tiers include:
 
   
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
 
   
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
 
   
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
Derivative Financial Instruments
The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. The Company’s derivative instruments are recorded at fair value on the balance sheet with changes in the fair value reported in the statement of operations. Derivative assets and liabilities are classified on the balance sheets as current or
non-current
based on whether or not
net-cash
settlement or conversion of the instrument could be required within 12 months of the balance sheet date.
Warrant Liability
The Company accounts for the Public and Private Placement warrants issued in connection with the Public Offering in accordance with the guidance contained in ASC815-40and ASC 480,
Distinguishing Liabilities from Equity.
Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, the Company will classify each warrant as a liability at its fair value. This liability is subject tore-measurement at each balance sheet date. With each such
re-measurement,
the warrant liability will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operations.
Net Income (Loss) Per Ordinary Share
The Company complies with accounting and disclosure requirements of ASC Topic 260, “Earnings Per Share.” The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Income and losses are shared pro rata between the two classes of shares. Net income (loss) per ordinary share is calculated by dividing the net income (loss) by the weighted average ordinary shares outstanding for the respective period. Net loss for the period from inception to IPO was allocated fully to Class B ordinary shares. With respect to the accretion of Class A ordinary shares subject to possible redemption, the Company treated accretion in the same manner as a dividend, paid to the shareholder in the calculation of the net income (loss) per ordinary share.
The earnings per share presented in the Statement of Operations is based on the following:
 
    
Three Months
Ended
September 30,
2022
    
Nine
Months Ended
September 30,
2022
    
Three Months
Ended
September 30,
2021
    
For the
Period from
April 19, 2021
(Inception)
through
September 30,
2021
 
Net income (loss)
   $ 4,262,070      $ 11,637,242      $ (1,690    $ (15,393
Accretion of temporary equity to redemption value
     (1,245,745      (1,632,690                    
    
 
 
    
 
 
    
 
 
    
 
 
 
Net income (loss) including accretion of temporary equity to redemption value
   $ 3,016,325      $ 10,004,552      $ (1,690    $ (15,393
    
 
 
    
 
 
    
 
 
    
 
 
 
 
10

    
Three Months Ended
September 30, 2022
    
Nine Months Ended
September 30, 2022
 
    
Class A
    
Class B
    
Class A
    
Class B
 
Basic and diluted net income per share:
                                   
Numerator:
                                   
Allocation of net income including accretion of temporary equity
   $ 2,413,060        603,265      $ 8,003,642      $ 2,000,910  
Allocation of accretion of temporary equity to redemption value
     1,245,745        —          1,632,690        —    
Allocation of income
   $ 3,658,805        603,265      $ 9,636,332      $ 2,000,910  
    
 
 
    
 
 
    
 
 
    
 
 
 
Denominator:
                                   
Weighted-average shares outstanding
     27,600,000        6,900,000        27,600,000        6,900,000  
Basic and diluted net income per share
   $ 0.13      $ 0.09      $ 0.35      $ 0.29  
 
    
Three Months Ended
September 30, 2021
    
For the Period from
April 19, 2021 (Inception) through
September 30, 2021
 
    
Class A
    
Class B
    
Class A
    
Class B
 
Basic and diluted net loss per share:
                                   
Numerator:
                                   
Allocation of net loss including accretion of temporary equity
   $           (1,690    $         $ (15,393
Allocation of accretion of temporary equity to redemption value
               —                    —    
Allocation of loss
   $           (1,690    $         $ (15,393
    
 
 
    
 
 
    
 
 
    
 
 
 
Denominator:
                                   
Weighted-average shares outstanding
               6,900,000                  6,900,000  
Basic and diluted net loss per share
   $         $ (0.00    $         $ (0.00
Net income (loss) per share is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period, excluding ordinary shares forfeited. The Company has not considered the effect of the 27,840,000 ordinary shares issuable upon exercise of the Public Warrants and Private Placement Warrants in the calculation of diluted loss per share, since the exercise of such warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive.
Class A Ordinary Shares Subject to Possible Redemption
The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholder’s equity. The Company’s Class A ordinary shares sold in the IPO feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events.
The Company has made a policy election in accordance with
ASC480-10-S99-3A
and will recognize changes in redemption value in additional
paid-in
capital (or accumulated deficit in the absence of additional
paid-in
capital) immediately as they occur. The Company recorded accretion of $1,245,745 and $1,634,827, and $33,092,121 in accumulated deficit for the three and nine months ended September 30, 2022 and the period from April 19, 2021 (inception) through December 31, 2021, respectively.
Income Taxes
The Company accounts for income taxes under FASB ASC 740, “Income Taxes” (“ASC 740”).
ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.
FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of September 30, 2022 and December 31, 2021.
The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statements. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of September 30, 2022 and December 31, 2021, there were no unrecognized tax benefits and no amounts were accrued for the payment of interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.
 
11

Recent Accounting Pronouncements
In August 2020, the FASB issued Accounting Standards Update (“ASU”)
2020-06,
Debt—Debt with Conversion and Other Options (Subtopic
470-20)
and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic
815-40)
(“ASU
2020-06”)
to simplify accounting for certain financial instruments. ASU
2020-06
eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU
2020-06
amends the diluted earnings per share guidance, including the requirement to use the
if-converted
method for all convertible instruments. As a smaller reporting company, ASU
2020-06
is effective January 1, 2024 for fiscal years beginning after December 15, 2023 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that ASU
2020-06
would have on its financial position, results of operations or cash flows. The Company has not adopted this guidance as of September 30, 2022.
Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statement.
Note 3 — Public Offering
On October 22, 2021, the Company consummated its IPO of 27,600,000 Units, which included the full exercise of the underwriters’ over-allotment option, at a price of $10.00 per Unit, generating gross proceeds of $276,000,000. Each Unit consists of one Class A ordinary share and
one-half
of one redeemable warrant (each, a “Public Warrant”). Each whole Public Warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share.
All of the 27,600,000 Class A ordinary shares sold as part of the Units in the IPO contain a redemption feature which allows for the redemption of such public shares in connection with the Company’s liquidation, if there is a shareholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s certificate of incorporation. In accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity” and with the SEC and its staff’s guidance on redeemable equity instruments, which has been codified in
ASC480-10-S99,
redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity.
The Class A ordinary shares is subject to SEC and its staff’s guidance on redeemable equity instruments, which has been codified in
ASC480-10-S99.If
it is probable that the equity instrument will become redeemable, the Company has the option to either accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or to recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company recognizes changes in redemption value immediately as they occur. Immediately upon the closing of the IPO, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional
paid-in
capital and accumulated deficit.
As of September 30, 2022 and December 31, 2021, the ordinary shares reflected on the balance sheets are reconciled in the following table:

 

Gross proceeds
   $ 276,000,000  
Less:
        
Proceeds allocated to Public Warrants
     (12,144,000
Class A ordinary share issuance costs
     (15,428,121
Plus:
        
Accretion of carrying value to redemption value
     33,092,121  
    
 
 
 
Class A ordinary shares subject to possible redemption as of December 31,
2021
  
$
281,520,000  
Accretion of carrying value to redemption value
     389,082  
    
 
 
 
Class A ordinary shares subject to possible redemption as of June 30, 2022
  
$
281,909,082  
Accretion of carrying value to redemption value
     1,245,745  
    
 
 
 
Class A ordinary shares subject to possible redemption as of September 30,
2022
  
$
283,154,827
 
    
 
 
 
Note 4 — Private Placement
The Sponsor purchased 11,240,000 warrants, which included the underwriters’ exercise of the full over-allotment option (the “Private Placement Warrants”), each exercisable to purchase one Class A ordinary share at $11.50 per share, subject to adjustment, at a price of $1.00 per warrant and $11,240,000 in the aggregate, in a private placement that occurred concurrently with the closing of the Public Offering. Additionally, Salient Capital Advisors, LLC, acting in its capacity as investment advisor on behalf of one or more client accounts (“Salient Client Accounts”) purchased 2,800,000 warrants on the same terms as the Sponsor in a private placement that occurred concurrently with the closing of the Public Offering. The private placement resulted in an aggregate of 14,040,000 warrants and $14,040,000 in proceeds, a portion of which was placed in the Trust account.
Note 5 — Related Party Transactions
Founder Shares
On April 27, 2021, the Sponsor paid $25,000, or approximately $0.004 per share, to cover certain offering costs in consideration for 5,750,000 Class B ordinary shares, par value $0.0001. In September 2021, certain shareholders surrendered, for no consideration, an aggregate of 1,437,500 Class B ordinary shares, leaving 5,750,000 Founder Shares outstanding. In October 2021, a share dividend was issued which resulted in 6,900,000 Founder Shares outstanding; of which 900,000 were subject to surrender if the underwriter had not exercised their full over-allotment option. All share values and related amounts have been retroactively restated to reflect the dividend.
On September 10, 2021, the Sponsor transferred 115,000 Class B ordinary shares to each of its three independent directors. Additionally, on September 27, 2021, the Company sold 831,393 Class B ordinary shares to the Salient Client Accounts at a price of approximately $0.004 per share. As of September 30, 2022, the Sponsor held 4,573,607 Class B ordinary shares.
 
12

The initial shareholders and each member of the management team have entered into an agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of the Business Combination; (ii) waive their redemption rights with respect to their Founder Shares and Public Shares in connection with a shareholder vote to approve an amendment to the amended and restated memorandum and articles of association (A) that would modify the substance or timing of the Company’s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the Business Combination or to redeem 100% of the Company’s public shares if it does not complete the Business Combination within 15 months from the closing of the Public Offering (or up to 21 months, if extended) to complete a Business Combination or (B) with respect to any other provision relating to the rights of holders of the Class A ordinary shares and (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to consummate an Business Combination within 15 months from the closing of this offering (or up to 21 months if extended) to complete a Business Combination as described in the prospectus (although they will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares they hold if the Company fails to complete the Business Combination within the prescribed time frame). If the Company seeks shareholder approval, it will complete the Business Combination only if it is approved by an ordinary resolution or such higher approval threshold as may be required by Cayman Islands law and pursuant to the amended and restated memorandum and articles of association. In such case, the initial shareholders and each member of the management team have agreed to vote their Founder Shares and Public Shares in favor of the Business Combination.

13

Promissory Note — Related Party
On April 27, 2021, the Sponsor agreed to loan the Company up to $300,000 to be used for a portion of the expenses of the Public Offering. The Company borrowed a total of $262,268. This loan was
non-interest
bearing, unsecured and due at the earlier of December 31, 2021 or the closing of the Public Offering. The loan was to be repaid upon the closing of the Public Offering out of the offering proceeds not held in the Trust Account. In connection with the closing of the Public Offering, the Company paid down $90,922 of the outstanding balance. As of September 30, 2022 and December 31, 2021, the Company had $171,346 outstanding under the promissory note.
Working Capital Loans
In order to finance transaction costs in connection with an intended Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes the initial Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the Trust Account. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital Loans. Up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity at a price of $1.00 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. As of September 30, 2022 and December 31, 2021, the Company had no borrowings under the Working Capital Loans.
Office Space, Secretarial and Administrative Services
Commencing on the date that the Company’s securities are first listed on the NASDAQ through the earlier of consummation of the initial Business Combination and the liquidation, the Company will pay the Sponsor a total of $10,000 per month for office space, utilities, secretarial support and administrative services. As of September 30, 2022 and December 31, 2021, the Company had incurred $90,000 and $24,193, respectively pursuant to this agreement, which was accrued in “Due to related party”.
Note 6 — Prepaid Expenses
The Company’s prepaid expenses as of September 30, 2022 and December 31, 2021 primarily consisted of insurance.
 
    
September 30, 2022
    
December 31, 2021
 
    
Current
    
Current
    
Non-current
 
Prepaid Insurance
   $ 159,382      $ 528,861      $ 26,081  
Other Prepaid Items
     14,875        21,573        —    
    
 
 
    
 
 
    
 
 
 
    
$
174,257
 
  
$
550,434
 
  
$
26,081
 
    
 
 
    
 
 
    
 
 
 
Note 7 — Commitments & Contingencies
Registration and Shareholder Rights
The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) will be entitled to registration rights pursuant to a registration and expected shareholder rights agreement signed at the closing of our Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s completion of its initial Business Combination. However, the registration and expected shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable
lock-up
period, which occurs (i) in the case of the Founder Shares, and (ii) in the case of the private placement warrants and the respective Class A ordinary shares issuable upon exercise of the private placement warrants, 30 days after the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Working Capital Loans and warrants that may be issued upon conversion of Working Capital Loans) will be entitled to registration rights pursuant to a registration and expected shareholder rights agreement signed at the closing of our Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company’s register such securities.
 
14

In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of its initial Business Combination. However, the registration and expected shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lockup period, which occurs (i) in the case of the Founder Shares, as described in the following paragraph, and (ii) in the case of the Private Placement Warrants and the respective Class A ordinary shares underlying such warrants, 30 days after the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
Except as described herein, the Sponsor and its directors and executive officers have agreed not to transfer, assign or sell any of their Founder Shares until the earliest of (A) one year after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the closing price of the Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any30-tradingday period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company complete a liquidation, merger, share exchange or other similar transaction that results in all of the public shareholders having the right to exchange their ordinary shares for cash, securities or other property. Any permitted transferees would be subject to the same restrictions and other agreements of the Sponsor and its directors and executive officers with respect to any founder shares. Any permitted transferees will be subject to the same restrictions and other agreements of the Sponsor with respect to any Founder Shares. The Company refers to such transfer restrictions throughout the Public Offering as the lock- up.
In addition, pursuant to the registration and expected shareholder rights agreement, the Sponsor, upon and following consummation of an initial Business Combination, will be entitled to nominate three individuals for election to the board of directors, as long as the Sponsor holds any securities covered by the registration and expected shareholder rights agreement.
Underwriting Agreement
The Company granted the underwriters
a45-dayoption
to purchase up to 3,600,000 additional Units to cover over-allotments, if any, at the Public Offering price less the underwriting discounts and commissions. The underwriters exercised the full over-allotment at the consummation of the Public Offering on October 22, 2021.
The underwriters earned an underwriting discount of two percent (2%) of the gross proceeds of the Public Offering, or $5,520,000, which was paid in cash at closing of the offering.
Additionally, the underwriters are entitled to a deferred underwriting discount of 3.5% of the gross proceeds of the Public Offering upon the completion of the Company’s initial Business Combination.
Note 8 — Warrant Liabilities
The Company accounts for the 27,840,000 warrants issued in connection with the Public Offering (13,800,000 Public Warrants and 14,040,000 Private Placement Warrants) in accordance with the guidance contained in
ASC815-40.
Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, the Company will classify each warrant as a liability at its fair value. This liability is subject to remeasurement at each balance sheet date.
With each such remeasurement, the warrant liability will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operation.
Public Warrants
Each whole warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment as discussed herein. In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading
 
15

price of the Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described adjacent to “Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described adjacent to the caption “Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price.
The warrants will become exercisable 30 days after the completion of the Company’s initial Business Combination and will expire five years after the completion of the Company’s initial Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.
The Company has agreed that as soon as practicable, but in no event later than 20 business days after the closing of the initial Business Combination, it will use its commercially reasonable efforts to file with the SEC a post-effective amendment to the registration statement of which this prospectus forms a part or a new registration statement for the registration, under the Securities Act, of the Class A ordinary shares issuable upon exercise of the warrants, and the Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of the initial Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; provided that if the Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elect, it will not be required to file or maintain in effect a registration statement, but the Company will use its commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. The “fair market value” as used in this paragraph shall mean the volume weighted average price of the Class A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption, but it will use its commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. In such event, each holder would pay the exercise price by surrendering the warrants for that number of Class A ordinary shares equal to the lesser of (A) the quotient obtained by dividing (x) the product of the number of Class A ordinary shares underlying the warrants, multiplied by the excess of the “fair market value” (defined below) less the exercise price of the warrants by (y) the fair market value and (B) 0.361. The “fair market value” as used in this paragraph shall mean the volume weighted average price of the Class A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent.
Redemption of warrants when the price per Class
 A ordinary share equals or exceeds $18.00
. Once the warrants become exercisable, the Company may redeem not less than all of the outstanding warrants (except as described herein with respect to the Private Placement Warrants):
 
   
in whole and not in part;
 
   
at a price of $0.01 per warrant;
 
   
upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and
 
   
if, and only if, the closing price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “Description of Securities—Warrants—Public Shareholders’ Warrants—Anti-dilution Adjustments”) for any 20 trading days within
a30-tradingday
period ending three trading days before the Company sends the notice of redemption to the warrant holders.
 
16

Redemption of warrants when the price per Class
 A ordinary share equals or exceeds $10.00
. Once the warrants become exercisable, the Company may redeem not less than all of the outstanding warrants:
 
   
in whole and not in part;
 
   
at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption; and
 
   
if, and only if, the closing price of the Class A ordinary shares equals or exceeds $10.00 per public share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “Description of Securities—Warrants—Public Shareholders’ Warrants—Anti-dilution Adjustments”) for any 20 trading days within the30-tradingday period ending three trading days before the Company sends the notice of redemption to the warrant holders;
Private Warrants
If the Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the warrants included in the units sold in the Public Offering. Any amendment to the terms of the Private Placement Warrants or any provision of the warrant agreement with respect to the Private Placement Warrants will require a vote of holders of at least 50% of the number of the then outstanding Private Placement Warrants.
The accounting treatment of derivative financial instruments requires that the Company record a derivative liability upon the closing of the IPO. Accordingly, the Company has classified each warrant as a liability at its fair value and the warrants were allocated a portion of the proceeds from the issuance of the Units equal to its fair value determined by a Black Scholes model. This liability is subject tore-measurement at each balance sheet date. With each such
re-measurement,
the warrant liability will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operations. The Company will reassess the classification at each balance sheet date. If the classification changes as a result of events during the period, the warrants will be reclassified as of the date of the event that causes the reclassification. As such, the Company recorded$24,920,400 of warrant liability upon issuance as of October 22,2021. For the period from April 19,2021(inception) through December 31,2021, the Company recorded a change in the fair value of the warrant liabilities in the amount of $10,944,240 on the statement of operations, resulting in warrant liabilities of $13,976,160 as of December 31,2021 on the balance sheet. For the nine months ended September 30,2022, the Company recorded a change in the fair value of the warrant liabilities in the amount of $11,608,560 on the statement of operations, resulting in warrant liabilities of $2,367,600 as of September 30,2022 on the balance sheet.
Note 9 — Recurring Fair Value Measurements
As of September 30, 2022 and December 31, 2021, investments held in the Trust Account consisted of U.S. Money Market Funds. Fair values of these investments are determined by Level 1 inputs utilizing quoted prices (unadjusted) in active markets for identical assets.
The Company accounts for the Public Warrants and Private Placement Warrants as liabilities in accordance with the guidance contained in
ASC 815-40,
Derivatives and Hedging—Contracts in Entity’s Own Equity. Because the Company does not control the occurrence of events, such as a tender offer or exchange, that may trigger cash settlement of the warrants where not all of the shareholders also receive cash, the warrants do not meet the criteria for equity treatment thereunder, as such, the warrants must be recorded as a derivative liability.
Additionally, certain adjustments to the settlement amount of the Private Placement Warrants are based on a variable that is not an input to the fair value of a
“fixed-for-fixed”
option as defined under
ASC815-40,
and thus the Private Placement Warrants are not considered indexed to the Company’s own share and not eligible for an exception from derivative accounting.
The Company’s Public Warrants are traded on the Nasdaq. As such, the Public Warrant valuation is based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. The fair value of the Public Warrant liability is classified within Level 1 of the fair value hierarchy.
At December 31, 2021, the Company’s Private Warrant liability is based on a valuation model utilizing management judgment and pricing inputs from observable and unobservable markets with less volume and transaction frequency than active markets. Significant deviations from these estimates and inputs could result in a material change in fair value. The fair value of the Private Warrant liability is classified within Level 3 of the fair value hierarchy.
At September 30, 2021, the Company considers the Private Warrants to be economically equivalent to the Public Warrants. As such, the valuation of the Private Warrants was used to value the Private Warrants. The fair value of the Private Warrant liability is classified within Level 2 of the fair value hierarchy.
The following tables presents fair value information as of September 30, 2022 and December 31, 2021 of the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value.
 
September 30, 2022
  
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
                                   
Marketable securities held in trust account
   $ 283,154,827      $ —        $ —        $ 283,154,827  
Liabilities:
                                   
Public Warrants
   $ 1,104,000      $ —        $ —        $ 1,104,000  
Private Warrants
     —          1,263,600                  1,263,600  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total liabilities
   $ 1,104,000      $ 1,263,600      $         $ 2,367,600  
    
 
 
    
 
 
    
 
 
    
 
 
 
         
December 31, 2021
  
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
                                   
Marketable securities held in trust account
   $ 281,522,137      $ —        $ —        $ 281,522,137  
Liabilities:
                                   
Public Warrants
   $ 6,900,000      $ —        $ —        $ 6,900,000  
Private Warrants
     —          —          7,076,160        7,076,160  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total liabilities
   $ 6,900,000      $ —        $ 7,076,160      $ 13,976,160  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
17

The following table provides a summary of the changes in the fair value of the Company’s Level 3 financial instruments that are measured at fair value on a recurring basis:

 
 
  
Private
Placement
Warrants
 
  
Public
Warrants
 
  
Warrant
Liabilities
 
Warrant liability – initial measurement
   $ 12,776,400      $ 12,144,000      $ 24,920,400  
Change in fair value of warrant liabilities
     (5,700,240      (5,244,000      (10,944,240
Transfer to Level 1
     —          (6,900,000      (6,900,000
    
 
 
    
 
 
    
 
 
 
Warrant liabilities at December 31, 2021
  
$
7,076,160     
$
—       
$
7,076,160  
Change in fair value of warrant liabilities
     (3,285,360      —          (3,285,360
    
 
 
    
 
 
    
 
 
 
Warrant liabilities at March 31, 2022
  
$
3,790,800     
$
—       
$
3,790,800  
Change in fair value of warrant liabilities
     (561,600      —          (561,600
    
 
 
    
 
 
    
 
 
 
Warrant liabilities at June 30, 2022
  
$
3,229,200     
$
—       
$
3,229,200  
Change in fair value of warrant
liabilities (1)
     (1,965,600                (1,965,600 )
Transfer to Level 2
 
 
 (1,263,600
)
 
 
 
 
 
 (1,263,600
)
    
 
 
    
 
 
    
 
 
 
Warrant liabilities at September 30, 2022
   $         $         $     
    
 
 
    
 
 
    
 
 
 
 
(1)
Assumes the Private Placement Warrants were transferred on September 30, 2022.
Transfers to/from Levels 1, 2 and 3 are recognized at the end of the reporting period. The estimated fair value of the Public Warrants transferred from a Level 3 measurement to a Level 1 fair value measurement in September 2021 after the Public Warrants were separately listed and traded. The estimated fair value of the Private Placement Warrants transferred from a Level 3 measurement to a Level 2 fair value measurement in September 2022 due to the use of an observable market quote for a similar asset in an active market.
The estimated fair value of the Private Placement Warrants at December 31, 2021 was determined using a Black Scholes model with assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its ordinary shares based on projected volatility of comparable public companies that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury
zero-coupon
yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is based on management assumptions regarding the timing and likelihood of completing a business combination. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.
The following table presents quantitative information about the Company’s Level 3 liabilities that are measured at fair value on a recurring basis as of December 31, 2021.
 
    
December 31, 2021
 
Exercise price
   $ 11.50  
Share price
   $ 9.92  
Risk-free rate
     1.32
Expected volatility
     8.3
Term (years)
     5.81  
Note 10 — Shareholders’ Equity (Deficit)
Preference shares
—The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of September 30, 2022 and December 31, 2021, there were no preference shares issued or outstanding.
Class
 A ordinary shares
—The Company is authorized to issue 250,000,000 Class A ordinary shares with a par value of $0.0001 per share. As of September 30, 2022 and December 31, 2021, there were no Class A ordinary shares issued or outstanding other than the 27,600,000 Class A ordinary shares subject to possible redemption that are accounted for outside of the shareholder’s equity (deficit) section of our balance sheets.
Class
 B ordinary shares
—The Company is authorized to issue 25,000,000 Class B ordinary shares with a par value of $0.0001 per share. Holders are entitled to one vote for each share of Class B ordinary shares. As of September 30, 2022 and December 31, 2021, there were 6,900,000 Class B ordinary shares issued and outstanding. Of the 6,900,000 Class B ordinary shares, up to 900,000 shares were subject to forfeiture to the Company for no consideration to the extent that the underwriters’ over-allotment option was not exercised in full or in part, so that the initial shareholders will collectively own 20% of the Company’s issued and outstanding ordinary shares after the Public Offering. The underwriters exercised their full over-allotment on October 22, 2021.
Holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company’s shareholders except as required by law. Unless specified in the Company’s amended and restated memorandum and articles of association, or as required by applicable provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of the Company’s ordinary shares that are voted is required to approve any such matter voted on by its shareholders.
 
18

The Class B ordinary shares will automatically convert into Class A ordinary shares (which such Class A ordinary shares delivered upon conversion will not have any redemption rights or be entitled to liquidating distributions from the Trust Account if the Company fails to consummate an initial Business Combination) at the time of the initial Business Combination or earlier at the option of the holders thereof at a ratio such that the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an
as-converted
basis, 20% of the sum of (i) the total number of ordinary shares issued and outstanding upon completion of the Public Offering, plus (ii) the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor, any of its affiliates or any members of the Company’s management team upon conversion of Working Capital Loans. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than
one-to-one.
This is different than some other similarly structured blank check companies in which the initial shareholders will only be issued an aggregate of 20% of the total number of shares to be outstanding prior to the initial Business Combination.
 
19


Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

References to the “Company,” “our,” “us” or “we” refer to ESGEN Acquisition Corporation. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited condensed financial statements and the notes thereto contained elsewhere in this Quarterly Report on Form10-Q (this “Quarterly Report”). Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report contains, and our officers and representatives may from time to time make, “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding

 

   

our ability to select an appropriate target business or businesses;

 

   

our ability to complete our initial business combination;

 

   

our expectations around the performance of a prospective target business or businesses;

 

   

our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination;

 

   

our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination;

 

   

our potential ability to obtain additional financing to complete our initial business combination;

 

   

our pool of prospective target businesses;

 

   

our ability to consummate an initial business combination due to the uncertainty resulting from the COVID-19pandemic, as well as from the emergence of variant strains of COVID-19, including the efficacy and adoption of recently developed vaccines with respect to COVID-19 and variant strains thereof;

 

   

the ability of our officers and directors to generate a number of potential business combination opportunities;

 

   

our public securities’ potential liquidity and trading;

 

   

the lack of a market for our securities;

 

   

the use of proceeds not held in the trust account or available to us from interest income on the trust account balance;

 

   

the trust account not being subject to claims of third parties; or

 

   

our financial performance following our initial public offering.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, those factors described under the heading “Risk Factors.” Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. You should not take any statement regarding past trends or activities as representation that the trends or activities will continue in the future. Accordingly, you should not put undue reliance on these statements.

Overview

We were incorporated as a Cayman Islands exempted company on April 19, 2021 for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (the “Business Combination”). We have not selected any Business Combination target. We will not be limited to a particular industry or geographic region in our identification and acquisition of a target company.

Our sponsor is ESGEN LLC, a Delaware limited liability company (the “Sponsor”).

 

20


Table of Contents

The registration statement for our initial public offering (“initial public offering” or “Public Offering”) was declared effective on October 19, 2021. On October 22, 2021, we consummated our initial public offering of 27,600,000 units (the “Units” and, with respect to the ordinary shares included in the Units being offered, the “Public Shares”) at $10.00 per Unit (which included the full exercise of the underwriters’ over-allotment option), and the sale of 14,040,000 warrants (the “Private Placement Warrants”) each exercisable to purchase one Class A ordinary share at $11.50 per share, at a price of $1.00 per Private Placement Warrant in a private placement to our sponsor that closed simultaneously with the initial public offering.

Transaction costs amounted to $16,138,202 consisting of $5,520,000 of underwriting commissions, $9,660,000 of deferred underwriting commissions and $958,202 of other cash offering costs. Of this amount, $15,428,121 was charged to shareholder’s deficit and $710,081 was allocated to the warrants and expensed.

Following the closing of our initial public offering on October 22, 2021, $281,520,000 ($10.20 per Unit) from the net proceeds sold in our initial public offering, including proceeds of the sale of the Private Placement Warrants, was deposited in a trust account (“Trust Account”) and will only be invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations.

We will have 15 months (unless otherwise extended) from the closing of our initial public offering to consummate the initial Business Combination. If we have not consummated the initial Business Combination within the Combination Period, we will: (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at aper-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to us to pay income taxes, if any (less up to $100,000 of interest to pay winding up and dissolution expenses) divided by the number of the then-outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii), to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.

 

21


Table of Contents

Results of Operations

All of our activity from April 19, 2021 (inception) through September 30, 2022, was in preparation for our initial public offering, and since our initial public offering, our activity has been limited to the search for a prospective initial Business Combination. We will not generate any operating revenues until the closing and completion of our initial Business Combination.

For the three months ended September 30, 2022, we had income of $4,262,070, which consisted of a gain on change in fair value of warrant liabilities of $3,345,600, interest income from marketable securities held in trust account of $1,245,745, partially offset by operating costs of $329,275.

For the nine months ended September 30, 2022, we had income of $11,637,242, which consisted of a gain on change in fair value of warrant liabilities of $11,608,560, interest income from marketable securities held in trust account of $1,632,690, partially offset by operating costs of $1,604,008.

For the three months ended September 30, 2021, we had net loss of $1,690, which consisted of formation and operating costs.

For the period from April 19, 2021 (inception) to September 30, 2021, we had a loss of $15,393, which consisted of formation and operating costs.

Liquidity and Capital Resources

As of September 30, 2022, the Company had cash of $890,273 and owes $1,089,536 in accrued offering costs and expenses and an additional $285,539 to related parties.

Prior to the completion of our initial public offering, our liquidity needs had been satisfied through a capital contribution from the Sponsor of $25,000 and a loan to us of up to $300,000 by our Sponsor under an unsecured promissory note, which had an outstanding balance of $171,346 at September 30, 2022. In addition, in order to finance transaction costs in connection with a Business Combination, our Sponsor, an affiliate of our Sponsor or certain of our officers and directors may, but are not obligated to, provide us Working Capital Loans. As of September 30, 2022, there were no amounts outstanding under any Working Capital Loans.

Based on the foregoing, management believes that we will not have sufficient working capital and borrowing capacity to meet our needs through the earlier of the consummation of a Business Combination or one year from this filing. Over this time period, we will be using these funds for paying existing accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination.

In connection with the Company’s assessment of going concern considerations in accordance with ASC Subtopic205-40, “Presentation of Financial Statements – Going Concern”, the Company has until January 22, 2023 (unless extended) to consummate a Business Combination. If a Business Combination is not consummated by this date and an extension not obtained, there will be a mandatory liquidation and subsequent dissolution of the Company. Although the Company intends to consummate a Business Combination on or before January 22, 2023, it is uncertain whether the Company will be able to consummate a Business Combination by this time. Management has determined that the mandatory liquidation, should a Business Combination not occur, and an extension is not obtained, as well as the potential for us to have insufficient funds available to operate our business prior to a Business Combination, and potential subsequent dissolution, raises substantial doubt about the Company’s ability to continue as a going concern. It is uncertain whether the Company will be able to consummate a Business Combination or obtain an extension by this time. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after January 22, 2023.

Contractual Obligations

Other than the below, we do not have any long-term debt obligations, capital lease obligations, operating lease obligations, purchase obligations or long-term liabilities.

Underwriting Agreement

We granted the underwriters a45-dayoption to purchase up to 3,600,000 additional Units to cover over-allotments, if any, at our initial public offering price less the underwriting discounts and commissions. The underwriters exercised the full over-allotment at the consummation of our initial public offering on October 22, 2021.

The underwriters earned an underwriting discount of two percent (2%) of the gross proceeds of our initial public offering, or $5,520,000, which we paid in cash at closing of the Public Offering.

Additionally, the underwriters are entitled to a deferred underwriting discount of 3.5% of the gross proceeds of our initial public offering upon the completion of our initial Business Combination.

Office Space, Secretarial and Administrative Services

Commencing on the date that our securities are first listed on the NASDAQ through the earlier of consummation of our initial Business Combination and the liquidation, we are expected to pay our Sponsor a total of $10,000 per month for office space, utilities, secretarial support and administrative services. As of September 30, 2022, we had incurred $114,193 pursuant to this agreement, which was accrued in “Due to related party”.

 

22


Table of Contents

Registration Rights

The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to a registration and shareholder rights agreement signed at the closing of our initial public offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that we register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to our completion of the initial Business Combination. However, the registration and shareholder rights agreement provides that we will not permit any registration statement filed under the Securities Act of 1933, as amended (the “Securities Act”) to become effective until termination of the applicable lock-up period, which occurs (i) in the case of the Founder Shares, and (ii) in the case of the Private Placement Warrants and the respective Class A ordinary shares issuable upon exercise of the Private Placement Warrants, 30 days after the completion of the initial Business Combination. We will bear the expenses incurred in connection with the filing of any such registration statements. The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Working Capital Loans and warrants that may be issued upon conversion of Working Capital Loans) will be entitled to registration rights pursuant to a registration and expected shareholder rights agreement signed at the closing of our initial public offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities.

 

23


Table of Contents

In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of its initial Business Combination. However, the registration and shareholder rights agreement provides that we will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lockup period, which occurs (i) in the case of the Founder Shares, as described in the following paragraph, and (ii) in the case of the Private Placement Warrants and the respective Class A ordinary shares underlying such warrants, 30 days after the completion of the initial Business Combination. We will bear the expenses incurred in connection with the filing of any such registration statements.

Except as described herein, the Sponsor and its directors and executive officers have agreed not to transfer, assign or sell any of their Founder Shares until the earliest of (A) one year after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the closing price of the Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any30-tradingday period commencing at least 150 days after the initial Business Combination, or (y) the date on which we complete a liquidation, merger, share exchange or other similar transaction that results in all of the public shareholders having the right to exchange their ordinary shares for cash, securities or other property. Any permitted transferees would be subject to the same restrictions and other agreements of the Sponsor and its directors and executive officers with respect to any founder shares. Any permitted transferees will be subject to the same restrictions and other agreements of the Sponsor with respect to any Founder Shares.

In addition, pursuant to the registration and shareholder rights agreement, the Sponsor, upon and following consummation of an initial Business Combination, will be entitled to nominate three individuals for election to the board of directors, as long as the Sponsor holds any securities covered by the registration and shareholder rights agreement.

Going Concern

As of September 30, 2022, the Company had cash of $890,273 and owes $1,089,536 in accrued offering costs and expenses and an additional $285,539 to related parties. The Company anticipates that the cash held outside of the Trust Account as of September 30, 2022 will not be sufficient to allow the Company to operate for at least the next 12 months from the issuance of the financial statements, assuming that a Business Combination is not consummated during that time. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. There is no assurance that the Company’s plans to consummate an initial Business Combination will be successful or successful within the Combination Period.

In connection with the Company’s assessment of going concern considerations in accordance with ASC Subtopic205-40, “Presentation of Financial Statements – Going Concern”, the Company has until January 22, 2023 (unless extended) to consummate a Business Combination. If a Business Combination is not consummated by this date and an extension not obtained, there will be a mandatory liquidation and subsequent dissolution of the Company. Although the Company intends to consummate a Business Combination on or before January 22, 2023, it is uncertain whether the Company will be able to consummate a Business Combination by this time. Management has determined that the mandatory liquidation, should a Business Combination not occur, and an extension is not obtained, as well as the potential for us to have insufficient funds available to operate our business prior to a Business Combination, and potential subsequent dissolution, raises substantial doubt about the Company’s ability to continue as a going concern. It is uncertain whether the Company will be able to consummate a Business Combination or obtain an extension by this time. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after January 22, 2023.

 

24


Table of Contents

Critical Accounting Estimates

The preparation of these financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. We have identified the following critical accounting estimates:

Warrant Liability

The Company accounts for the Public and Private Placement warrants issued in connection with the Public Offering in accordance with the guidance contained in ASC815-40and ASC 480, Distinguishing Liabilities from Equity. Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, the Company classified each warrant as a liability at its fair value. This liability is subject tore-measurement at each balance sheet date. With each such re-measurement, the warrant liability will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operations.

Offering Costs Associated with Initial Public Offering

We comply with the requirements of Accounting Standards Codification (“ASC”) 340-10-S99-1and SEC Staff Accounting Bulletin Topic 5A — “Expenses of Offering”. Offering costs consist of legal, accounting, underwriting and other costs incurred through the balance sheet date that are related to our initial public offering. Offering costs amounted to $16,138,202 and of this, $15,428,121 was charged to temporary equity and $710,081 was deemed allocable to the warrants and charged to expense upon the completion of our initial public offering.

Class A Ordinary Shares Subject to Possible Redemption

We account for our Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholder’s equity. Our Class A ordinary shares sold in our initial public offering feature certain redemption rights that are considered to be outside of our control and subject to the occurrence of uncertain future events. Accordingly, as of September 30, 2022 and December 31, 2021, 27,600,000 Class A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholder’s (deficit) equity section of our balance sheets.

Net Income (Loss) Per Ordinary Share

We apply the two-class method in calculating earnings per share. Ordinary share subject to possible redemption which is not currently redeemable and is not redeemable at fair value, has been excluded from the calculation of basic net income (loss) per ordinary share since such shares, if redeemed, only participate in their pro rata share of the Trust Account earnings. Our net income (loss) is adjusted for the portion of income that is attributable to ordinary share subject to possible redemption, as these shares only participate in the earnings of the Trust Account and not our income or losses.

Recent Accounting Pronouncements

In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. As a smaller reporting company, ASU 2020-06 is effective January 1, 2024 for fiscal years beginning after December 15, 2023 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. We are currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows. We have not adopted this guidance as of September 30, 2022.

Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the financial statement.

Off-Balance Sheet Arrangements

As of September 30, 2022, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K and did not have any commitments or contractual obligations.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company as defined by Rule12b-2of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and are not required to provide the information otherwise required under this item. As of September 30, 2022, we were not subject to any market or interest rate risk. The net proceeds of the Public Offering, including amounts in the Trust Account, were invested in U.S. government securities with a maturity of 185 days or less or in money market funds that meet certain conditions under Rule2a-7under the Investment Company Act of 1940, as amended, that invest only in direct U.S. government treasury obligations. Due to the short-term nature of these investments, we believe there will be no associated material exposure to interest rate risk.

We have not engaged in any hedging activities since our inception, and we do not expect to engage in any hedging activities with respect to the market risk to which we are exposed.

 

25


Table of Contents

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report, is recorded, processed, summarized and reported within the time period specified in the SEC’s rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our principal executive officer and principal financial and accounting officer (our “Certifying Officers”), the effectiveness of our disclosure controls and procedures as of September 30, 2022, pursuant to Rule13a-15(b)under the Exchange Act and determined that our disclosures controls and procedures were not effective. A material weakness, as defined in the SEC regulations, is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis.

As previously disclosed in the Form10-K for the year ended December 31, 2021, our disclosure controls and procedures were not effective because of the identification of a material weakness in our internal control over financial reporting relating to a lack of qualified resources within the accounting department. In particular, the Company was not able to correctly calculate allocations of earnings per share in accordance with appropriate accounting guidelines.

In light of this material weakness, we performed additional analysis as deemed necessary to ensure that our financial statements were prepared in accordance with U.S. generally accepted accounting principles. Management plans to remediate the material weakness identified above by enhancing our processes to identify and appropriately apply applicable accounting requirements and increased communication among our personnel and third-party professionals with whom we consult regarding accounting applications. The elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects.

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Changes in Internal Control over Financial Reporting

Other than the material weakness described above, there were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors.

There have been no material changes from the risk factors previously disclosed in the Company’s Annual Report on Form10-Kas filed with the SEC on April 1, 2022 (the “Annual Report”).

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds from Registered Securities

Subsequent to the quarterly period covered by this Quarterly Report, on October 22, 2021, we consummated the Public Offering of 27,600,000 Units, including the over-allotment Units. The Units were sold at a price of $10.00 per Unit, generating gross proceeds of $276,000,000 million. The underwriters were granted a45-dayoption from the date of the final prospectus relating to the Public Offering to purchase up to 3,600,000 additional Units to cover over-allotments, if any, at $10.00 per Unit, less underwriting discounts and commissions. Simultaneously with the closing of the Public Offering, the underwriters fully exercised the over-allotment option and, on October 22, 2021, the underwriters purchased the over-allotment Units.

On October 22, 2021, simultaneously with the closing of the Public Offering and pursuant to a separate Private Placement Warrants Purchase Agreement, dated October 22, 2021, by and among the Company, the Sponsor and the Salient Clients, the Company completed the private sale of an aggregate of 14,040,000 Private Placement Warrants at a purchase price of $1.00 per Private Placement Warrant to the Sponsor and Salient Clients, generating gross proceeds of $14,040,000.

 

26


Table of Contents

Barclays Capital Inc. and Citibank Global Markets Inc. served as underwriters for the Public Offering. The securities sold in the Public Offering were registered under the Securities Act on a registration statement on FormS-1 (FileNo. 333-259836). The SEC declared the registration statement effective on October 19, 2021.

From April 19, 2021 (inception) through the closing of the Public Offering, we incurred approximately $16.1 million for costs and expenses related to the Public Offering. In connection with the closing of the Public Offering, we paid a total of approximately $5.5 million in underwriting discounts and commissions. In addition, the underwriters agreed to defer approximately $9.7 million in underwriting discounts and commissions, which amount will be payable upon consummation of the initial Business Combination. There has been no material change in the planned use of proceeds from the Public Offering as described in our Annual Report.

 

27


Table of Contents

In connection with the Public Offering, we incurred offering costs of approximately $16.1 million, inclusive of approximately $9.7 million in deferred underwriting commissions. Other incurred offering costs consisted principally of preparation fees related to the Public Offering. After deducting the underwriting discounts and commissions (excluding the deferred portion, which amount will be payable upon consummation of the initial Business Combination, if consummated) and the Public Offering expenses, $281.5 million of the net proceeds from our Public Offering and certain of the proceeds from the private placement of the Private Placement Warrants (or $10.00 per Unit sold in the Public Offering) was placed in the Trust Account. The net proceeds of the Public Offering and certain proceeds from the sale of the Private Placement Warrants are held in the Trust Account and invested as described elsewhere in this Quarterly Report.

There has been no material change in the planned use of the proceeds from the Public Offering and Private Placement as is described in the Company’s Annual Report.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

 

28


Table of Contents

Item 6. Exhibits

 

Exhibit No.

  

Description

31.1*    Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*    Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**    Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes- Oxley Act of 2002
32.2**    Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes- Oxley Act of 2002
101.INS    Inline XBRL Instance Document
101.SCH    Inline XBRL Taxonomy Extension Schema Document
101.CAL    Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF    Inline XBRL Taxonomy Extension Definition Document
101.LAB    Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE    Inline XBRL Taxonomy Extension Presentation Linkbase Document
EX-104    Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

 

*

Filed herewith.

**

Furnished.

 

29


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: November 10, 2022     ESGEN Acquisition Corporation
    By:   /s/ Andrea Bernatova
      Andrea Bernatova
      Chief Executive Officer

 

Date: November 10, 2022     ESGEN Acquisition Corporation
    By:   /s/ Nader Daylami
      Nader Daylami
      Chief Financial Officer

 

30

EX-31.1 2 d374880dex311.htm EX-31.1 EX-31.1

EXHIBIT 31.1

CERTIFICATION

PURSUANT TO RULES 13a-14(a) AND 15d-14(a)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Andrea Bernatova, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 of ESGEN Acquisition Corporation;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b.

[Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313];

 

  c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: November 10, 2022

 

By:   /s/ Andrea Bernatova
  Name: Andrea Bernatova
 

Title: Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 d374880dex312.htm EX-31.2 EX-31.2

EXHIBIT 31.2

CERTIFICATION

PURSUANT TO RULES 13a-14(a) AND 15d-14(a)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Nader Daylami, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 of ESGEN Acquisition Corporation:

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b.

[Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313];

 

  c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: November 10, 2022

 

By:   /s/ Nader Daylami
  Name: Nader Daylami
 

Title: Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

EX-32.1 4 d374880dex321.htm EX-32.1 EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of ESGEN Acquisition Corporation (the “Company”) on Form 10-Q for the quarter ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Andrea Bernatova, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 10, 2022

 

By:   /s/ Andrea Bernatova
  Name: Andrea Bernatova
 

Title: Chief Executive Officer

(Principal Executive Officer)

EX-32.2 5 d374880dex322.htm EX-32.2 EX-32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of ESGEN Acquisition Corporation (the “Company”) on Form 10-Q for the quarter ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Nader Daylami, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 10, 2022

 

By:   /s/ Nader Daylami
  Name: Nader Daylami
 

Title: Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

EX-101.SCH 6 esac-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - CONDENSED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - CONDENSED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDER'S (DEFICIT) EQUITY link:presentationLink link:definitionLink link:calculationLink 1007 - Statement - CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDER'S (DEFICIT) EQUITY ( Parenthetical ) link:presentationLink link:definitionLink link:calculationLink 1008 - Statement - CONDENSED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Organization and Business Operation link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Public Offering link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Private Placement link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Prepaid Expenses link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Commitments & Contingencies link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Warrant Liabilities link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Recurring Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Shareholder's Equity (Deficit) link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Public Offering (Tables) link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Prepaid Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Recurring Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Organization and Business Operation (Details) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Significant Accounting Policies - Reconciliation of Net Loss per Common Share (Details) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Public Offering (Details) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Public Offering - Summary of Ordinary Shares Reflected on Balance Sheet (Details) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Private Placement (Details) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Related Party Transactions - Founder Shares (Details) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Related Party Transactions - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Prepaid Expenses (Details) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Commitments & Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Warrant Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Recurring Fair Value Measurements - Fair value hierarchy for liabilities measured at fair value on recurring basis (Details) link:presentationLink link:definitionLink link:calculationLink 1036 - Disclosure - Recurring Fair Value Measurements - changes in the fair value (Details) link:presentationLink link:definitionLink link:calculationLink 1037 - Disclosure - Recurring Fair Value Measurements - Companys Level 3 liabilities that are measured at fair value on a recurring basis (Details) link:presentationLink link:definitionLink link:calculationLink 1038 - Disclosure - Shareholder's Equity - Preferred Stock Shares (Details) link:presentationLink link:definitionLink link:calculationLink 1039 - Disclosure - Shareholder's Equity-Common Stock Shares (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 esac-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 esac-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 esac-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 10 esac-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover Page - shares
9 Months Ended
Sep. 30, 2022
Nov. 10, 2022
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2022  
Entity File Number 001-40927  
Entity Registrant Name ESGEN Acquisition Corporation  
Entity Incorporation, State or Country Code E9  
Entity Tax Identification Number 98-1601409  
Entity Address, Address Line One 5956 Sherry Lane  
Entity Address, Address Line Two Suite 1400  
Entity Address, City or Town Dallas  
Entity Address, State or Province TX  
Entity Address, Postal Zip Code 75225  
City Area Code 214  
Local Phone Number 987-6100  
Entity Current Reporting Status No  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company true  
Entity Central Index Key 0001865506  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Common Class A [Member]    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   27,600,000
Title of 12(b) Security Class A ordinary shares included as part of the units  
Trading Symbol ESAC  
Security Exchange Name NASDAQ  
Common Class B [Member]    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   6,900,000
Units, each consisting of one share of Class A Common Stock and one-half of one Warrant    
Document Information [Line Items]    
Title of 12(b) Security Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant  
Trading Symbol ESACU  
Security Exchange Name NASDAQ  
Warrants Each Whole Warrant Exercisable For One Share Of Class Common Stock At Exercise Price [Member]    
Document Information [Line Items]    
Title of 12(b) Security Warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50  
Trading Symbol ESACW  
Security Exchange Name NASDAQ  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED BALANCE SHEETS - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash $ 890,273 $ 1,323,903
Prepaid expenses - current 174,257 550,434
Total current assets 1,064,530 1,874,337
Prepaid expense - noncurrent   26,081
Marketable securities held in Trust Account 283,154,827 281,522,137
Total Assets 284,219,357 283,422,555
Current liabilities    
Accounts payable and accrued expenses 1,089,536 411,416
Due to related party 114,193 24,193
Promissory note - related party 171,346 171,346
Total current liabilities 1,375,075 606,955
Warrant Liabilities 2,367,600 13,976,160
Deferred underwriters' discount 9,660,000 9,660,000
Total Liabilities 13,402,675 24,243,115
Class A ordinary shares subject to possible redemption, 27,600,000 shares at redemption value of $10.20 283,154,827 281,520,000
Shareholders' Deficit:    
Preferred share, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding 0 0
Additional Paid in Capital 0 0
Accumulated deficit (12,338,835) (22,341,250)
Total shareholders' deficit (12,338,145) (22,340,560)
Total Liabilities, Redeemable Ordinary Shares and Shareholders' Deficit 284,219,357 283,422,555
Class A Common Stock    
Shareholders' Deficit:    
Common stock 0 0
Common Class B [Member]    
Shareholders' Deficit:    
Common stock $ 690 $ 690
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
Temporary Equity, Shares Outstanding 27,600,000  
Preferred stock, par value, (per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Class A Common Stock    
Temporary Equity, Shares Outstanding 27,600,000  
Common shares, par value, (per share) $ 0.0001 $ 0.0001
Common shares, shares authorized 250,000,000 250,000,000
Common shares, shares issued 0 0
Common shares, shares outstanding 0 0
Class B Common Stock    
Common shares, par value, (per share) $ 0.0001 $ 0.0001
Common shares, shares authorized 25,000,000 25,000,000
Common shares, shares issued 6,900,000 6,900,000
Common shares, shares outstanding 6,900,000 6,900,000
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 5 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2021
Sep. 30, 2022
Legal and professional fees $ 145,588     $ 937,110
Insurance 133,302     395,559
Other operating costs 20,385     181,339
Formation and operating costs 0 $ 1,690 $ 15,393 0
Operating cost—related party 30,000 0   90,000
Loss from operations (329,275) (1,690) (15,393) (1,604,008)
Other income:        
Interest income on marketable securities held in Trust Account 1,245,745 0 1,632,690
Change in fair value of warrant liabilities 3,345,600 0 11,608,560
Total other income 4,591,345 0 0 13,241,250
Net income (loss) $ 4,262,070 $ (1,690) $ (15,393) $ 11,637,242
Common Class A [Member]        
Other income:        
Weighted Average Number of Shares Outstanding, Basic 27,600,000 0 0 27,600,000
Weighted Average Number of Shares Outstanding, Diluted 27,600,000 0 0 27,600,000
Basic net income per share $ 0.13 $ 0 $ 0 $ 0.35
Diluted net income per share $ 0.13 $ 0 $ 0 $ 0.35
Common Class B [Member]        
Other income:        
Weighted Average Number of Shares Outstanding, Basic [1] 6,900,000 6,900,000 6,900,000 6,900,000
Weighted Average Number of Shares Outstanding, Diluted [1] 6,900,000 6,900,000 6,900,000 6,900,000
Basic net income per share $ 0.09 $ 0 $ 0 $ 0.29
Diluted net income per share $ 0.09 $ 0 $ 0 $ 0.29
[1] On April 27, 2021, the Sponsor paid $25,000, or approximately $0.004 per share, to cover certain offering costs in consideration for 5,750,000 Class B ordinary shares, par value $0.0001. In September 2021, certain shareholders surrendered, for no consideration, an aggregate of 1,437,500 Class B ordinary shares, leaving 5,750,000 Founder Shares outstanding. In October 2021, a share dividend was issued which resulted in 6,900,000 Founder Shares outstanding; of which 900,000 were subject to surrender if the underwriter had not exercised their full over-allotment option. The underwriters exercised their over-allotment option in full on October 21, 2021. All share values and related amounts have been retroactively restated to reflect the dividend.
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)
Apr. 27, 2021
Sep. 30, 2022
Dec. 31, 2021
Sep. 27, 2021
Sale of Stock, Consideration Received on Transaction $ 0      
Shares Issued, Price Per Share   $ 10    
Aggregate Number Of Shares Owned 1,437,500      
Common Stock Dividends, Shares 6,900,000      
Common Class B [Member]        
Common Stock, Shares, Outstanding   6,900,000 6,900,000  
Founder Shares [Member]        
Aggregate Of Sponsor Shares Surrendered 900,000      
Founder Shares [Member] | Common Class B [Member]        
Shares Issued, Price Per Share $ 0.0001     $ 0.004
Founder Shares [Member] | Sponsor | Common Class B [Member]        
Sale of Stock, Consideration Received on Transaction $ 25,000      
Shares Issued, Price Per Share $ 0.004      
Consideration received, shares 5,750,000      
Aggregate Number Of Shares Owned   4,573,607    
Common Stock, Shares, Outstanding 5,750,000      
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDER'S (DEFICIT) EQUITY - USD ($)
Total
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Common Class A [Member]
Common Stock [Member]
Common Class B [Member]
Common Stock [Member]
Balance at the beginning at Apr. 18, 2021 $ 25,000 $ 24,310 $ 0 $ 0 $ 690
Balance at the beginning (in shares) at Apr. 18, 2021       0 6,900,000 [1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income (loss) (15,393)   (15,393)    
Balance at the end at Sep. 30, 2021 9,607 24,310 (15,393) $ 0 $ 690
Balance at the end (in shares) at Sep. 30, 2021       0 6,900,000 [1]
Balance at the beginning at Jun. 30, 2021 11,297 24,310 (13,703) $ 0 $ 690
Balance at the beginning (in shares) at Jun. 30, 2021       0 6,900,000 [1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income (loss) (1,690)   (1,690)    
Balance at the end at Sep. 30, 2021 9,607 24,310 (15,393) $ 0 $ 690
Balance at the end (in shares) at Sep. 30, 2021       0 6,900,000 [1]
Balance at the beginning at Dec. 31, 2021 (22,340,560) 0 (22,341,250) $ 281,520,000 $ 690
Balance at the beginning (in shares) at Dec. 31, 2021       27,600,000 6,900,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Accretion of ordinary share subject to possible redemption (1,634,827)   (1,634,827) $ 1,634,827  
Net income (loss) 11,637,242   11,637,242    
Balance at the end at Sep. 30, 2022 (12,338,145) 0 (12,338,835) $ 283,154,827 $ 690
Balance at the end (in shares) at Sep. 30, 2022       27,600,000 6,900,000
Balance at the beginning at Jun. 30, 2022 (15,354,470) 0 (15,355,160) $ 281,909,082 $ 690
Balance at the beginning (in shares) at Jun. 30, 2022       27,600,000 6,900,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Accretion of ordinary share subject to possible redemption (1,245,745)   (1,245,745) $ 1,245,745  
Net income (loss) 4,262,070   4,262,070    
Balance at the end at Sep. 30, 2022 $ (12,338,145) $ 0 $ (12,338,835) $ 283,154,827 $ 690
Balance at the end (in shares) at Sep. 30, 2022       27,600,000 6,900,000
[1] On April 27, 2021, the Sponsor paid $25,000, or approximately $0.004 per share, to cover certain offering costs in consideration for 5,750,000 Class B ordinary shares, par value $0.0001. In September 2021, certain shareholders surrendered, for no consideration, an aggregate of 1,437,500 Class B ordinary shares, leaving 5,750,000 Founder Shares outstanding. In October 2021, a share dividend was issued which resulted in 6,900,000 Founder Shares outstanding; of which 900,000 were subject to surrender if the underwriter had not exercised their full over-allotment option. The underwriters exercised their over-allotment option in full on October 21, 2021. All share values and related amounts have been retroactively restated to reflect the dividend.
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDER'S (DEFICIT) EQUITY ( Parenthetical ) - USD ($)
Apr. 27, 2021
Sep. 30, 2022
Dec. 31, 2021
Sep. 27, 2021
Sale of Stock, Consideration Received on Transaction $ 0      
Shares Issued, Price Per Share   $ 10    
Aggregate Number Of Shares Owned 1,437,500      
Common Stock Dividends, Shares 6,900,000      
Common Class B [Member]        
Common Stock, Shares, Outstanding   6,900,000 6,900,000  
Founder Shares [Member]        
Aggregate Of Sponsor Shares Surrendered 900,000      
Founder Shares [Member] | Common Class B [Member]        
Shares Issued, Price Per Share $ 0.0001     $ 0.004
Founder Shares [Member] | Sponsor | Common Class B [Member]        
Sale of Stock, Consideration Received on Transaction $ 25,000      
Shares Issued, Price Per Share $ 0.004      
Consideration received, shares 5,750,000      
Aggregate Number Of Shares Owned   4,573,607    
Common Stock, Shares, Outstanding 5,750,000      
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED STATEMENTS OF CASH FLOWS - USD ($)
3 Months Ended 5 Months Ended 8 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2021
Dec. 31, 2021
Sep. 30, 2022
Cash flows from Operating Activities:          
Net income (loss) $ 4,262,070 $ (1,690) $ (15,393)   $ 11,637,242
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]          
Formation costs paid by Sponsor     11,693    
Interest earned on cash held in Trust Account (1,245,745) 0   (1,632,690)
Change in fair value of warrant liabilities (3,345,600) 0 $ (10,944,240) (11,608,560)
Increase (Decrease) in Operating Capital [Abstract]          
Prepaid assets       402,258
Accrued expenses     3,700   678,120
Due to related party       90,000
Net cash used in operating activities       (433,630)
Net change in cash       (433,630)
Cash, beginning of the period     1,323,903
Cash, end of the period $ 890,273 $ 1,323,903 890,273
Supplemental disclosure of cash flow information:          
Change in value of Class A ordinary shares subject to possible redemption       1,634,827
Deferred offering costs paid by Sponsor in exchange for issuance of Class B ordinary shares     25,000  
Deferred offering costs paid by Sponsor under the promissory note     243,913  
Deferred offering costs included in accrued offerings costs     $ 462,712  
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Business Operation
9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Business Operation
Note 1 — Organization and Business Operation
ESGEN Acquisition Corporation (the “Company”) was incorporated as a Cayman Islands exempted company on April 19, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (the “Business Combination”). The Company has not selected any Business Combination target. The Company will not be limited to a particular industry or geographic region in its identification and acquisition of a target company.
As of September 30, 2022, the Company had not commenced any operations. All activity for the period from April 19, 2021 (inception) through September 30, 2022, relates to the Company’s formation and the initial public offering (“Public Offering” or “IPO”) described below and since the closing of the IPO, the search for a prospective initial business combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate
non-operating
income in the form of interest income on cash and cash equivalents from the proceeds derived from the Public Offering (as defined below). The Company has selected December 31 as its fiscal year end.
The Company’s sponsor is ESGEN LLC, a Delaware limited liability company (the “Sponsor”).
The registration statement for the Company’s IPO was declared effective on October 19, 2021 (the “Effective Date”). On October 22, 2021, the Company consummated its IPO of 27,600,000 units (the “Units” and, with respect to the ordinary shares included in the Units being offered, the “Public Shares”) at $10.00 per Unit (which included the full exercise of the underwriters’ over-allotment option), which is discussed in Note 3 and the sale of 14,040,000 warrants (the “Private Placement Warrants”) each exercisable to purchase one Class A ordinary share at $11.50 per share, at a price of $1.00 per Private Placement Warrant in a private placement to the Sponsor that closed simultaneously with the Public Offering.
Transaction costs amounted to $16,138,202 consisting of $5,520,000 of underwriting commissions, $9,660,000 of deferred underwriting commissions and $958,202 of other cash offering costs. Of this amount, $15,428,121 was charged to shareholder’s deficit and $710,081 was allocated to the warrants and expensed.
The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (as defined below) (excluding the deferred underwriting commissions and taxes payable on the interest earned on the Trust Account) at the time of signing a definitive agreement in connection with the initial Business Combination. However, the Company will complete the initial Business Combination only if the post-Business Combination company in which its public shareholders own shares will own or acquire 50% or more of the outstanding voting securities of the target or is otherwise not required to register as an investment company under the Investment Company Act (the “Investment Company Act”). There is no assurance that the Company will be able to complete a Business Combination successfully.
Following the closing of the IPO on October 22, 2021, $281,520,000 ($10.20 per Unit) from the net proceeds sold in the IPO, including proceeds of the sale of the Private Placement Warrants, was deposited in a trust account (“Trust Account”) and will only be invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule2a-7promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations.
Except with respect to interest or other income earned on the funds held in the Trust Account that may be released to the Company to pay its income taxes, if any, the amended and restated memorandum and articles of association, as discussed below and subject to the requirements of law and regulation, will provide that the proceeds from the Public Offering and the sale of the Private Placement Warrants held in the Trust Account will not be released from the Trust Account (1) to the Company, until the completion of the initial Business Combination, or (2) to the public shareholders, until the earliest of (a) the completion of the initial Business Combination, and then only in connection with those Class A ordinary shares that such shareholders properly elected to redeem, subject to the limitations described herein, (b) the redemption of any public shares properly tendered in connection with a shareholder vote to amend the amended and restated memorandum and articles of association (A) to modify the substance or timing of the Company’s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the public shares if the Company does not complete its initial Business Combination within 15 months (unless otherwise extended as described in the prospectus relating to the IPO) from the closing of this offering (the “Combination Period”) or (B) with respect to any other
provision relating to the rights of holders of the Class A ordinary shares, and (c) the redemption of the public shares if the Company has not consummated the Business Combination within Combination Period, subject to applicable law. Public shareholders who redeem their Class A ordinary shares in connection with a shareholder vote described in clause (b) in the preceding sentence shall not be entitled to funds from the Trust Account upon the subsequent completion of an initial Business Combination or liquidation if the Company has not consummated an initial Business Combination within Combination Period, with respect to such Class A ordinary shares so redeemed.
The Company will provide its public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a proposed Business Combination or conduct a tender offer will be made by the Company, solely in its discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require the Company to seek shareholder approval under applicable law or stock exchange listing requirement.
The Company will provide its public shareholders with the opportunity to redeem all or a portion of their Class A ordinary shares upon the completion of its initial Business Combination at aper-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the initial Business Combination, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any, divided by the number of then-outstanding public shares, subject to the limitations described herein. The amount in the Trust Account is initially $10.20 per public share. The per share amount the Company will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters.
The ordinary shares subject to redemption were recorded at redemption value and classified as temporary equity upon the completion of the Public Offering, in accordance with Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination.
The Company will have 15 months (unless otherwise extended as described in the prospectus relating to the IPO) from the closing of the Public Offering to consummate the initial Business Combination. If the Company has not consummated the initial Business Combination within the Combination Period, the Company will: (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at aper-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any (less up to $100,000 of interest to pay winding up and dissolution expenses) divided by the number of the then-outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and its board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii), to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.
The Sponsor and each member of the management team have entered into an agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their Founder Shares; (ii) waive their redemption rights with respect to their Founder Shares and public shares in connection with a shareholder vote to approve an amendment to the Company’s amended and restated memorandum and articles of association (A) that would modify the substance or timing of the Company’s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the public shares if the Company does not complete its initial Business Combination within 15 months from the closing of the Public Offering (or up to 21 months if we extend the time to complete a business combination) or (B) with respect to any other provision relating to the rights of holders of the Company’s Class A ordinary shares and (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to consummate an initial business combination within Combination Period.
The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company (other than the Company’s independent registered public accounting firm), or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per public share due to reductions in the value of the Trust Account, in each case net of the interest that may be withdrawn to pay the Company’s income tax obligations, provided that such liability will not apply to any claims
by a third party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriters of the Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. However, the Company has not asked the Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believe that the sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure you that the Sponsor would be able to satisfy those obligations. None of the Company’s officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses.
COVID-19
Pandemic
In March 2020, the World Health Organization characterized the outbreak of the novel strain of coronavirus, specifically identified as
COVID-19,
as a global pandemic. This has resulted in governments enacting emergency measures to combat the spread of the virus. These measures, which include the implementation of travel bans, self-imposed quarantine periods and social distancing, have caused material disruption to business, resulting in a global economic slowdown. Equity markets have experienced significant volatility and weakness and the governments and central banks have reacted with significant monetary and fiscal interventions designed to stabilize economic conditions.
The current challenging economic climate may lead to adverse changes in cash flows, working capital levels and/or debt balances, which may also have a direct impact on the Company’s operating results and financial position in the future. The ultimate duration and magnitude of the impact and the efficacy of government interventions on the economy and the financial effect on the Company is not known at this time. The extent of such impact will depend on future developments, which are highly uncertain and not in the Company’s control, including new information which may emerge concerning the spread and severity of
COVID-19
and actions taken to address its impact, among others. The repercussions of this health crisis could have a material adverse effect on the Company’s business, financial condition, liquidity and operating results.
In response to
COVID-19,
the Company has implemented working practices to address potential impacts to its operations, employees and customers, and will take further measures in the future if and as required. At present, we do not believe there has been any appreciable impact on the Company specifically associated with
COVID-19.
Liquidity and Capital Resources
The Company’s liquidity needs prior to the consummation of the Public Offering had been satisfied through a payment from the Sponsor of $25,000 to cover certain offering costs in consideration for the Founder Shares and the loan under an unsecured promissory note from the Sponsor of $262,268 (See Note 5). Subsequent to the consummation of the Public Offering, the Company expects that it will need additional capital to satisfy its liquidity needs beyond the net proceeds from the consummation of the Public Offering and the proceeds held outside of the Trust Account for paying existing accounts payable, identifying and evaluating prospective business combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the initial Business Combination. In order to finance transaction costs in connection with a Business Combination, the Sponsor, an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans. As of September 30,2022, there were no amounts outstanding under any Working Capital Loans.
Going Concern
As of September 30, 2022, the Company had $890,273 in cash held outside of the Trust Account and owes $1,089,536 in accrued offering costs and expenses and an additional $285,539 to related parties. The Company anticipates that the cash held outside of the Trust Account as of September 30, 2022 will not be sufficient to allow the Company to operate for at least the next 12 months from the issuance of the financial statements, assuming that a Business Combination is not consummated during that time. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans.
In connection with the Company’s assessment of going concern considerations in accordance with ASC
Subtopic205-40,
“Presentation of Financial Statements – Going Concern”, the Company has until January 22, 2023 (unless extended) to consummate a Business Combination. If a Business Combination is not consummated by this date and an extension not obtained, there will be a mandatory liquidation and subsequent dissolution of the Company. Although the Company intends to consummate a Business Combination on or before January 22, 2023, it is uncertain whether the Company will be able to consummate a Business Combination by this time. Management has determined that the mandatory liquidation, should a Business Combination not occur, and an extension is not obtained, as well as the potential for us to have insufficient funds available to operate our business prior to a Business Combination, raises substantial doubt about the Company’s ability to continue as a going concern.
Risks and Uncertainties
Management is currently evaluating the impact of theCOVID-19pandemic and has concluded that while it is reasonably possible that the pandemic could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Significant Accounting Policies
Note 2 — Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to
Form 10-Q
and Article 8 of Regulation
S-X
of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.
The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on
Form 10-K,
which contains the initial audited financial statements and notes thereto for the period from April 19, 2021 (inception) to December 31, 2021, as filed with the SEC on April 1, 2022. The interim results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the period ending December 31, 2022 or for any future interim periods.
The Company has until January 22, 2023 (or July 22, 2023 if fully extended) to complete a Business Combination.
 
Emerging Growth Company Status
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents
The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company has $890,273 and $1,323,903 in cash and cash equivalents as of September 30, 2022 and December 31, 2021, respectively.
Marketable Securities Held in Trust Account
Following the closing of the Public Offering on October 22, 2021, an amount of $281,520,000 from the net proceeds of the sale of the Units in the Public Offering and the sale of the Private Placement Warrants were placed in the Trust Account and may be invested only in U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule2a-7under the Investment Company Act which invest only in direct U.S. government treasury obligations. The Trust Account is intended as a holding place for funds pending the earliest to occur of: (i) the completion of the initial Business Combination; (ii) the redemption of any public shares properly submitted in connection with a shareholder vote to amend the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to redeem 100% of the public shares if the Company does not complete the initial Business Combination within 15 months (unless otherwise extended as described in the prospectus relating to the IPO) from the closing of the Public Offering or (B) with respect to any other provision relating to shareholders’ rights or
pre-initial
Business Combination activity; or (iii) absent an initial Business Combination within 15 months (unless otherwise extended) from the closing of the Public Offering, the return of the funds held in the Trust Account to the public shareholders as part of redemption of the public shares.
Offering Costs Associated with Initial Public Offering
The Company complies with the requirements of
ASC340-10-S99-1and
SEC Staff Accounting Bulletin Topic 5A—“Expenses of Offering”. Offering costs consist of legal, accounting, underwriting and other costs incurred through the balance sheet date that are related to the Public Offering. Offering costs are charged against the carrying value of the ordinary shares or the statement of operations based on the relative value of the ordinary shares and the Public Warrants to the proceeds received from the Units sold upon the completion of the Public Offering. Offering costs amounted to $16,138,202 and of this, $15,428,121 was charged to temporary equity and $710,081 was deemed allocable to the warrants and charged to expense upon the completion of the IPO.
Fair Value of Financial Instruments
The fair value of the Company’s assets and liabilities, which qualify as financial instruments under FASB ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheets, primarily due to its short-term nature.
 
Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The Company’s financial instruments are classified as either Level 1, Level 2 or Level 3. These tiers include:
 
   
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
 
   
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
 
   
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
Derivative Financial Instruments
The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. The Company’s derivative instruments are recorded at fair value on the balance sheet with changes in the fair value reported in the statement of operations. Derivative assets and liabilities are classified on the balance sheets as current or
non-current
based on whether or not
net-cash
settlement or conversion of the instrument could be required within 12 months of the balance sheet date.
Warrant Liability
The Company accounts for the Public and Private Placement warrants issued in connection with the Public Offering in accordance with the guidance contained in ASC815-40and ASC 480,
Distinguishing Liabilities from Equity.
Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, the Company will classify each warrant as a liability at its fair value. This liability is subject tore-measurement at each balance sheet date. With each such
re-measurement,
the warrant liability will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operations.
Net Income (Loss) Per Ordinary Share
The Company complies with accounting and disclosure requirements of ASC Topic 260, “Earnings Per Share.” The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Income and losses are shared pro rata between the two classes of shares. Net income (loss) per ordinary share is calculated by dividing the net income (loss) by the weighted average ordinary shares outstanding for the respective period. Net loss for the period from inception to IPO was allocated fully to Class B ordinary shares. With respect to the accretion of Class A ordinary shares subject to possible redemption, the Company treated accretion in the same manner as a dividend, paid to the shareholder in the calculation of the net income (loss) per ordinary share.
The earnings per share presented in the Statement of Operations is based on the following:
 
    
Three Months
Ended
September 30,
2022
    
Nine
Months Ended
September 30,
2022
    
Three Months
Ended
September 30,
2021
    
For the
Period from
April 19, 2021
(Inception)
through
September 30,
2021
 
Net income (loss)
   $ 4,262,070      $ 11,637,242      $ (1,690    $ (15,393
Accretion of temporary equity to redemption value
     (1,245,745      (1,632,690      —          —    
    
 
 
    
 
 
    
 
 
    
 
 
 
Net income (loss) including accretion of temporary equity to redemption value
   $ 3,016,325      $ 10,004,552      $ (1,690    $ (15,393
    
 
 
    
 
 
    
 
 
    
 
 
 
 
    
Three Months Ended
September 30, 2022
    
Nine Months Ended
September 30, 2022
 
    
Class A
    
Class B
    
Class A
    
Class B
 
Basic and diluted net income per share:
                                   
Numerator:
                                   
Allocation of net income including accretion of temporary equity
   $ 2,413,060        603,265      $ 8,003,642      $ 2,000,910  
Allocation of accretion of temporary equity to redemption value
     1,245,745        —          1,632,690        —    
Allocation of income
   $ 3,658,805        603,265      $ 9,636,332      $ 2,000,910  
    
 
 
    
 
 
    
 
 
    
 
 
 
Denominator:
                                   
Weighted-average shares outstanding
     27,600,000        6,900,000        27,600,000        6,900,000  
Basic and diluted net income per share
   $ 0.13      $ 0.09      $ 0.35      $ 0.29  
 
    
Three Months Ended
September 30, 2021
    
For the Period from
April 19, 2021 (Inception) through
September 30, 2021
 
    
Class A
    
Class B
    
Class A
    
Class B
 
Basic and diluted net loss per share:
                                   
Numerator:
                                   
Allocation of net loss including accretion of temporary equity
   $ —          (1,690    $ —        $ (15,393
Allocation of accretion of temporary equity to redemption value
     —          —          —          —    
Allocation of loss
   $ —          (1,690    $ —        $ (15,393
    
 
 
    
 
 
    
 
 
    
 
 
 
Denominator:
                                   
Weighted-average shares outstanding
     —          6,900,000        —          6,900,000  
Basic and diluted net loss per share
   $ —        $ (0.00    $ —        $ (0.00
Net income (loss) per share is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period, excluding ordinary shares forfeited. The Company has not considered the effect of the 27,840,000 ordinary shares issuable upon exercise of the Public Warrants and Private Placement Warrants in the calculation of diluted loss per share, since the exercise of such warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive.
Class A Ordinary Shares Subject to Possible Redemption
The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholder’s equity. The Company’s Class A ordinary shares sold in the IPO feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events.
The Company has made a policy election in accordance with
ASC480-10-S99-3A
and will recognize changes in redemption value in additional
paid-in
capital (or accumulated deficit in the absence of additional
paid-in
capital) immediately as they occur. The Company recorded accretion of $1,245,745 and $1,634,827, and $33,092,121 in accumulated deficit for the three and nine months ended September 30, 2022 and the period from April 19, 2021 (inception) through December 31, 2021, respectively.
Income Taxes
The Company accounts for income taxes under FASB ASC 740, “Income Taxes” (“ASC 740”).
ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.
FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of September 30, 2022 and December 31, 2021.
The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statements. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of September 30, 2022 and December 31, 2021, there were no unrecognized tax benefits and no amounts were accrued for the payment of interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.
 
Recent Accounting Pronouncements
In August 2020, the FASB issued Accounting Standards Update (“ASU”)
2020-06,
Debt—Debt with Conversion and Other Options (Subtopic
470-20)
and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic
815-40)
(“ASU
2020-06”)
to simplify accounting for certain financial instruments. ASU
2020-06
eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU
2020-06
amends the diluted earnings per share guidance, including the requirement to use the
if-converted
method for all convertible instruments. As a smaller reporting company, ASU
2020-06
is effective January 1, 2024 for fiscal years beginning after December 15, 2023 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that ASU
2020-06
would have on its financial position, results of operations or cash flows. The Company has not adopted this guidance as of September 30, 2022.
Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statement.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Public Offering
9 Months Ended
Sep. 30, 2022
Public Offering  
Public Offering
Note 3 — Public Offering
On October 22, 2021, the Company consummated its IPO of 27,600,000 Units, which included the full exercise of the underwriters’ over-allotment option, at a price of $10.00 per Unit, generating gross proceeds of $276,000,000. Each Unit consists of one Class A ordinary share and
one-half
of one redeemable warrant (each, a “Public Warrant”). Each whole Public Warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share.
All of the 27,600,000 Class A ordinary shares sold as part of the Units in the IPO contain a redemption feature which allows for the redemption of such public shares in connection with the Company’s liquidation, if there is a shareholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s certificate of incorporation. In accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity” and with the SEC and its staff’s guidance on redeemable equity instruments, which has been codified in
ASC480-10-S99,
redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity.
The Class A ordinary shares is subject to SEC and its staff’s guidance on redeemable equity instruments, which has been codified in
ASC480-10-S99.If
it is probable that the equity instrument will become redeemable, the Company has the option to either accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or to recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company recognizes changes in redemption value immediately as they occur. Immediately upon the closing of the IPO, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional
paid-in
capital and accumulated deficit.
As of September 30, 2022 and December 31, 2021, the ordinary shares reflected on the balance sheets are reconciled in the following table:

 

Gross proceeds
   $ 276,000,000  
Less:
        
Proceeds allocated to Public Warrants
     (12,144,000
Class A ordinary share issuance costs
     (15,428,121
Plus:
        
Accretion of carrying value to redemption value
     33,092,121  
    
 
 
 
Class A ordinary shares subject to possible redemption as of December 31,
2021
  
$
281,520,000  
Accretion of carrying value to redemption value
     389,082  
    
 
 
 
Class A ordinary shares subject to possible redemption as of June 30, 2022
  
$
281,909,082  
Accretion of carrying value to redemption value
     1,245,745  
    
 
 
 
Class A ordinary shares subject to possible redemption as of September 30,
2022
  
$
283,154,827
 
    
 
 
 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Private Placement
9 Months Ended
Sep. 30, 2022
Private Placement.  
Private Placement
Note 4 — Private Placement
The Sponsor purchased 11,240,000 warrants, which included the underwriters’ exercise of the full over-allotment option (the “Private Placement Warrants”), each exercisable to purchase one Class A ordinary share at $11.50 per share, subject to adjustment, at a price of $1.00 per warrant and $11,240,000 in the aggregate, in a private placement that occurred concurrently with the closing of the Public Offering. Additionally, Salient Capital Advisors, LLC, acting in its capacity as investment advisor on behalf of one or more client accounts (“Salient Client Accounts”) purchased 2,800,000 warrants on the same terms as the Sponsor in a private placement that occurred concurrently with the closing of the Public Offering. The private placement resulted in an aggregate of 14,040,000 warrants and $14,040,000 in proceeds, a portion of which was placed in the Trust account.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Party Transactions
9 Months Ended
Sep. 30, 2022
Related Party Transactions [Abstract]  
Related Party Transactions
Note 5 — Related Party Transactions
Founder Shares
On April 27, 2021, the Sponsor paid $25,000, or approximately $0.004 per share, to cover certain offering costs in consideration for 5,750,000 Class B ordinary shares, par value $0.0001. In September 2021, certain shareholders surrendered, for no consideration, an aggregate of 1,437,500 Class B ordinary shares, leaving 5,750,000 Founder Shares outstanding. In October 2021, a share dividend was issued which resulted in 6,900,000 Founder Shares outstanding; of which 900,000 were subject to surrender if the underwriter had not exercised their full over-allotment option. All share values and related amounts have been retroactively restated to reflect the dividend.
On September 10, 2021, the Sponsor transferred 115,000 Class B ordinary shares to each of its three independent directors. Additionally, on September 27, 2021, the Company sold 831,393 Class B ordinary shares to the Salient Client Accounts at a price of approximately $0.004 per share. As of September 30, 2022, the Sponsor held 4,573,607 Class B ordinary shares.
 
The initial shareholders and each member of the management team have entered into an agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of the Business Combination; (ii) waive their redemption rights with respect to their Founder Shares and Public Shares in connection with a shareholder vote to approve an amendment to the amended and restated memorandum and articles of association (A) that would modify the substance or timing of the Company’s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the Business Combination or to redeem 100% of the Company’s public shares if it does not complete the Business Combination within 15 months from the closing of the Public Offering (or up to 21 months, if extended) to complete a Business Combination or (B) with respect to any other provision relating to the rights of holders of the Class A ordinary shares and (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to consummate an Business Combination within 15 months from the closing of this offering (or up to 21 months if extended) to complete a Business Combination as described in the prospectus (although they will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares they hold if the Company fails to complete the Business Combination within the prescribed time frame). If the Company seeks shareholder approval, it will complete the Business Combination only if it is approved by an ordinary resolution or such higher approval threshold as may be required by Cayman Islands law and pursuant to the amended and restated memorandum and articles of association. In such case, the initial shareholders and each member of the management team have agreed to vote their Founder Shares and Public Shares in favor of the Business Combination.

Promissory Note — Related Party
On April 27, 2021, the Sponsor agreed to loan the Company up to $300,000 to be used for a portion of the expenses of the Public Offering. The Company borrowed a total of $262,268. This loan was
non-interest
bearing, unsecured and due at the earlier of December 31, 2021 or the closing of the Public Offering. The loan was to be repaid upon the closing of the Public Offering out of the offering proceeds not held in the Trust Account. In connection with the closing of the Public Offering, the Company paid down $90,922 of the outstanding balance. As of September 30, 2022 and December 31, 2021, the Company had $171,346 outstanding under the promissory note.
Working Capital Loans
In order to finance transaction costs in connection with an intended Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes the initial Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the Trust Account. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital Loans. Up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity at a price of $1.00 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. As of September 30, 2022 and December 31, 2021, the Company had no borrowings under the Working Capital Loans.
Office Space, Secretarial and Administrative Services
Commencing on the date that the Company’s securities are first listed on the NASDAQ through the earlier of consummation of the initial Business Combination and the liquidation, the Company will pay the Sponsor a total of $10,000 per month for office space, utilities, secretarial support and administrative services. As of September 30, 2022 and December 31, 2021, the Company had incurred $90,000 and $24,193, respectively pursuant to this agreement, which was accrued in “Due to related party”.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Prepaid Expenses
9 Months Ended
Sep. 30, 2022
Prepaid Expense, Current [Abstract]  
Prepaid Expenses
Note 6 — Prepaid Expenses
The Company’s prepaid expenses as of September 30, 2022 and December 31, 2021 primarily consisted of insurance.
 
    
September 30, 2022
    
December 31, 2021
 
    
Current
    
Current
    
Non-current
 
Prepaid Insurance
   $ 159,382      $ 528,861      $ 26,081  
Other Prepaid Items
     14,875        21,573        —    
    
 
 
    
 
 
    
 
 
 
    
$
174,257
 
  
$
550,434
 
  
$
26,081
 
    
 
 
    
 
 
    
 
 
 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments & Contingencies
9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments & Contingencies
Note 7 — Commitments & Contingencies
Registration and Shareholder Rights
The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) will be entitled to registration rights pursuant to a registration and expected shareholder rights agreement signed at the closing of our Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s completion of its initial Business Combination. However, the registration and expected shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable
lock-up
period, which occurs (i) in the case of the Founder Shares, and (ii) in the case of the private placement warrants and the respective Class A ordinary shares issuable upon exercise of the private placement warrants, 30 days after the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Working Capital Loans and warrants that may be issued upon conversion of Working Capital Loans) will be entitled to registration rights pursuant to a registration and expected shareholder rights agreement signed at the closing of our Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company’s register such securities.
 
In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of its initial Business Combination. However, the registration and expected shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lockup period, which occurs (i) in the case of the Founder Shares, as described in the following paragraph, and (ii) in the case of the Private Placement Warrants and the respective Class A ordinary shares underlying such warrants, 30 days after the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
Except as described herein, the Sponsor and its directors and executive officers have agreed not to transfer, assign or sell any of their Founder Shares until the earliest of (A) one year after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the closing price of the Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any30-tradingday period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company complete a liquidation, merger, share exchange or other similar transaction that results in all of the public shareholders having the right to exchange their ordinary shares for cash, securities or other property. Any permitted transferees would be subject to the same restrictions and other agreements of the Sponsor and its directors and executive officers with respect to any founder shares. Any permitted transferees will be subject to the same restrictions and other agreements of the Sponsor with respect to any Founder Shares. The Company refers to such transfer restrictions throughout the Public Offering as the lock- up.
In addition, pursuant to the registration and expected shareholder rights agreement, the Sponsor, upon and following consummation of an initial Business Combination, will be entitled to nominate three individuals for election to the board of directors, as long as the Sponsor holds any securities covered by the registration and expected shareholder rights agreement.
Underwriting Agreement
The Company granted the underwriters
a45-dayoption
to purchase up to 3,600,000 additional Units to cover over-allotments, if any, at the Public Offering price less the underwriting discounts and commissions. The underwriters exercised the full over-allotment at the consummation of the Public Offering on October 22, 2021.
The underwriters earned an underwriting discount of two percent (2%) of the gross proceeds of the Public Offering, or $5,520,000, which was paid in cash at closing of the offering.
Additionally, the underwriters are entitled to a deferred underwriting discount of 3.5% of the gross proceeds of the Public Offering upon the completion of the Company’s initial Business Combination.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Warrant Liabilities
9 Months Ended
Sep. 30, 2022
Warrant Liabilities  
Warrant Liabilities
Note 8 — Warrant Liabilities
The Company accounts for the 27,840,000 warrants issued in connection with the Public Offering (13,800,000 Public Warrants and 14,040,000 Private Placement Warrants) in accordance with the guidance contained in
ASC815-40.
Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, the Company will classify each warrant as a liability at its fair value. This liability is subject to remeasurement at each balance sheet date.
With each such remeasurement, the warrant liability will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operation.
Public Warrants
Each whole warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment as discussed herein. In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading
price of the Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described adjacent to “Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described adjacent to the caption “Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price.
The warrants will become exercisable 30 days after the completion of the Company’s initial Business Combination and will expire five years after the completion of the Company’s initial Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.
The Company has agreed that as soon as practicable, but in no event later than 20 business days after the closing of the initial Business Combination, it will use its commercially reasonable efforts to file with the SEC a post-effective amendment to the registration statement of which this prospectus forms a part or a new registration statement for the registration, under the Securities Act, of the Class A ordinary shares issuable upon exercise of the warrants, and the Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of the initial Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; provided that if the Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elect, it will not be required to file or maintain in effect a registration statement, but the Company will use its commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. The “fair market value” as used in this paragraph shall mean the volume weighted average price of the Class A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption, but it will use its commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. In such event, each holder would pay the exercise price by surrendering the warrants for that number of Class A ordinary shares equal to the lesser of (A) the quotient obtained by dividing (x) the product of the number of Class A ordinary shares underlying the warrants, multiplied by the excess of the “fair market value” (defined below) less the exercise price of the warrants by (y) the fair market value and (B) 0.361. The “fair market value” as used in this paragraph shall mean the volume weighted average price of the Class A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent.
Redemption of warrants when the price per Class
 A ordinary share equals or exceeds $18.00
. Once the warrants become exercisable, the Company may redeem not less than all of the outstanding warrants (except as described herein with respect to the Private Placement Warrants):
 
   
in whole and not in part;
 
   
at a price of $0.01 per warrant;
 
   
upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and
 
   
if, and only if, the closing price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “Description of Securities—Warrants—Public Shareholders’ Warrants—Anti-dilution Adjustments”) for any 20 trading days within
a30-tradingday
period ending three trading days before the Company sends the notice of redemption to the warrant holders.
 
Redemption of warrants when the price per Class
 A ordinary share equals or exceeds $10.00
. Once the warrants become exercisable, the Company may redeem not less than all of the outstanding warrants:
 
   
in whole and not in part;
 
   
at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption; and
 
   
if, and only if, the closing price of the Class A ordinary shares equals or exceeds $10.00 per public share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “Description of Securities—Warrants—Public Shareholders’ Warrants—Anti-dilution Adjustments”) for any 20 trading days within the30-tradingday period ending three trading days before the Company sends the notice of redemption to the warrant holders;
Private Warrants
If the Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the warrants included in the units sold in the Public Offering. Any amendment to the terms of the Private Placement Warrants or any provision of the warrant agreement with respect to the Private Placement Warrants will require a vote of holders of at least 50% of the number of the then outstanding Private Placement Warrants.
The accounting treatment of derivative financial instruments requires that the Company record a derivative liability upon the closing of the IPO. Accordingly, the Company has classified each warrant as a liability at its fair value and the warrants were allocated a portion of the proceeds from the issuance of the Units equal to its fair value determined by a Black Scholes model. This liability is subject tore-measurement at each balance sheet date. With each such
re-measurement,
the warrant liability will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operations. The Company will reassess the classification at each balance sheet date. If the classification changes as a result of events during the period, the warrants will be reclassified as of the date of the event that causes the reclassification. As such, the Company recorded$24,920,400 of warrant liability upon issuance as of October 22,2021. For the period from April 19,2021(inception) through December 31,2021, the Company recorded a change in the fair value of the warrant liabilities in the amount of $10,944,240 on the statement of operations, resulting in warrant liabilities of $13,976,160 as of December 31,2021 on the balance sheet. For the nine months ended September 30,2022, the Company recorded a change in the fair value of the warrant liabilities in the amount of $11,608,560 on the statement of operations, resulting in warrant liabilities of $2,367,600 as of September 30,2022 on the balance sheet.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Recurring Fair Value Measurements
9 Months Ended
Sep. 30, 2022
Derivative Instrument Detail [Abstract]  
Recurring Fair Value Measurements
Note 9 — Recurring Fair Value Measurements
As of September 30, 2022 and December 31, 2021, investments held in the Trust Account consisted of U.S. Money Market Funds. Fair values of these investments are determined by Level 1 inputs utilizing quoted prices (unadjusted) in active markets for identical assets.
The Company accounts for the Public Warrants and Private Placement Warrants as liabilities in accordance with the guidance contained in
ASC 815-40,
Derivatives and Hedging—Contracts in Entity’s Own Equity. Because the Company does not control the occurrence of events, such as a tender offer or exchange, that may trigger cash settlement of the warrants where not all of the shareholders also receive cash, the warrants do not meet the criteria for equity treatment thereunder, as such, the warrants must be recorded as a derivative liability.
Additionally, certain adjustments to the settlement amount of the Private Placement Warrants are based on a variable that is not an input to the fair value of a
“fixed-for-fixed”
option as defined under
ASC815-40,
and thus the Private Placement Warrants are not considered indexed to the Company’s own share and not eligible for an exception from derivative accounting.
The Company’s Public Warrants are traded on the Nasdaq. As such, the Public Warrant valuation is based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. The fair value of the Public Warrant liability is classified within Level 1 of the fair value hierarchy.
At December 31, 2021, the Company’s Private Warrant liability is based on a valuation model utilizing management judgment and pricing inputs from observable and unobservable markets with less volume and transaction frequency than active markets. Significant deviations from these estimates and inputs could result in a material change in fair value. The fair value of the Private Warrant liability is classified within Level 3 of the fair value hierarchy.
At September 30, 2021, the Company considers the Private Warrants to be economically equivalent to the Public Warrants. As such, the valuation of the Private Warrants was used to value the Private Warrants. The fair value of the Private Warrant liability is classified within Level 2 of the fair value hierarchy.
The following tables presents fair value information as of September 30, 2022 and December 31, 2021 of the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value.
 
September 30, 2022
  
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
                                   
Marketable securities held in trust account
   $ 283,154,827      $ —        $ —        $ 283,154,827  
Liabilities:
                                   
Public Warrants
   $ 1,104,000      $ —        $ —        $ 1,104,000  
Private Warrants
     —          1,263,600        —          1,263,600  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total liabilities
   $ 1,104,000      $ 1,263,600      $ —        $ 2,367,600  
    
 
 
    
 
 
    
 
 
    
 
 
 
         
December 31, 2021
  
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
                                   
Marketable securities held in trust account
   $ 281,522,137      $ —        $ —        $ 281,522,137  
Liabilities:
                                   
Public Warrants
   $ 6,900,000      $ —        $ —        $ 6,900,000  
Private Warrants
     —          —          7,076,160        7,076,160  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total liabilities
   $ 6,900,000      $ —        $ 7,076,160      $ 13,976,160  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
The following table provides a summary of the changes in the fair value of the Company’s Level 3 financial instruments that are measured at fair value on a recurring basis:

 
 
  
Private
Placement
Warrants
 
  
Public
Warrants
 
  
Warrant
Liabilities
 
Warrant liability – initial measurement
   $ 12,776,400      $ 12,144,000      $ 24,920,400  
Change in fair value of warrant liabilities
     (5,700,240      (5,244,000      (10,944,240
Transfer to Level 1
     —          (6,900,000      (6,900,000
    
 
 
    
 
 
    
 
 
 
Warrant liabilities at December 31, 2021
  
$
7,076,160     
$
—       
$
7,076,160  
Change in fair value of warrant liabilities
     (3,285,360      —          (3,285,360
    
 
 
    
 
 
    
 
 
 
Warrant liabilities at March 31, 2022
  
$
3,790,800     
$
—       
$
3,790,800  
Change in fair value of warrant liabilities
     (561,600      —          (561,600
    
 
 
    
 
 
    
 
 
 
Warrant liabilities at June 30, 2022
  
$
3,229,200     
$
—       
$
3,229,200  
Change in fair value of warrant
liabilities (1)
     (1,965,600      —          (1,965,600 )
Transfer to Level 2
 
 
 (1,263,600
)
 
 
 
 
 
 (1,263,600
)
    
 
 
    
 
 
    
 
 
 
Warrant liabilities at September 30, 2022
   $ —        $ —        $ —    
    
 
 
    
 
 
    
 
 
 
 
(1)
Assumes the Private Placement Warrants were transferred on September 30, 2022.
Transfers to/from Levels 1, 2 and 3 are recognized at the end of the reporting period. The estimated fair value of the Public Warrants transferred from a Level 3 measurement to a Level 1 fair value measurement in September 2021 after the Public Warrants were separately listed and traded. The estimated fair value of the Private Placement Warrants transferred from a Level 3 measurement to a Level 2 fair value measurement in September 2022 due to the use of an observable market quote for a similar asset in an active market.
The estimated fair value of the Private Placement Warrants at December 31, 2021 was determined using a Black Scholes model with assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its ordinary shares based on projected volatility of comparable public companies that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury
zero-coupon
yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is based on management assumptions regarding the timing and likelihood of completing a business combination. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.
The following table presents quantitative information about the Company’s Level 3 liabilities that are measured at fair value on a recurring basis as of December 31, 2021.
 
    
December 31, 2021
 
Exercise price
   $ 11.50  
Share price
   $ 9.92  
Risk-free rate
     1.32
Expected volatility
     8.3
Term (years)
     5.81  
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Shareholder's Equity (Deficit)
9 Months Ended
Sep. 30, 2022
Stockholders' Equity Note [Abstract]  
Shareholder's Equity (Deficit)
Note 10 — Shareholders’ Equity (Deficit)
Preference shares
—The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of September 30, 2022 and December 31, 2021, there were no preference shares issued or outstanding.
Class
 A ordinary shares
—The Company is authorized to issue 250,000,000 Class A ordinary shares with a par value of $0.0001 per share. As of September 30, 2022 and December 31, 2021, there were no Class A ordinary shares issued or outstanding other than the 27,600,000 Class A ordinary shares subject to possible redemption that are accounted for outside of the shareholder’s equity (deficit) section of our balance sheets.
Class
 B ordinary shares
—The Company is authorized to issue 25,000,000 Class B ordinary shares with a par value of $0.0001 per share. Holders are entitled to one vote for each share of Class B ordinary shares. As of September 30, 2022 and December 31, 2021, there were 6,900,000 Class B ordinary shares issued and outstanding. Of the 6,900,000 Class B ordinary shares, up to 900,000 shares were subject to forfeiture to the Company for no consideration to the extent that the underwriters’ over-allotment option was not exercised in full or in part, so that the initial shareholders will collectively own 20% of the Company’s issued and outstanding ordinary shares after the Public Offering. The underwriters exercised their full over-allotment on October 22, 2021.
Holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company’s shareholders except as required by law. Unless specified in the Company’s amended and restated memorandum and articles of association, or as required by applicable provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of the Company’s ordinary shares that are voted is required to approve any such matter voted on by its shareholders.
The Class B ordinary shares will automatically convert into Class A ordinary shares (which such Class A ordinary shares delivered upon conversion will not have any redemption rights or be entitled to liquidating distributions from the Trust Account if the Company fails to consummate an initial Business Combination) at the time of the initial Business Combination or earlier at the option of the holders thereof at a ratio such that the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an
as-converted
basis, 20% of the sum of (i) the total number of ordinary shares issued and outstanding upon completion of the Public Offering, plus (ii) the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor, any of its affiliates or any members of the Company’s management team upon conversion of Working Capital Loans. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than
one-to-one.
This is different than some other similarly structured blank check companies in which the initial shareholders will only be issued an aggregate of 20% of the total number of shares to be outstanding prior to the initial Business Combination.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to
Form 10-Q
and Article 8 of Regulation
S-X
of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.
The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on
Form 10-K,
which contains the initial audited financial statements and notes thereto for the period from April 19, 2021 (inception) to December 31, 2021, as filed with the SEC on April 1, 2022. The interim results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the period ending December 31, 2022 or for any future interim periods.
The Company has until January 22, 2023 (or July 22, 2023 if fully extended) to complete a Business Combination.
 
Emerging Growth Company Status
Emerging Growth Company Status
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents
Cash and Cash Equivalents
The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company has $890,273 and $1,323,903 in cash and cash equivalents as of September 30, 2022 and December 31, 2021, respectively.
Marketable Securities Held in Trust Account
Marketable Securities Held in Trust Account
Following the closing of the Public Offering on October 22, 2021, an amount of $281,520,000 from the net proceeds of the sale of the Units in the Public Offering and the sale of the Private Placement Warrants were placed in the Trust Account and may be invested only in U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule2a-7under the Investment Company Act which invest only in direct U.S. government treasury obligations. The Trust Account is intended as a holding place for funds pending the earliest to occur of: (i) the completion of the initial Business Combination; (ii) the redemption of any public shares properly submitted in connection with a shareholder vote to amend the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to redeem 100% of the public shares if the Company does not complete the initial Business Combination within 15 months (unless otherwise extended as described in the prospectus relating to the IPO) from the closing of the Public Offering or (B) with respect to any other provision relating to shareholders’ rights or
pre-initial
Business Combination activity; or (iii) absent an initial Business Combination within 15 months (unless otherwise extended) from the closing of the Public Offering, the return of the funds held in the Trust Account to the public shareholders as part of redemption of the public shares.
Offering Costs Associated with Initial Public Offering
Offering Costs Associated with Initial Public Offering
The Company complies with the requirements of
ASC340-10-S99-1and
SEC Staff Accounting Bulletin Topic 5A—“Expenses of Offering”. Offering costs consist of legal, accounting, underwriting and other costs incurred through the balance sheet date that are related to the Public Offering. Offering costs are charged against the carrying value of the ordinary shares or the statement of operations based on the relative value of the ordinary shares and the Public Warrants to the proceeds received from the Units sold upon the completion of the Public Offering. Offering costs amounted to $16,138,202 and of this, $15,428,121 was charged to temporary equity and $710,081 was deemed allocable to the warrants and charged to expense upon the completion of the IPO.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
The fair value of the Company’s assets and liabilities, which qualify as financial instruments under FASB ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheets, primarily due to its short-term nature.
 
Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The Company’s financial instruments are classified as either Level 1, Level 2 or Level 3. These tiers include:
 
   
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
 
   
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
 
   
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
Derivative Financial Instruments
Derivative Financial Instruments
The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. The Company’s derivative instruments are recorded at fair value on the balance sheet with changes in the fair value reported in the statement of operations. Derivative assets and liabilities are classified on the balance sheets as current or
non-current
based on whether or not
net-cash
settlement or conversion of the instrument could be required within 12 months of the balance sheet date.
Warrant Liability
Warrant Liability
The Company accounts for the Public and Private Placement warrants issued in connection with the Public Offering in accordance with the guidance contained in ASC815-40and ASC 480,
Distinguishing Liabilities from Equity.
Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, the Company will classify each warrant as a liability at its fair value. This liability is subject tore-measurement at each balance sheet date. With each such
re-measurement,
the warrant liability will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operations.
Net Income (Loss) Per Ordinary Share
Net Income (Loss) Per Ordinary Share
The Company complies with accounting and disclosure requirements of ASC Topic 260, “Earnings Per Share.” The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Income and losses are shared pro rata between the two classes of shares. Net income (loss) per ordinary share is calculated by dividing the net income (loss) by the weighted average ordinary shares outstanding for the respective period. Net loss for the period from inception to IPO was allocated fully to Class B ordinary shares. With respect to the accretion of Class A ordinary shares subject to possible redemption, the Company treated accretion in the same manner as a dividend, paid to the shareholder in the calculation of the net income (loss) per ordinary share.
The earnings per share presented in the Statement of Operations is based on the following:
 
    
Three Months
Ended
September 30,
2022
    
Nine
Months Ended
September 30,
2022
    
Three Months
Ended
September 30,
2021
    
For the
Period from
April 19, 2021
(Inception)
through
September 30,
2021
 
Net income (loss)
   $ 4,262,070      $ 11,637,242      $ (1,690    $ (15,393
Accretion of temporary equity to redemption value
     (1,245,745      (1,632,690      —          —    
    
 
 
    
 
 
    
 
 
    
 
 
 
Net income (loss) including accretion of temporary equity to redemption value
   $ 3,016,325      $ 10,004,552      $ (1,690    $ (15,393
    
 
 
    
 
 
    
 
 
    
 
 
 
 
    
Three Months Ended
September 30, 2022
    
Nine Months Ended
September 30, 2022
 
    
Class A
    
Class B
    
Class A
    
Class B
 
Basic and diluted net income per share:
                                   
Numerator:
                                   
Allocation of net income including accretion of temporary equity
   $ 2,413,060        603,265      $ 8,003,642      $ 2,000,910  
Allocation of accretion of temporary equity to redemption value
     1,245,745        —          1,632,690        —    
Allocation of income
   $ 3,658,805        603,265      $ 9,636,332      $ 2,000,910  
    
 
 
    
 
 
    
 
 
    
 
 
 
Denominator:
                                   
Weighted-average shares outstanding
     27,600,000        6,900,000        27,600,000        6,900,000  
Basic and diluted net income per share
   $ 0.13      $ 0.09      $ 0.35      $ 0.29  
 
    
Three Months Ended
September 30, 2021
    
For the Period from
April 19, 2021 (Inception) through
September 30, 2021
 
    
Class A
    
Class B
    
Class A
    
Class B
 
Basic and diluted net loss per share:
                                   
Numerator:
                                   
Allocation of net loss including accretion of temporary equity
   $ —          (1,690    $ —        $ (15,393
Allocation of accretion of temporary equity to redemption value
     —          —          —          —    
Allocation of loss
   $ —          (1,690    $ —        $ (15,393
    
 
 
    
 
 
    
 
 
    
 
 
 
Denominator:
                                   
Weighted-average shares outstanding
     —          6,900,000        —          6,900,000  
Basic and diluted net loss per share
   $ —        $ (0.00    $ —        $ (0.00
Net income (loss) per share is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period, excluding ordinary shares forfeited. The Company has not considered the effect of the 27,840,000 ordinary shares issuable upon exercise of the Public Warrants and Private Placement Warrants in the calculation of diluted loss per share, since the exercise of such warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive.
Class A Ordinary Shares Subject to Possible Redemption
Class A Ordinary Shares Subject to Possible Redemption
The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholder’s equity. The Company’s Class A ordinary shares sold in the IPO feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events.
The Company has made a policy election in accordance with
ASC480-10-S99-3A
and will recognize changes in redemption value in additional
paid-in
capital (or accumulated deficit in the absence of additional
paid-in
capital) immediately as they occur. The Company recorded accretion of $1,245,745 and $1,634,827, and $33,092,121 in accumulated deficit for the three and nine months ended September 30, 2022 and the period from April 19, 2021 (inception) through December 31, 2021, respectively.
Income Taxes
Income Taxes
The Company accounts for income taxes under FASB ASC 740, “Income Taxes” (“ASC 740”).
ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.
FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of September 30, 2022 and December 31, 2021.
The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statements. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of September 30, 2022 and December 31, 2021, there were no unrecognized tax benefits and no amounts were accrued for the payment of interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.
 
Recent Accounting Pronouncements
Recent Accounting Pronouncements
In August 2020, the FASB issued Accounting Standards Update (“ASU”)
2020-06,
Debt—Debt with Conversion and Other Options (Subtopic
470-20)
and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic
815-40)
(“ASU
2020-06”)
to simplify accounting for certain financial instruments. ASU
2020-06
eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU
2020-06
amends the diluted earnings per share guidance, including the requirement to use the
if-converted
method for all convertible instruments. As a smaller reporting company, ASU
2020-06
is effective January 1, 2024 for fiscal years beginning after December 15, 2023 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that ASU
2020-06
would have on its financial position, results of operations or cash flows. The Company has not adopted this guidance as of September 30, 2022.
Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statement.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Schedule of compute basic and diluted net income per share
The earnings per share presented in the Statement of Operations is based on the following:
 
    
Three Months
Ended
September 30,
2022
    
Nine
Months Ended
September 30,
2022
    
Three Months
Ended
September 30,
2021
    
For the
Period from
April 19, 2021
(Inception)
through
September 30,
2021
 
Net income (loss)
   $ 4,262,070      $ 11,637,242      $ (1,690    $ (15,393
Accretion of temporary equity to redemption value
     (1,245,745      (1,632,690      —          —    
    
 
 
    
 
 
    
 
 
    
 
 
 
Net income (loss) including accretion of temporary equity to redemption value
   $ 3,016,325      $ 10,004,552      $ (1,690    $ (15,393
    
 
 
    
 
 
    
 
 
    
 
 
 
 
    
Three Months Ended
September 30, 2022
    
Nine Months Ended
September 30, 2022
 
    
Class A
    
Class B
    
Class A
    
Class B
 
Basic and diluted net income per share:
                                   
Numerator:
                                   
Allocation of net income including accretion of temporary equity
   $ 2,413,060        603,265      $ 8,003,642      $ 2,000,910  
Allocation of accretion of temporary equity to redemption value
     1,245,745        —          1,632,690        —    
Allocation of income
   $ 3,658,805        603,265      $ 9,636,332      $ 2,000,910  
    
 
 
    
 
 
    
 
 
    
 
 
 
Denominator:
                                   
Weighted-average shares outstanding
     27,600,000        6,900,000        27,600,000        6,900,000  
Basic and diluted net income per share
   $ 0.13      $ 0.09      $ 0.35      $ 0.29  
 
    
Three Months Ended
September 30, 2021
    
For the Period from
April 19, 2021 (Inception) through
September 30, 2021
 
    
Class A
    
Class B
    
Class A
    
Class B
 
Basic and diluted net loss per share:
                                   
Numerator:
                                   
Allocation of net loss including accretion of temporary equity
   $ —          (1,690    $ —        $ (15,393
Allocation of accretion of temporary equity to redemption value
     —          —          —          —    
Allocation of loss
   $ —          (1,690    $ —        $ (15,393
    
 
 
    
 
 
    
 
 
    
 
 
 
Denominator:
                                   
Weighted-average shares outstanding
     —          6,900,000        —          6,900,000  
Basic and diluted net loss per share
   $ —        $ (0.00    $ —        $ (0.00
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Public Offering (Tables)
9 Months Ended
Sep. 30, 2022
Public Offering  
Summary of ordinary shares reflected on the balance sheet
As of September 30, 2022 and December 31, 2021, the ordinary shares reflected on the balance sheets are reconciled in the following table:

 

Gross proceeds
   $ 276,000,000  
Less:
        
Proceeds allocated to Public Warrants
     (12,144,000
Class A ordinary share issuance costs
     (15,428,121
Plus:
        
Accretion of carrying value to redemption value
     33,092,121  
    
 
 
 
Class A ordinary shares subject to possible redemption as of December 31,
2021
  
$
281,520,000  
Accretion of carrying value to redemption value
     389,082  
    
 
 
 
Class A ordinary shares subject to possible redemption as of June 30, 2022
  
$
281,909,082  
Accretion of carrying value to redemption value
     1,245,745  
    
 
 
 
Class A ordinary shares subject to possible redemption as of September 30,
2022
  
$
283,154,827
 
    
 
 
 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Prepaid Expenses (Tables)
9 Months Ended
Sep. 30, 2022
Prepaid Expense, Current [Abstract]  
Summary of Prepaid expenses
The Company’s prepaid expenses as of September 30, 2022 and December 31, 2021 primarily consisted of insurance.
 
    
September 30, 2022
    
December 31, 2021
 
    
Current
    
Current
    
Non-current
 
Prepaid Insurance
   $ 159,382      $ 528,861      $ 26,081  
Other Prepaid Items
     14,875        21,573        —    
    
 
 
    
 
 
    
 
 
 
    
$
174,257
 
  
$
550,434
 
  
$
26,081
 
    
 
 
    
 
 
    
 
 
 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Recurring Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2022
Derivative Instrument Detail [Abstract]  
Schedule of fair value hierarchy for liabilities measured at fair value on recurring basis
The following tables presents fair value information as of September 30, 2022 and December 31, 2021 of the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value.
 
September 30, 2022
  
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
                                   
Marketable securities held in trust account
   $ 283,154,827      $ —        $ —        $ 283,154,827  
Liabilities:
                                   
Public Warrants
   $ 1,104,000      $ —        $ —        $ 1,104,000  
Private Warrants
     —          1,263,600        —          1,263,600  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total liabilities
   $ 1,104,000      $ 1,263,600      $ —        $ 2,367,600  
    
 
 
    
 
 
    
 
 
    
 
 
 
         
December 31, 2021
  
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
                                   
Marketable securities held in trust account
   $ 281,522,137      $ —        $ —        $ 281,522,137  
Liabilities:
                                   
Public Warrants
   $ 6,900,000      $ —        $ —        $ 6,900,000  
Private Warrants
     —          —          7,076,160        7,076,160  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total liabilities
   $ 6,900,000      $ —        $ 7,076,160      $ 13,976,160  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
Schedule of change in the fair value of the warrant liabilities
The following table provides a summary of the changes in the fair value of the Company’s Level 3 financial instruments that are measured at fair value on a recurring basis:

 
 
  
Private
Placement
Warrants
 
  
Public
Warrants
 
  
Warrant
Liabilities
 
Warrant liability – initial measurement
   $ 12,776,400      $ 12,144,000      $ 24,920,400  
Change in fair value of warrant liabilities
     (5,700,240      (5,244,000      (10,944,240
Transfer to Level 1
     —          (6,900,000      (6,900,000
    
 
 
    
 
 
    
 
 
 
Warrant liabilities at December 31, 2021
  
$
7,076,160     
$
—       
$
7,076,160  
Change in fair value of warrant liabilities
     (3,285,360      —          (3,285,360
    
 
 
    
 
 
    
 
 
 
Warrant liabilities at March 31, 2022
  
$
3,790,800     
$
—       
$
3,790,800  
Change in fair value of warrant liabilities
     (561,600      —          (561,600
    
 
 
    
 
 
    
 
 
 
Warrant liabilities at June 30, 2022
  
$
3,229,200     
$
—       
$
3,229,200  
Change in fair value of warrant
liabilities (1)
     (1,965,600      —          (1,965,600 )
Transfer to Level 2
 
 
 (1,263,600
)
 
 
 
 
 
 (1,263,600
)
    
 
 
    
 
 
    
 
 
 
Warrant liabilities at September 30, 2022
   $ —        $ —        $ —    
    
 
 
    
 
 
    
 
 
 
 
(1)
Assumes the Private Placement Warrants were transferred on September 30, 2022.
Schedule of quantitative information regarding Level 3 fair value measurements inputs
The following table presents quantitative information about the Company’s Level 3 liabilities that are measured at fair value on a recurring basis as of December 31, 2021.
 
    
December 31, 2021
 
Exercise price
   $ 11.50  
Share price
   $ 9.92  
Risk-free rate
     1.32
Expected volatility
     8.3
Term (years)
     5.81  
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Business Operation (Details) - USD ($)
9 Months Ended
Oct. 22, 2021
Sep. 30, 2022
Dec. 31, 2021
Subsidiary, Sale of Stock [Line Items]      
Shares Issued, Price Per Share   $ 10  
Transaction Costs   $ 16,138,202  
Underwriting fees   5,520,000  
Deferred Offering Cost Non-Current   9,660,000  
Other offering costs   958,202  
Shareholders deficit   15,428,121  
Allocated to the warrants and expense   710,081  
Working Capital Loan   0 $ 0
Aggregate purchase price   25,000  
Net tangible assets   $ 5,000,001  
Condition for future business combination threshold Percentage Ownership   50  
Redemption of shares calculated based on business days prior to consummation of business combination   15 months  
Condition for future business combination threshold Net Tangible Assets   $ 100,000  
Obligation to redeem Public Shares if entity does not complete a Business Combination (as a percent)   100.00%  
Month To Complete Acquisition   15 months  
Cash held outside of the Trust Account   $ 890,273  
Accrued Offering Costs And Expenses   1,089,536  
Due to related party   90,000 $ 24,193
Additional amount owed to related party [Member]      
Subsidiary, Sale of Stock [Line Items]      
Due to related party   $ 285,539  
Working capital loans warrant      
Subsidiary, Sale of Stock [Line Items]      
Price of warrant   $ 1  
Working Capital Loan   $ 0  
IPO [Member]      
Subsidiary, Sale of Stock [Line Items]      
Sale of Units, net of underwriting discounts (in shares) 27,600,000    
Shares Issued, Price Per Share $ 10.2 $ 10  
Proceeds from Issuance Initial Public Offering $ 281,520,000    
Other offering costs 16,138,202    
Shareholders deficit 15,428,121    
Allocated to the warrants and expense $ 710,081    
IPO [Member] | Private Placement Warrants      
Subsidiary, Sale of Stock [Line Items]      
Shares Issued, Price Per Share $ 11.5    
Sale of Private Placement Warrants (in shares) 14,040,000    
Price of warrant $ 1    
IPO [Member] | Public Warrants      
Subsidiary, Sale of Stock [Line Items]      
Shares Issued, Price Per Share   $ 10.2  
Private Placement [Member] | Private Placement Warrants      
Subsidiary, Sale of Stock [Line Items]      
Sale of Private Placement Warrants (in shares)   14,040,000  
Percentage of business combinations aggregate fair market value   80.00%  
Over-Allotment Option [Member]      
Subsidiary, Sale of Stock [Line Items]      
Sale of Units, net of underwriting discounts (in shares)   3,600,000  
Shares Issued, Price Per Share $ 10    
Sponsor      
Subsidiary, Sale of Stock [Line Items]      
Proceeds from Related Party Debt   $ 262,268  
Redemption of shares calculated based on business days prior to consummation of business combination   15 months  
Obligation to redeem Public Shares if entity does not complete a Business Combination (as a percent)   100.00%  
Month To Complete Acquisition   21 months  
Sponsor | Private Placement [Member] | Private Placement Warrants      
Subsidiary, Sale of Stock [Line Items]      
Sale of Private Placement Warrants (in shares)   11,240,000  
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies (Details) - USD ($)
3 Months Ended 6 Months Ended 8 Months Ended 9 Months Ended
Oct. 22, 2021
Sep. 30, 2022
Jun. 30, 2022
Dec. 31, 2021
Sep. 30, 2022
Cash and cash equivalents   $ 890,273   $ 1,323,903 $ 890,273
Offering Cost   958,202     958,202
Shareholders deficit   15,428,121     15,428,121
Allocated to the warrants and expense         $ 710,081
Percentage Obligation To Redeem Public Shares If Entity Does Not Complete A Business Combination         100.00%
Month To Complete Acquisition         15 months
Unrecognized tax benefits   0   0 $ 0
Unrecognized tax benefits accrued for interest and penalties   0   0 $ 0
Anti-dilutive securities attributable to warrants (in shares)         27,840,000
Accretion of carrying value to redemption value   1,245,745 $ 389,082 33,092,121  
IPO [Member]          
Offering Cost $ 16,138,202        
Shareholders deficit 15,428,121        
Allocated to the warrants and expense 710,081        
Proceeds from Issuance Initial Public Offering $ 281,520,000        
Retained Earnings [Member]          
Accretion of carrying value to redemption value   1,245,745   33,092,121 $ 1,634,827
Common Class A [Member] | IPO [Member]          
Unrecognized tax benefits   $ 0   $ 0 $ 0
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies - Reconciliation of Net Loss per Common Share (Details) - USD ($)
3 Months Ended 5 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2021
Sep. 30, 2022
Net income (loss) $ 4,262,070 $ (1,690) $ (15,393) $ 11,637,242
Accretion of temporary equity to redemption value (1,245,745) 0 0 (1,632,690)
Net income (loss) including accretion of temporary equity to redemption value 3,016,325 (1,690) (15,393) 10,004,552
Common Class A [Member]        
Accretion of temporary equity to redemption value 1,245,745 0 0 1,632,690
Net income (loss) including accretion of temporary equity to redemption value 2,413,060 0 0 8,003,642
Allocation of income (loss) $ 3,658,805 $ 0 $ 0 $ 9,636,332
Weighted-average shares outstanding, basic 27,600,000 0 0 27,600,000
Weighted average shares outstanding, diluted 27,600,000 0 0 27,600,000
Basic net income (loss) per share $ 0.13 $ 0 $ 0 $ 0.35
Diluted net income per share $ 0.13 $ 0 $ 0 $ 0.35
Common Class B [Member]        
Net income (loss) including accretion of temporary equity to redemption value $ 603,265 $ (1,690) $ (15,393) $ 2,000,910
Allocation of income (loss) $ 603,265 $ (1,690) $ (15,393) $ 2,000,910
Weighted-average shares outstanding, basic [1] 6,900,000 6,900,000 6,900,000 6,900,000
Weighted average shares outstanding, diluted [1] 6,900,000 6,900,000 6,900,000 6,900,000
Basic net income (loss) per share $ 0.09 $ 0 $ 0 $ 0.29
Diluted net income per share $ 0.09 $ 0 $ 0 $ 0.29
[1] On April 27, 2021, the Sponsor paid $25,000, or approximately $0.004 per share, to cover certain offering costs in consideration for 5,750,000 Class B ordinary shares, par value $0.0001. In September 2021, certain shareholders surrendered, for no consideration, an aggregate of 1,437,500 Class B ordinary shares, leaving 5,750,000 Founder Shares outstanding. In October 2021, a share dividend was issued which resulted in 6,900,000 Founder Shares outstanding; of which 900,000 were subject to surrender if the underwriter had not exercised their full over-allotment option. The underwriters exercised their over-allotment option in full on October 21, 2021. All share values and related amounts have been retroactively restated to reflect the dividend.
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Public Offering (Details) - USD ($)
9 Months Ended
Oct. 22, 2021
Sep. 30, 2022
Subsidiary, Sale of Stock [Line Items]    
Shares Issued, Price Per Share   $ 10
Common Class A [Member]    
Subsidiary, Sale of Stock [Line Items]    
Shares Issued, Price Per Share   10
IPO [Member]    
Subsidiary, Sale of Stock [Line Items]    
Number of units sold 27,600,000  
Shares Issued, Price Per Share $ 10.2 10
IPO [Member] | Public Warrants    
Subsidiary, Sale of Stock [Line Items]    
Shares Issued, Price Per Share   $ 10.2
IPO [Member] | Public Warrants | Common Class A [Member]    
Subsidiary, Sale of Stock [Line Items]    
Number of shares in a unit 1  
Number of warrants in a unit   0.50
Number of shares issuable per warrant 1  
Exercise price of warrants $ 11.5  
Over-Allotment Option [Member]    
Subsidiary, Sale of Stock [Line Items]    
Number of units sold   3,600,000
Shares Issued, Price Per Share $ 10  
Gross proceeds $ 276,000,000  
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Public Offering - Summary of Ordinary Shares Reflected on Balance Sheet (Details) - USD ($)
3 Months Ended 6 Months Ended 8 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Dec. 31, 2021
Public Offering      
Gross proceeds     $ 276,000,000
Proceeds allocated to Public Warrants     (12,144,000)
Class A ordinary share issuance costs     (15,428,121)
Accretion of carrying value to redemption value $ 1,245,745 $ 389,082 33,092,121
Class A ordinary shares subject to possible redemption $ 283,154,827 $ 281,909,082 $ 281,520,000
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Private Placement (Details)
9 Months Ended
Sep. 30, 2022
USD ($)
$ / shares
shares
Over-Allotment Option [Member] | Private Placement Warrants | Common Class A [Member]  
Subsidiary, Sale of Stock [Line Items]  
Price of warrants | $ / shares $ 11.5
Private Placement [Member]  
Subsidiary, Sale of Stock [Line Items]  
Number of shares per warrant 2,800,000
Private Placement [Member] | Private Placement Warrants  
Subsidiary, Sale of Stock [Line Items]  
Number of warrants to purchase shares issued 14,040,000
Aggregate purchase price | $ $ 14,040,000
Private Placement [Member] | Private Placement Warrants | Common Class A [Member]  
Subsidiary, Sale of Stock [Line Items]  
Aggregate purchase price | $ $ 11,240,000
Number of shares per warrant 1
Exercise price of warrant | $ / shares $ 1
Private Placement [Member] | Private Placement Warrants | Sponsor  
Subsidiary, Sale of Stock [Line Items]  
Number of warrants to purchase shares issued 11,240,000
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Party Transactions - Founder Shares (Details)
9 Months Ended
Sep. 27, 2021
$ / shares
shares
Sep. 10, 2021
shares
Apr. 27, 2021
USD ($)
$ / shares
shares
Sep. 30, 2022
Month
$ / shares
shares
Dec. 31, 2021
shares
Related Party Transaction [Line Items]          
Consideration received | $     $ 0    
Shares Issued, Price Per Share | $ / shares       $ 10  
Share dividend     6,900,000    
Aggregate number of shares owned     1,437,500    
Common Class B [Member]          
Related Party Transaction [Line Items]          
Common shares, shares outstanding       6,900,000 6,900,000
Founder Shares [Member]          
Related Party Transaction [Line Items]          
Number of shares surrender     900,000    
Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders       100.00%  
Restrictions on transfer period of time after business combination completion       15 months  
Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination | Month       21  
Founder Shares [Member] | Common Class B [Member]          
Related Party Transaction [Line Items]          
Number of shares issued 831,393        
Shares Issued, Price Per Share | $ / shares $ 0.004   $ 0.0001    
Founder Shares [Member] | Sponsor | Common Class B [Member]          
Related Party Transaction [Line Items]          
Number of shares issued   115,000      
Consideration received | $     $ 25,000    
Consideration received, shares     5,750,000    
Shares Issued, Price Per Share | $ / shares     $ 0.004    
Common shares, shares outstanding     5,750,000    
Aggregate number of shares owned       4,573,607  
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Party Transactions - Additional Information (Details) - USD ($)
9 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Apr. 27, 2021
Related Party Transaction [Line Items]      
Outstanding balance of related party note     $ 90,922
Expenses incurred and paid $ 10,000    
Working Capital Loan 0 $ 0  
Due to related party 90,000 24,193  
Working capital loans warrant      
Related Party Transaction [Line Items]      
Loan conversion agreement warrant $ 1,500,000    
Price of warrant $ 1    
Working Capital Loan $ 0    
Promissory Note with Related Party      
Related Party Transaction [Line Items]      
Maximum borrowing capacity of related party promissory note     300,000
Outstanding amount $ 171,346 $ 171,346  
Borrowed amount     $ 262,268
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Prepaid Expenses (Details) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Prepaid Expense, Current [Abstract]    
Prepaid Insurance, Current $ 159,382 $ 528,861
Prepaid Insurance, Non Current   26,081
Other Prepaid Items, Current 14,875 21,573
Prepaid Expense, Current, Total $ 174,257 550,434
Total Prepaid Expenses, Non Current   $ 26,081
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments & Contingencies (Details)
9 Months Ended
Oct. 22, 2021
USD ($)
Sep. 30, 2022
Day
$ / shares
Related Party Transaction [Line Items]    
Threshold period for not to transfer, assign or sell any of their shares or warrants after the completion of the initial business combination   30 days
Maximum number of demands for registration of securities   3
Initial Public Offering    
Related Party Transaction [Line Items]    
Underwriting Discount Earned Percentage (2.00%)  
Deferred Underwriting Discount 3.50%  
Underwriter cash discount | $ $ 5,520,000  
Sponsor | Class A Common Stock    
Related Party Transaction [Line Items]    
Warrants And Rights Outstanding Exercisable Term After Business Combinations   30 days
Threshold period for not to transfer, assign or sell any of their shares or warrants after the completion of the initial business combination   1 year
Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences   150 days
Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination   20
Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share) | $ / shares   $ 12
Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination   30
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Warrant Liabilities (Details) - USD ($)
3 Months Ended 5 Months Ended 8 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2021
Dec. 31, 2021
Sep. 30, 2022
Oct. 22, 2021
Warrants outstanding           27,840,000
Warrants and Rights Outstanding $ 2,367,600     $ 13,976,160 $ 2,367,600 $ 24,920,400
Share Price $ 9.2       $ 9.2  
Threshold Period For Registration Statement To Be Effective After Which Warrants Can Be Exercised         60 days  
Fair Market Value Price $ 0.361       $ 0.361  
Public Warrants expiration term 5 years       5 years  
Percentage Of Gross Proceeds On Total Equity Proceeds 60.00%       60.00%  
Adjustment of exercise price of warrants based on market value (as a percent) 115.00%       115.00%  
Percentage of adjustment of redemption price of stock based on market value. 180.00%       180.00%  
Stock price trigger for redemption of public warrants $ 18       $ 18  
Threshold period for not to transfer, assign or sell any of their shares or warrants after the completion of the initial business combination         30 days  
Shares Issued, Price Per Share $ 10       $ 10  
Change in fair value of warrant liabilities $ 3,345,600 $ 0 $ 10,944,240 $ 11,608,560  
Class A Common Stock            
Trading Day Prior To The Date On Which The Notice Of Exercise         10 days  
Shares Issued, Price Per Share $ 10       $ 10  
Redemption Of Warrant Price Per Share Equals Or Exceeds18.00 [Member]            
Share Price 18       18  
Redemption price per public warrant (in dollars per share)         $ 0.01  
Minimum threshold written notice period for redemption of public warrants         30 days  
Threshold trading days for redemption of public warrants         20 days  
Redemption Of Warrant Price Per Share Equals Or Exceeds10.00 [Member]            
Share Price 0.1       $ 0.1  
Redemption price per public warrant (in dollars per share)         $ 10  
Minimum threshold written notice period for redemption of public warrants         30 days  
Threshold trading days for redemption of public warrants         20 days  
Shares Issued, Price Per Share 10       $ 10  
Public Warrants            
Warrants outstanding           13,800,000
Public Warrants | Class A Common Stock            
Shares Issued, Price Per Share $ 11.5       $ 11.5  
Private Warrants            
Warrants outstanding           14,040,000
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Recurring Fair Value Measurements - Fair value hierarchy for liabilities measured at fair value on recurring basis (Details) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities held in trust account $ 283,154,827 $ 281,522,137
Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities held in trust account 283,154,827 281,522,137
Total warrant liabilities 2,367,600 13,976,160
Fair Value, Recurring [Member] | Public Warrants    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total warrant liabilities 1,104,000 6,900,000
Fair Value, Recurring [Member] | Private Warrants    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total warrant liabilities 1,263,600 7,076,160
Level 1 | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities held in trust account 283,154,827 281,522,137
Total warrant liabilities 1,104,000 6,900,000
Level 1 | Fair Value, Recurring [Member] | Public Warrants    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total warrant liabilities 1,104,000 6,900,000
Level 3 | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total warrant liabilities 0 7,076,160
Level 3 | Fair Value, Recurring [Member] | Private Warrants    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total warrant liabilities 0 $ 7,076,160
Level 2 | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total warrant liabilities 1,263,600  
Level 2 | Fair Value, Recurring [Member] | Private Warrants    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total warrant liabilities $ 1,263,600  
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Recurring Fair Value Measurements - changes in the fair value (Details) - USD ($)
3 Months Ended 8 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Warrant liability - initial measurement $ 3,229,200 $ 3,790,800 $ 7,076,160 $ 24,920,400
Change in fair value of warrant liabilities (1,965,600) [1] (561,600) (3,285,360) (10,944,240)
Transfer to Level 1       (6,900,000)
Transfer to Level 2 (1,263,600)      
Warrant liabilities at end of the period 0 3,229,200 3,790,800 7,076,160
Public Warrants        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Warrant liability - initial measurement       12,144,000
Change in fair value of warrant liabilities 0 [1]     (5,244,000)
Transfer to Level 1       (6,900,000)
Warrant liabilities at end of the period 0      
Private Placement Warrants        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Warrant liability - initial measurement 3,229,200 3,790,800 7,076,160 12,776,400
Change in fair value of warrant liabilities (1,965,600) [1] (561,600) (3,285,360) (5,700,240)
Transfer to Level 2 (1,263,600)      
Warrant liabilities at end of the period $ 0 $ 3,229,200 $ 3,790,800 $ 7,076,160
[1] Assumes the Private Placement Warrants were transferred on September 30, 2022.
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Recurring Fair Value Measurements - Companys Level 3 liabilities that are measured at fair value on a recurring basis (Details)
Dec. 31, 2021
d
yr
Exercise price  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Derivative liability, Measurement input 11.5
Share price  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Derivative liability, Measurement input 9.92
Risk-free rate  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Derivative liability, Measurement input 1.32
Expected volatility  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Derivative liability, Measurement input 8.3
Term (years)  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Derivative liability, Measurement input | yr 5.81
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Shareholder's Equity - Preferred Stock Shares (Details) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
Stockholders' Equity Note [Abstract]    
Preferred shares, shares authorized 1,000,000 1,000,000
Preferred stock, par value, (per share) $ 0.0001 $ 0.0001
Preferred shares, shares issued 0 0
Preferred shares, shares outstanding 0 0
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Shareholder's Equity-Common Stock Shares (Details) - $ / shares
9 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Class of Stock [Line Items]    
Class A common stock subject to possible redemption, outstanding (in shares) 27,600,000  
Aggregate Percentage of Outstanding Shares Issued to Initial Shareholders Prior to Business Combination 20.00%  
Common Class A [Member]    
Class of Stock [Line Items]    
Common shares, shares authorized (in shares) 250,000,000 250,000,000
Common shares, par value (in dollars per share) $ 0.0001 $ 0.0001
Common shares, shares issued (in shares) 0 0
Common shares, shares outstanding (in shares) 0 0
Class A common stock subject to possible redemption, outstanding (in shares) 27,600,000  
Common Class B [Member]    
Class of Stock [Line Items]    
Common shares, shares authorized (in shares) 25,000,000 25,000,000
Common shares, par value (in dollars per share) $ 0.0001 $ 0.0001
Common shares, shares issued (in shares) 6,900,000 6,900,000
Common shares, shares outstanding (in shares) 6,900,000 6,900,000
Ratio to be applied to the stock in the conversion 20  
Maximum shares subject to forfeiture 900,000  
Adjustment one of redemption price of stock based on market value and newly issued price (as a percent) 20.00%  
XML 50 d374880d10q_htm.xml IDEA: XBRL DOCUMENT 0001865506 2022-09-30 0001865506 2021-12-31 0001865506 2022-07-01 2022-09-30 0001865506 2021-07-01 2021-09-30 0001865506 2022-01-01 2022-09-30 0001865506 2021-04-19 2021-09-30 0001865506 2021-10-22 0001865506 2021-04-19 2021-12-31 0001865506 2022-01-01 2022-03-31 0001865506 2022-04-01 2022-06-30 0001865506 2021-04-27 0001865506 2021-04-27 2021-04-27 0001865506 2022-01-01 2022-06-30 0001865506 2022-06-30 0001865506 2021-06-30 0001865506 2021-04-18 0001865506 2021-09-30 0001865506 2022-03-31 0001865506 esac:PrivatePlacementWarrantsMember esac:SponsorMember us-gaap:PrivatePlacementMember 2022-09-30 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:PrivatePlacementMember 2022-09-30 0001865506 us-gaap:CommonClassBMember 2022-09-30 0001865506 us-gaap:CommonClassAMember 2022-09-30 0001865506 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001865506 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:CommonClassAMember us-gaap:OverAllotmentOptionMember 2022-09-30 0001865506 esac:PublicWarrantsMember us-gaap:IPOMember 2022-09-30 0001865506 us-gaap:IPOMember 2022-09-30 0001865506 esac:RedemptionOfWarrantPricePerShareEqualsOrExceeds18.00Member 2022-09-30 0001865506 esac:RedemptionOfWarrantPricePerShareEqualsOrExceeds10.00Member 2022-09-30 0001865506 esac:WorkingCapitalLoansWarrantMember 2022-09-30 0001865506 us-gaap:PrivatePlacementMember 2022-09-30 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2022-09-30 0001865506 esac:PromissoryNoteWithRelatedPartyMember 2022-09-30 0001865506 us-gaap:CommonClassAMember us-gaap:IPOMember 2022-09-30 0001865506 esac:FounderSharesMember esac:SponsorMember us-gaap:CommonClassBMember 2022-09-30 0001865506 us-gaap:CommonClassAMember esac:PublicWarrantsMember 2022-09-30 0001865506 esac:AdditionalAmountOwedToRelatedPartyMember 2022-09-30 0001865506 esac:PublicWarrantsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001865506 esac:PublicWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001865506 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001865506 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001865506 us-gaap:MeasurementInputExercisePriceMember 2021-12-31 0001865506 us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001865506 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001865506 us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001865506 us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001865506 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001865506 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001865506 us-gaap:CommonClassAMember 2021-12-31 0001865506 us-gaap:CommonClassBMember 2021-12-31 0001865506 esac:PromissoryNoteWithRelatedPartyMember 2021-12-31 0001865506 us-gaap:CommonClassAMember us-gaap:IPOMember 2021-12-31 0001865506 esac:PublicWarrantsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001865506 esac:PublicWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001865506 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001865506 esac:PrivatePlacementWarrantsMember 2022-07-01 2022-09-30 0001865506 esac:PublicWarrantsMember 2022-07-01 2022-09-30 0001865506 us-gaap:CommonClassAMember 2022-07-01 2022-09-30 0001865506 us-gaap:CommonClassBMember 2022-07-01 2022-09-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001865506 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001865506 us-gaap:CommonClassAMember 2021-07-01 2021-09-30 0001865506 us-gaap:CommonClassBMember 2021-07-01 2021-09-30 0001865506 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001865506 us-gaap:OverAllotmentOptionMember 2022-01-01 2022-09-30 0001865506 us-gaap:CommonClassAMember 2022-01-01 2022-09-30 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2022-01-01 2022-09-30 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:PrivatePlacementMember 2022-01-01 2022-09-30 0001865506 esac:SponsorMember us-gaap:CommonClassAMember 2022-01-01 2022-09-30 0001865506 us-gaap:CommonClassBMember 2022-01-01 2022-09-30 0001865506 esac:PublicWarrantsMember us-gaap:CommonClassAMember us-gaap:IPOMember 2022-01-01 2022-09-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001865506 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001865506 esac:FounderSharesMember 2022-01-01 2022-09-30 0001865506 esac:SponsorMember 2022-01-01 2022-09-30 0001865506 esac:RedemptionOfWarrantPricePerShareEqualsOrExceeds18.00Member 2022-01-01 2022-09-30 0001865506 esac:RedemptionOfWarrantPricePerShareEqualsOrExceeds10.00Member 2022-01-01 2022-09-30 0001865506 esac:UnitsEachConsistingOfOneShareOfClassCommonStockAndOneHalfOfOneWarrantMember 2022-01-01 2022-09-30 0001865506 esac:WarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceMember 2022-01-01 2022-09-30 0001865506 us-gaap:CommonClassAMember 2021-04-19 2021-09-30 0001865506 us-gaap:CommonClassBMember 2021-04-19 2021-09-30 0001865506 us-gaap:RetainedEarningsMember 2021-04-19 2021-09-30 0001865506 us-gaap:IPOMember 2021-10-22 2021-10-22 0001865506 esac:PublicWarrantsMember us-gaap:CommonClassAMember us-gaap:IPOMember 2021-10-22 2021-10-22 0001865506 esac:PrivateWarrantsMember 2021-10-22 0001865506 esac:PublicWarrantsMember 2021-10-22 0001865506 us-gaap:IPOMember 2021-10-22 0001865506 us-gaap:OverAllotmentOptionMember 2021-10-22 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:IPOMember 2021-10-22 0001865506 esac:PublicWarrantsMember us-gaap:CommonClassAMember us-gaap:IPOMember 2021-10-22 0001865506 esac:PrivatePlacementWarrantsMember 2021-04-19 2021-12-31 0001865506 esac:PublicWarrantsMember 2021-04-19 2021-12-31 0001865506 us-gaap:RetainedEarningsMember 2021-04-19 2021-12-31 0001865506 esac:FounderSharesMember esac:SponsorMember us-gaap:CommonClassBMember 2021-04-27 2021-04-27 0001865506 esac:PromissoryNoteWithRelatedPartyMember 2021-04-27 0001865506 esac:FounderSharesMember esac:SponsorMember us-gaap:CommonClassBMember 2021-04-27 0001865506 esac:FounderSharesMember us-gaap:CommonClassBMember 2021-04-27 0001865506 esac:FounderSharesMember 2021-04-27 0001865506 esac:FounderSharesMember esac:SponsorMember us-gaap:CommonClassBMember 2021-09-10 2021-09-10 0001865506 esac:FounderSharesMember us-gaap:CommonClassBMember 2021-09-27 2021-09-27 0001865506 esac:FounderSharesMember us-gaap:CommonClassBMember 2021-09-27 0001865506 esac:PrivatePlacementWarrantsMember 2022-01-01 2022-03-31 0001865506 esac:PrivatePlacementWarrantsMember 2022-04-01 2022-06-30 0001865506 us-gaap:CommonClassAMember 2022-11-10 0001865506 us-gaap:CommonClassBMember 2022-11-10 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-06-30 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-06-30 0001865506 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001865506 us-gaap:RetainedEarningsMember 2022-06-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-09-30 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-09-30 0001865506 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001865506 us-gaap:RetainedEarningsMember 2022-09-30 0001865506 esac:PrivatePlacementWarrantsMember 2022-09-30 0001865506 esac:PublicWarrantsMember 2022-09-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-06-30 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-06-30 0001865506 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001865506 us-gaap:RetainedEarningsMember 2021-06-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-09-30 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-09-30 0001865506 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001865506 us-gaap:RetainedEarningsMember 2021-09-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-12-31 0001865506 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001865506 us-gaap:RetainedEarningsMember 2021-12-31 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-04-18 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-04-18 0001865506 us-gaap:AdditionalPaidInCapitalMember 2021-04-18 0001865506 us-gaap:RetainedEarningsMember 2021-04-18 0001865506 esac:PrivatePlacementWarrantsMember 2021-04-18 0001865506 esac:PublicWarrantsMember 2021-04-18 0001865506 esac:PrivatePlacementWarrantsMember 2021-12-31 0001865506 esac:PrivatePlacementWarrantsMember 2022-03-31 0001865506 esac:PrivatePlacementWarrantsMember 2022-06-30 iso4217:USD shares pure utr:Day utr:Year utr:Month iso4217:USD shares utr:D utr:Y false 0001865506 --12-31 Q3 false 10-Q true 2022-09-30 2022 ESGEN Acquisition Corporation E9 001-40927 98-1601409 5956 Sherry Lane Suite 1400 Dallas TX 75225 214 987-6100 Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant ESACU NASDAQ Class A ordinary shares included as part of the units ESAC NASDAQ Warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 ESACW NASDAQ No Yes Non-accelerated Filer true true false true 27600000 6900000 0.50 890273 1323903 174257 550434 1064530 1874337 26081 283154827 281522137 284219357 283422555 1089536 411416 114193 24193 171346 171346 1375075 606955 2367600 13976160 9660000 9660000 13402675 24243115 27600000 283154827 281520000 0.0001 0.0001 1000000 1000000 0 0 0 0 0 0 0.0001 0.0001 250000000 250000000 0 0 0 0 27600000 0 0 0.0001 0.0001 25000000 25000000 6900000 6900000 6900000 6900000 690 690 0 0 -12338835 -22341250 -12338145 -22340560 284219357 283422555 145588 937110 133302 395559 20385 181339 0 1690 0 15393 30000 0 90000 -329275 -1690 -1604008 -15393 1245745 0 1632690 -3345600 0 -11608560 4591345 0 13241250 0 4262070 -1690 11637242 -15393 27600000 27600000 0 0 27600000 27600000 0.13 0.13 0 0 0.35 0.35 6900000 6900000 6900000 6900000 6900000 6900000 6900000 6900000 0.09 0.09 0 0 0.29 0.29 0 0 25000 0.004 5750000 0.0001 0 1437500 5750000 6900000 900000 27600000 281909082 6900000 690 0 -15355160 -15354470 -1245745 1245745 1245745 4262070 4262070 27600000 283154827 6900000 690 0 -12338835 -12338145 27600000 281520000 6900000 690 0 -22341250 -22340560 -1634827 1634827 1634827 11637242 11637242 27600000 283154827 6900000 690 0 -12338835 -12338145 0 0 6900000 690 24310 -13703 11297 -1690 -1690 0 0 6900000 690 24310 -15393 9607 0 0 6900000 690 24310 0 25000 -15393 -15393 0 0 6900000 690 24310 -15393 9607 25000 0.004 5750000 0.0001 0 1437500 5750000 6900000 900000 11637242 -15393 11693 1632690 -11608560 -402258 678120 3700 90000 -433630 -433630 1323903 890273 1634827 25000 243913 462712 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1 — Organization and Business Operation </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ESGEN Acquisition Corporation (the “Company”) was incorporated as a Cayman Islands exempted company on April 19, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (the “Business Combination”). The Company has not selected any Business Combination target. The Company will not be limited to a particular industry or geographic region in its identification and acquisition of a target company. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of September 30, 2022, the Company had not commenced any operations. All activity for the period from April 19, 2021 (inception) through September 30, 2022, relates to the Company’s formation and the initial public offering (“Public Offering” or “IPO”) described below and since the closing of the IPO, the search for a prospective initial business combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest income on cash and cash equivalents from the proceeds derived from the Public Offering (as defined below). The Company has selected December 31 as its fiscal year end. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s sponsor is ESGEN LLC, a Delaware limited liability company (the “Sponsor”). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registration statement for the Company’s IPO was declared effective on October 19, 2021 (the “Effective Date”). On October 22, 2021, the Company consummated its IPO of 27,600,000 units (the “Units” and, with respect to the ordinary shares included in the Units being offered, the “Public Shares”) at $10.00 per Unit (which included the full exercise of the underwriters’ over-allotment option), which is discussed in Note 3 and the sale of 14,040,000 warrants (the “Private Placement Warrants”) each exercisable to purchase one Class A ordinary share at $11.50 per share, at a price of $1.00 per Private Placement Warrant in a private placement to the Sponsor that closed simultaneously with the Public Offering. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs amounted to $16,138,202 consisting of $5,520,000 of underwriting commissions, $9,660,000 of deferred underwriting commissions and $958,202 of other cash offering costs. Of this amount, $15,428,121 was charged to shareholder’s deficit and $710,081 was allocated to the warrants and expensed. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (as defined below) (excluding the deferred underwriting commissions and taxes payable on the interest earned on the Trust Account) at the time of signing a definitive agreement in connection with the initial Business Combination. However, the Company will complete the initial Business Combination only if the post-Business Combination company in which its public shareholders own shares will own or acquire 50% or more of the outstanding voting securities of the target or is otherwise not required to register as an investment company under the Investment Company Act (the “Investment Company Act”). There is no assurance that the Company will be able to complete a Business Combination successfully. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the closing of the IPO on October 22, 2021, $281,520,000 ($10.20 per Unit) from the net proceeds sold in the IPO, including proceeds of the sale of the Private Placement Warrants, was deposited in a trust account (“Trust Account”) and will only be invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule2a-7promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except with respect to interest or other income earned on the funds held in the Trust Account that may be released to the Company to pay its income taxes, if any, the amended and restated memorandum and articles of association, as discussed below and subject to the requirements of law and regulation, will provide that the proceeds from the Public Offering and the sale of the Private Placement Warrants held in the Trust Account will not be released from the Trust Account (1) to the Company, until the completion of the initial Business Combination, or (2) to the public shareholders, until the earliest of (a) the completion of the initial Business Combination, and then only in connection with those Class A ordinary shares that such shareholders properly elected to redeem, subject to the limitations described herein, (b) the redemption of any public shares properly tendered in connection with a shareholder vote to amend the amended and restated memorandum and articles of association (A) to modify the substance or timing of the Company’s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the public shares if the Company does not complete its initial Business Combination within 15 months (unless otherwise extended as described in the prospectus relating to the IPO) from the closing of this offering (the “Combination Period”) or (B) with respect to any other </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">provision relating to the rights of holders of the Class A ordinary shares, and (c) the redemption of the public shares if the Company has not consummated the Business Combination within Combination Period, subject to applicable law. Public shareholders who redeem their Class A ordinary shares in connection with a shareholder vote described in clause (b) in the preceding sentence shall not be entitled to funds from the Trust Account upon the subsequent completion of an initial Business Combination or liquidation if the Company has not consummated an initial Business Combination within Combination Period, with respect to such Class A ordinary shares so redeemed. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will provide its public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a proposed Business Combination or conduct a tender offer will be made by the Company, solely in its discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require the Company to seek shareholder approval under applicable law or stock exchange listing requirement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will provide its public shareholders with the opportunity to redeem all or a portion of their Class A ordinary shares upon the completion of its initial Business Combination at aper-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the initial Business Combination, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any, divided by the number of then-outstanding public shares, subject to the limitations described herein. The amount in the Trust Account is initially $10.20 per public share. The per share amount the Company will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ordinary shares subject to redemption were recorded at redemption value and classified as temporary equity upon the completion of the Public Offering, in accordance with Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will have 15 months (unless otherwise extended as described in the prospectus relating to the IPO) from the closing of the Public Offering to consummate the initial Business Combination. If the Company has not consummated the initial Business Combination within the Combination Period, the Company will: (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at aper-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any (less up to $100,000 of interest to pay winding up and dissolution expenses) divided by the number of the then-outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and its board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii), to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsor and each member of the management team have entered into an agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their Founder Shares; (ii) waive their redemption rights with respect to their Founder Shares and public shares in connection with a shareholder vote to approve an amendment to the Company’s amended and restated memorandum and articles of association (A) that would modify the substance or timing of the Company’s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the public shares if the Company does not complete its initial Business Combination within 15 months from the closing of the Public Offering (or up to 21 months if we extend the time to complete a business combination) or (B) with respect to any other provision relating to the rights of holders of the Company’s Class A ordinary shares and (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to consummate an initial business combination within Combination Period. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company (other than the Company’s independent registered public accounting firm), or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per public share due to reductions in the value of the Trust Account, in each case net of the interest that may be withdrawn to pay the Company’s income tax obligations, provided that such liability will not apply to any claims </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by a third party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriters of the Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. However, the Company has not asked the Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believe that the sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure you that the Sponsor would be able to satisfy those obligations. None of the Company’s officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Pandemic </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In March 2020, the World Health Organization characterized the outbreak of the novel strain of coronavirus, specifically identified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> as a global pandemic. This has resulted in governments enacting emergency measures to combat the spread of the virus. These measures, which include the implementation of travel bans, self-imposed quarantine periods and social distancing, have caused material disruption to business, resulting in a global economic slowdown. Equity markets have experienced significant volatility and weakness and the governments and central banks have reacted with significant monetary and fiscal interventions designed to stabilize economic conditions. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The current challenging economic climate may lead to adverse changes in cash flows, working capital levels and/or debt balances, which may also have a direct impact on the Company’s operating results and financial position in the future. The ultimate duration and magnitude of the impact and the efficacy of government interventions on the economy and the financial effect on the Company is not known at this time. The extent of such impact will depend on future developments, which are highly uncertain and not in the Company’s control, including new information which may emerge concerning the spread and severity of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and actions taken to address its impact, among others. The repercussions of this health crisis could have a material adverse effect on the Company’s business, financial condition, liquidity and operating results. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> the Company has implemented working practices to address potential impacts to its operations, employees and customers, and will take further measures in the future if and as required. At present, we do not believe there has been any appreciable impact on the Company specifically associated with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Capital Resources </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s liquidity needs prior to the consummation of the Public Offering had been satisfied through a payment from the Sponsor of $25,000 to cover certain offering costs in consideration for the Founder Shares and the loan under an unsecured promissory note from the Sponsor of $262,268 (See Note 5). Subsequent to the consummation of the Public Offering, the Company expects that it will need additional capital to satisfy its liquidity needs beyond the net proceeds from the consummation of the Public Offering and the proceeds held outside of the Trust Account for paying existing accounts payable, identifying and evaluating prospective business combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the initial Business Combination. In order to finance transaction costs in connection with a Business Combination, the Sponsor, an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans. As of September 30,2022, there were no amounts outstanding under any Working Capital Loans. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Going Concern </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September 30, 2022, the Company had $890,273 in cash held outside of the Trust Account and owes $1,089,536 in accrued offering costs and expenses and an additional $285,539 to related parties. The Company anticipates that the cash held outside of the Trust Account as of September 30, 2022 will not be sufficient to allow the Company to operate for at least the next 12 months from the issuance of the financial statements, assuming that a Business Combination is not consummated during that time. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with the Company’s assessment of going concern considerations in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Subtopic205-40,</div> “Presentation of Financial Statements – Going Concern”, the Company has until January 22, 2023 (unless extended) to consummate a Business Combination. If a Business Combination is not consummated by this date and an extension not obtained, there will be a mandatory liquidation and subsequent dissolution of the Company. Although the Company intends to consummate a Business Combination on or before January 22, 2023, it is uncertain whether the Company will be able to consummate a Business Combination by this time. Management has determined that the mandatory liquidation, should a Business Combination not occur, and an extension is not obtained, as well as the potential for us to have insufficient funds available to operate our business prior to a Business Combination, raises substantial doubt about the Company’s ability to continue as a going concern. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks and Uncertainties </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management is currently evaluating the impact of theCOVID-19pandemic and has concluded that while it is reasonably possible that the pandemic could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div> 27600000 10 14040000 11.5 1 16138202 5520000 9660000 958202 15428121 710081 0.80 50 281520000 10.2 1 P15M 10.2 5000001 100000 1 P15M P21M 10 10 25000 262268 0 890273 1089536 285539 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 2 — Significant Accounting Policies </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form 10-Q</div> and Article 8 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form 10-K,</div> which contains the initial audited financial statements and notes thereto for the period from April 19, 2021 (inception) to December 31, 2021, as filed with the SEC on April 1, 2022. The interim results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the period ending December 31, 2022 or for any future interim periods. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has until January 22, 2023 (or July 22, 2023 if fully extended) to complete a Business Combination.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Emerging Growth Company Status </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company has $890,273 and $1,323,903 in cash and cash equivalents as of September 30, 2022 and December 31, 2021, respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable Securities Held in Trust Account </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Following the closing of the Public Offering on October 22, 2021, an amount of $281,520,000 from the net proceeds of the sale of the Units in the Public Offering and the sale of the Private Placement Warrants were placed in the Trust Account and may be invested only in U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule2a-7under the Investment Company Act which invest only in direct U.S. government treasury obligations. The Trust Account is intended as a holding place for funds pending the earliest to occur of: (i) the completion of the initial Business Combination; (ii) the redemption of any public shares properly submitted in connection with a shareholder vote to amend the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to redeem 100% of the public shares if the Company does not complete the initial Business Combination within 15 months (unless otherwise extended as described in the prospectus relating to the IPO) from the closing of the Public Offering or (B) with respect to any other provision relating to shareholders’ rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-initial</div> Business Combination activity; or (iii) absent an initial Business Combination within 15 months (unless otherwise extended) from the closing of the Public Offering, the return of the funds held in the Trust Account to the public shareholders as part of redemption of the public shares. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering Costs Associated with Initial Public Offering </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company complies with the requirements of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASC340-10-S99-1and</div></div></div> SEC Staff Accounting Bulletin Topic 5A—“Expenses of Offering”. Offering costs consist of legal, accounting, underwriting and other costs incurred through the balance sheet date that are related to the Public Offering. Offering costs are charged against the carrying value of the ordinary shares or the statement of operations based on the relative value of the ordinary shares and the Public Warrants to the proceeds received from the Units sold upon the completion of the Public Offering. Offering costs amounted to $16,138,202 and of this, $15,428,121 was charged to temporary equity and $710,081 was deemed allocable to the warrants and charged to expense upon the completion of the IPO. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value of Financial Instruments </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company’s assets and liabilities, which qualify as financial instruments under FASB ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheets, primarily due to its short-term nature.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The Company’s financial instruments are classified as either Level 1, Level 2 or Level 3. These tiers include: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </div></div></td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative Financial Instruments </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. The Company’s derivative instruments are recorded at fair value on the balance sheet with changes in the fair value reported in the statement of operations. Derivative assets and liabilities are classified on the balance sheets as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> based on whether or not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">net-cash</div> settlement or conversion of the instrument could be required within 12 months of the balance sheet date. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for the Public and Private Placement warrants issued in connection with the Public Offering in accordance with the guidance contained in ASC815-40and ASC 480, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Distinguishing Liabilities from Equity. </div></div>Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, the Company will classify each warrant as a liability at its fair value. This liability is subject tore-measurement at each balance sheet date. With each such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement,</div> the warrant liability will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operations. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Income (Loss) Per Ordinary Share </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company complies with accounting and disclosure requirements of ASC Topic 260, “Earnings Per Share.” The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Income and losses are shared pro rata between the two classes of shares. Net income (loss) per ordinary share is calculated by dividing the net income (loss) by the weighted average ordinary shares outstanding for the respective period. Net loss for the period from inception to IPO was allocated fully to Class B ordinary shares. With respect to the accretion of Class A ordinary shares subject to possible redemption, the Company treated accretion in the same manner as a dividend, paid to the shareholder in the calculation of the net income (loss) per ordinary share. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The earnings per share presented in the Statement of Operations is based on the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 51%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months<br/> Ended<br/> September 30,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine<br/> Months Ended<br/> September 30,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months<br/> Ended<br/> September 30,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the<br/> Period from<br/> April 19, 2021<br/> (Inception)<br/> through<br/> September 30,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,262,070</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,637,242</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,690</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,393</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of temporary equity to redemption value</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,245,745</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,632,690</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) including accretion of temporary equity to redemption value</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,016,325</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,004,552</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,690</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,393</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 57%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> September 30, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/> September 30, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income per share:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income including accretion of temporary equity</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,413,060</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">603,265</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,003,642</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,000,910</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of accretion of temporary equity to redemption value</div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">1,245,745</td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">1,632,690</td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of income</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,658,805</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">603,265</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,636,332</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,000,910</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares outstanding</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,600,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,600,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income per share</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.13</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.09</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.35</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.29</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 61%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> September 30, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Period from<br/> April 19, 2021 (Inception) through<br/> September 30, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net loss including accretion of temporary equity</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,690</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,393</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of accretion of temporary equity to redemption value</div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of loss</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,690</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,393</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares outstanding</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.00</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.00</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per share is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period, excluding ordinary shares forfeited. The Company has not considered the effect of the 27,840,000 ordinary shares issuable upon exercise of the Public Warrants and Private Placement Warrants in the calculation of diluted loss per share, since the exercise of such warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class A Ordinary Shares Subject to Possible Redemption </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholder’s equity. The Company’s Class A ordinary shares sold in the IPO feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company has made a policy election in accordance with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASC480-10-S99-3A</div></div></div> and will recognize changes in redemption value in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital (or accumulated deficit in the absence of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital) immediately as they occur. The Company recorded accretion of $1,245,745 and $1,634,827, and $33,092,121 in accumulated deficit for the three and nine months ended September 30, 2022 and the period from April 19, 2021 (inception) through December 31, 2021, respectively. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under FASB ASC 740, “Income Taxes” (“ASC 740”). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of September 30, 2022 and December 31, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statements. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of September 30, 2022 and December 31, 2021, there were no unrecognized tax benefits and no amounts were accrued for the payment of interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Accounting Pronouncements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2020, the FASB issued Accounting Standards Update (“ASU”) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> Debt—Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40)</div> (“ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06”)</div> to simplify accounting for certain financial instruments. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> amends the diluted earnings per share guidance, including the requirement to use the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">if-converted</div> method for all convertible instruments. As a smaller reporting company, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> is effective January 1, 2024 for fiscal years beginning after December 15, 2023 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> would have on its financial position, results of operations or cash flows. The Company has not adopted this guidance as of September 30, 2022. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form 10-Q</div> and Article 8 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form 10-K,</div> which contains the initial audited financial statements and notes thereto for the period from April 19, 2021 (inception) to December 31, 2021, as filed with the SEC on April 1, 2022. The interim results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the period ending December 31, 2022 or for any future interim periods. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has until January 22, 2023 (or July 22, 2023 if fully extended) to complete a Business Combination.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Emerging Growth Company Status </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company has $890,273 and $1,323,903 in cash and cash equivalents as of September 30, 2022 and December 31, 2021, respectively. </div></div> 890273 1323903 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable Securities Held in Trust Account </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Following the closing of the Public Offering on October 22, 2021, an amount of $281,520,000 from the net proceeds of the sale of the Units in the Public Offering and the sale of the Private Placement Warrants were placed in the Trust Account and may be invested only in U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule2a-7under the Investment Company Act which invest only in direct U.S. government treasury obligations. The Trust Account is intended as a holding place for funds pending the earliest to occur of: (i) the completion of the initial Business Combination; (ii) the redemption of any public shares properly submitted in connection with a shareholder vote to amend the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to redeem 100% of the public shares if the Company does not complete the initial Business Combination within 15 months (unless otherwise extended as described in the prospectus relating to the IPO) from the closing of the Public Offering or (B) with respect to any other provision relating to shareholders’ rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-initial</div> Business Combination activity; or (iii) absent an initial Business Combination within 15 months (unless otherwise extended) from the closing of the Public Offering, the return of the funds held in the Trust Account to the public shareholders as part of redemption of the public shares. </div> 281520000 1 P15M <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering Costs Associated with Initial Public Offering </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company complies with the requirements of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASC340-10-S99-1and</div></div></div> SEC Staff Accounting Bulletin Topic 5A—“Expenses of Offering”. Offering costs consist of legal, accounting, underwriting and other costs incurred through the balance sheet date that are related to the Public Offering. Offering costs are charged against the carrying value of the ordinary shares or the statement of operations based on the relative value of the ordinary shares and the Public Warrants to the proceeds received from the Units sold upon the completion of the Public Offering. Offering costs amounted to $16,138,202 and of this, $15,428,121 was charged to temporary equity and $710,081 was deemed allocable to the warrants and charged to expense upon the completion of the IPO. </div> 16138202 15428121 710081 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value of Financial Instruments </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company’s assets and liabilities, which qualify as financial instruments under FASB ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheets, primarily due to its short-term nature.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The Company’s financial instruments are classified as either Level 1, Level 2 or Level 3. These tiers include: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </div></div></td></tr></table> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative Financial Instruments </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. The Company’s derivative instruments are recorded at fair value on the balance sheet with changes in the fair value reported in the statement of operations. Derivative assets and liabilities are classified on the balance sheets as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> based on whether or not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">net-cash</div> settlement or conversion of the instrument could be required within 12 months of the balance sheet date. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for the Public and Private Placement warrants issued in connection with the Public Offering in accordance with the guidance contained in ASC815-40and ASC 480, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Distinguishing Liabilities from Equity. </div></div>Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, the Company will classify each warrant as a liability at its fair value. This liability is subject tore-measurement at each balance sheet date. With each such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement,</div> the warrant liability will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operations. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Income (Loss) Per Ordinary Share </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company complies with accounting and disclosure requirements of ASC Topic 260, “Earnings Per Share.” The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Income and losses are shared pro rata between the two classes of shares. Net income (loss) per ordinary share is calculated by dividing the net income (loss) by the weighted average ordinary shares outstanding for the respective period. Net loss for the period from inception to IPO was allocated fully to Class B ordinary shares. With respect to the accretion of Class A ordinary shares subject to possible redemption, the Company treated accretion in the same manner as a dividend, paid to the shareholder in the calculation of the net income (loss) per ordinary share. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The earnings per share presented in the Statement of Operations is based on the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 51%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months<br/> Ended<br/> September 30,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine<br/> Months Ended<br/> September 30,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months<br/> Ended<br/> September 30,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the<br/> Period from<br/> April 19, 2021<br/> (Inception)<br/> through<br/> September 30,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,262,070</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,637,242</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,690</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,393</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of temporary equity to redemption value</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,245,745</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,632,690</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) including accretion of temporary equity to redemption value</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,016,325</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,004,552</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,690</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,393</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 57%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> September 30, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/> September 30, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income per share:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income including accretion of temporary equity</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,413,060</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">603,265</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,003,642</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,000,910</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of accretion of temporary equity to redemption value</div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">1,245,745</td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">1,632,690</td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of income</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,658,805</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">603,265</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,636,332</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,000,910</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares outstanding</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,600,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,600,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income per share</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.13</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.09</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.35</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.29</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 61%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> September 30, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Period from<br/> April 19, 2021 (Inception) through<br/> September 30, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net loss including accretion of temporary equity</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,690</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,393</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of accretion of temporary equity to redemption value</div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of loss</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,690</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,393</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares outstanding</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.00</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.00</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per share is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period, excluding ordinary shares forfeited. The Company has not considered the effect of the 27,840,000 ordinary shares issuable upon exercise of the Public Warrants and Private Placement Warrants in the calculation of diluted loss per share, since the exercise of such warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The earnings per share presented in the Statement of Operations is based on the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 51%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months<br/> Ended<br/> September 30,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine<br/> Months Ended<br/> September 30,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months<br/> Ended<br/> September 30,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the<br/> Period from<br/> April 19, 2021<br/> (Inception)<br/> through<br/> September 30,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,262,070</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,637,242</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,690</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,393</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of temporary equity to redemption value</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,245,745</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,632,690</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) including accretion of temporary equity to redemption value</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,016,325</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,004,552</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,690</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,393</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 57%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> September 30, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/> September 30, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income per share:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income including accretion of temporary equity</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,413,060</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">603,265</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,003,642</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,000,910</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of accretion of temporary equity to redemption value</div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">1,245,745</td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">1,632,690</td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of income</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,658,805</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">603,265</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,636,332</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,000,910</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares outstanding</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,600,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,600,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income per share</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.13</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.09</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.35</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.29</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 61%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> September 30, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Period from<br/> April 19, 2021 (Inception) through<br/> September 30, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net loss including accretion of temporary equity</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,690</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,393</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of accretion of temporary equity to redemption value</div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of loss</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,690</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,393</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares outstanding</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.00</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.00</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> </table> 4262070 11637242 -1690 -15393 1245745 1632690 0 0 3016325 10004552 -1690 -15393 2413060 603265 8003642 2000910 -1245745 -1632690 3658805 603265 9636332 2000910 27600000 27600000 6900000 6900000 27600000 27600000 6900000 6900000 0.13 0.13 0.09 0.09 0.35 0.35 0.29 0.29 0 -1690 0 -15393 0 0 0 -1690 0 -15393 0 0 6900000 6900000 0 0 6900000 6900000 0 0 0 0 0 0 0 0 27840000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class A Ordinary Shares Subject to Possible Redemption </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholder’s equity. The Company’s Class A ordinary shares sold in the IPO feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company has made a policy election in accordance with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASC480-10-S99-3A</div></div></div> and will recognize changes in redemption value in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital (or accumulated deficit in the absence of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital) immediately as they occur. The Company recorded accretion of $1,245,745 and $1,634,827, and $33,092,121 in accumulated deficit for the three and nine months ended September 30, 2022 and the period from April 19, 2021 (inception) through December 31, 2021, respectively. </div> 1245745 1634827 33092121 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under FASB ASC 740, “Income Taxes” (“ASC 740”). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of September 30, 2022 and December 31, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statements. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of September 30, 2022 and December 31, 2021, there were no unrecognized tax benefits and no amounts were accrued for the payment of interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> 0 0 0 0 0 0 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Accounting Pronouncements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2020, the FASB issued Accounting Standards Update (“ASU”) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> Debt—Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40)</div> (“ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06”)</div> to simplify accounting for certain financial instruments. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> amends the diluted earnings per share guidance, including the requirement to use the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">if-converted</div> method for all convertible instruments. As a smaller reporting company, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> is effective January 1, 2024 for fiscal years beginning after December 15, 2023 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> would have on its financial position, results of operations or cash flows. The Company has not adopted this guidance as of September 30, 2022. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 3 — Public Offering </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On October 22, 2021, the Company consummated its IPO of 27,600,000 Units, which included the full exercise of the underwriters’ over-allotment option, at a price of $10.00 per Unit, generating gross proceeds of $276,000,000. Each Unit consists of one Class A ordinary share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden59393820">one</span>-half</div> of one redeemable warrant (each, a “Public Warrant”). Each whole Public Warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">All of the 27,600,000 Class A ordinary shares sold as part of the Units in the IPO contain a redemption feature which allows for the redemption of such public shares in connection with the Company’s liquidation, if there is a shareholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s certificate of incorporation. In accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity” and with the SEC and its staff’s guidance on redeemable equity instruments, which has been codified in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASC480-10-S99,</div></div> redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Class A ordinary shares is subject to SEC and its staff’s guidance on redeemable equity instruments, which has been codified in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASC480-10-S99.If</div></div> it is probable that the equity instrument will become redeemable, the Company has the option to either accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or to recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company recognizes changes in redemption value immediately as they occur. Immediately upon the closing of the IPO, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and accumulated deficit. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September 30, 2022 and December 31, 2021, the ordinary shares reflected on the balance sheets are reconciled in the following table: </div><br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><br/></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 83%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">276,000,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds allocated to Public Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,144,000</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class A ordinary share issuance costs</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,428,121</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,092,121</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class A ordinary shares subject to possible redemption as of December 31, <br/>2021</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">281,520,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">389,082</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em;">Class A ordinary shares subject to possible redemption as of June 30, 2022</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">281,909,082</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,245,745</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class A ordinary shares subject to possible redemption as of September 30, <br/>2022</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">283,154,827</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 27600000 10 276000000 1 1 1 11.5 27600000 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September 30, 2022 and December 31, 2021, the ordinary shares reflected on the balance sheets are reconciled in the following table: </div><br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><br/></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 83%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">276,000,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds allocated to Public Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,144,000</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class A ordinary share issuance costs</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,428,121</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,092,121</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class A ordinary shares subject to possible redemption as of December 31, <br/>2021</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">281,520,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">389,082</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em;">Class A ordinary shares subject to possible redemption as of June 30, 2022</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">281,909,082</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,245,745</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class A ordinary shares subject to possible redemption as of September 30, <br/>2022</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">283,154,827</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 276000000 -12144000 -15428121 33092121 281520000 389082 281909082 1245745 283154827 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 4 — Private Placement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsor purchased 11,240,000 warrants, which included the underwriters’ exercise of the full over-allotment option (the “Private Placement Warrants”), each exercisable to purchase one Class A ordinary share at $11.50 per share, subject to adjustment, at a price of $1.00 per warrant and $11,240,000 in the aggregate, in a private placement that occurred concurrently with the closing of the Public Offering. Additionally, Salient Capital Advisors, LLC, acting in its capacity as investment advisor on behalf of one or more client accounts (“Salient Client Accounts”) purchased 2,800,000 warrants on the same terms as the Sponsor in a private placement that occurred concurrently with the closing of the Public Offering. The private placement resulted in an aggregate of 14,040,000 warrants and $14,040,000 in proceeds, a portion of which was placed in the Trust account. </div></div> 11240000 1 11.5 1 11240000 2800000 14040000 14040000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 5 — Related Party Transactions </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Founder Shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On April 27, 2021, the Sponsor paid $25,000, or approximately $0.004 per share, to cover certain offering costs in consideration for 5,750,000 Class B ordinary shares, par value $0.0001. In September 2021, certain shareholders surrendered, for no consideration, an aggregate of 1,437,500 Class B ordinary shares, leaving 5,750,000 Founder Shares outstanding. In October 2021, a share dividend was issued which resulted in 6,900,000 Founder Shares outstanding; of which 900,000 were subject to surrender if the underwriter had not exercised their full over-allotment option. All share values and related amounts have been retroactively restated to reflect the dividend. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September 10, 2021, the Sponsor transferred 115,000 Class B ordinary shares to each of its three independent directors. Additionally, on September 27, 2021, the Company sold 831,393 Class B ordinary shares to the Salient Client Accounts at a price of approximately $0.004 per share. As of September 30, 2022, the Sponsor held 4,573,607 Class B ordinary shares.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The initial shareholders and each member of the management team have entered into an agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of the Business Combination; (ii) waive their redemption rights with respect to their Founder Shares and Public Shares in connection with a shareholder vote to approve an amendment to the amended and restated memorandum and articles of association (A) that would modify the substance or timing of the Company’s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the Business Combination or to redeem 100% of the Company’s public shares if it does not complete the Business Combination within 15 months from the closing of the Public Offering (or up to 21 months, if extended) to complete a Business Combination or (B) with respect to any other provision relating to the rights of holders of the Class A ordinary shares and (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to consummate an Business Combination within 15 months from the closing of this offering (or up to 21 months if extended) to complete a Business Combination as described in the prospectus (although they will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares they hold if the Company fails to complete the Business Combination within the prescribed time frame). If the Company seeks shareholder approval, it will complete the Business Combination only if it is approved by an ordinary resolution or such higher approval threshold as may be required by Cayman Islands law and pursuant to the amended and restated memorandum and articles of association. In such case, the initial shareholders and each member of the management team have agreed to vote their Founder Shares and Public Shares in favor of the Business Combination.</div><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Promissory Note — Related Party </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On April 27, 2021, the Sponsor agreed to loan the Company up to $300,000 to be used for a portion of the expenses of the Public Offering. The Company borrowed a total of $262,268. This loan was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing, unsecured and due at the earlier of December 31, 2021 or the closing of the Public Offering. The loan was to be repaid upon the closing of the Public Offering out of the offering proceeds not held in the Trust Account. In connection with the closing of the Public Offering, the Company paid down $90,922 of the outstanding balance. As of September 30, 2022 and December 31, 2021, the Company had $171,346 outstanding under the promissory note. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Working Capital Loans </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to finance transaction costs in connection with an intended Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes the initial Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the Trust Account. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital Loans. Up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity at a price of $1.00 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. As of September 30, 2022 and December 31, 2021, the Company had no borrowings under the Working Capital Loans. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Office Space, Secretarial and Administrative Services </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commencing on the date that the Company’s securities are first listed on the NASDAQ through the earlier of consummation of the initial Business Combination and the liquidation, the Company will pay the Sponsor a total of $10,000 per month for office space, utilities, secretarial support and administrative services. As of September 30, 2022 and December 31, 2021, the Company had incurred $90,000 and $24,193, respectively pursuant to this agreement, which was accrued in “Due to related party”. </div></div> 25000 0.004 5750000 0.0001 0 1437500 5750000 6900000 900000 115000 831393 0.004 4573607 1 P15M 21 P15M 300000 262268 90922 171346 171346 1500000 1 0 0 10000 90000 24193 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 6 — Prepaid Expenses </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s prepaid expenses as of September 30, 2022 and December 31, 2021 primarily consisted of insurance. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 62%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Current</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Current</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid Insurance</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">159,382</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">528,861</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,081</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Prepaid Items</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,875</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,573</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">174,257</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">550,434</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">26,081</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s prepaid expenses as of September 30, 2022 and December 31, 2021 primarily consisted of insurance. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 62%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Current</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Current</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid Insurance</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">159,382</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">528,861</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,081</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Prepaid Items</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,875</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,573</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">174,257</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">550,434</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">26,081</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 159382 528861 26081 14875 21573 174257 550434 26081 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 7 — Commitments &amp; Contingencies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Registration and Shareholder Rights </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) will be entitled to registration rights pursuant to a registration and expected shareholder rights agreement signed at the closing of our Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s completion of its initial Business Combination. However, the registration and expected shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period, which occurs (i) in the case of the Founder Shares, and (ii) in the case of the private placement warrants and the respective Class A ordinary shares issuable upon exercise of the private placement warrants, 30 days after the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Working Capital Loans and warrants that may be issued upon conversion of Working Capital Loans) will be entitled to registration rights pursuant to a registration and expected shareholder rights agreement signed at the closing of our Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company’s register such securities.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of its initial Business Combination. However, the registration and expected shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lockup period, which occurs (i) in the case of the Founder Shares, as described in the following paragraph, and (ii) in the case of the Private Placement Warrants and the respective Class A ordinary shares underlying such warrants, 30 days after the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except as described herein, the Sponsor and its directors and executive officers have agreed not to transfer, assign or sell any of their Founder Shares until the earliest of (A) one year after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the closing price of the Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any30-tradingday period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company complete a liquidation, merger, share exchange or other similar transaction that results in all of the public shareholders having the right to exchange their ordinary shares for cash, securities or other property. Any permitted transferees would be subject to the same restrictions and other agreements of the Sponsor and its directors and executive officers with respect to any founder shares. Any permitted transferees will be subject to the same restrictions and other agreements of the Sponsor with respect to any Founder Shares. The Company refers to such transfer restrictions throughout the Public Offering as the lock- up. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, pursuant to the registration and expected shareholder rights agreement, the Sponsor, upon and following consummation of an initial Business Combination, will be entitled to nominate three individuals for election to the board of directors, as long as the Sponsor holds any securities covered by the registration and expected shareholder rights agreement. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underwriting Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company granted the underwriters <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a45-dayoption</div> to purchase up to 3,600,000 additional Units to cover over-allotments, if any, at the Public Offering price less the underwriting discounts and commissions. The underwriters exercised the full over-allotment at the consummation of the Public Offering on October 22, 2021. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters earned an underwriting discount of two percent (2%) of the gross proceeds of the Public Offering, or $5,520,000, which was paid in cash at closing of the offering. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, the underwriters are entitled to a deferred underwriting discount of 3.5% of the gross proceeds of the Public Offering upon the completion of the Company’s initial Business Combination. </div></div> P30D P30D P1Y 12 20 30 P150D 3 3600000 -0.02 5520000 0.035 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 8 — Warrant Liabilities </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for the 27,840,000 warrants issued in connection with the Public Offering (13,800,000 Public Warrants and 14,040,000 Private Placement Warrants) in accordance with the guidance contained in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASC815-40.</div> Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, the Company will classify each warrant as a liability at its fair value. This liability is subject to remeasurement at each balance sheet date. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With each such remeasurement, the warrant liability will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operation. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public Warrants </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each whole warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment as discussed herein. In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">price of the Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described adjacent to “Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described adjacent to the caption “Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The warrants will become exercisable 30 days after the completion of the Company’s initial Business Combination and will expire five years after the completion of the Company’s initial Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has agreed that as soon as practicable, but in no event later than 20 business days after the closing of the initial Business Combination, it will use its commercially reasonable efforts to file with the SEC a post-effective amendment to the registration statement of which this prospectus forms a part or a new registration statement for the registration, under the Securities Act, of the Class A ordinary shares issuable upon exercise of the warrants, and the Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of the initial Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; provided that if the Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elect, it will not be required to file or maintain in effect a registration statement, but the Company will use its commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. The “fair market value” as used in this paragraph shall mean the volume weighted average price of the Class A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption, but it will use its commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. In such event, each holder would pay the exercise price by surrendering the warrants for that number of Class A ordinary shares equal to the lesser of (A) the quotient obtained by dividing (x) the product of the number of Class A ordinary shares underlying the warrants, multiplied by the excess of the “fair market value” (defined below) less the exercise price of the warrants by (y) the fair market value and (B) 0.361. The “fair market value” as used in this paragraph shall mean the volume weighted average price of the Class A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption of warrants when the price per Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> A ordinary share equals or exceeds $18.00</div></div>. Once the warrants become exercisable, the Company may redeem not less than all of the outstanding warrants (except as described herein with respect to the Private Placement Warrants): </div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a price of $0.01 per warrant; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if, and only if, the closing price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “Description of Securities—Warrants—Public Shareholders’ Warrants—Anti-dilution Adjustments”) for any 20 trading days within <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a30-tradingday</div> period ending three trading days before the Company sends the notice of redemption to the warrant holders. </div></td></tr></table><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption of warrants when the price per Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> A ordinary share equals or exceeds $10.00</div></div>. Once the warrants become exercisable, the Company may redeem not less than all of the outstanding warrants: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if, and only if, the closing price of the Class A ordinary shares equals or exceeds $10.00 per public share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “Description of Securities—Warrants—Public Shareholders’ Warrants—Anti-dilution Adjustments”) for any 20 trading days within the30-tradingday period ending three trading days before the Company sends the notice of redemption to the warrant holders; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private Warrants </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the warrants included in the units sold in the Public Offering. Any amendment to the terms of the Private Placement Warrants or any provision of the warrant agreement with respect to the Private Placement Warrants will require a vote of holders of at least 50% of the number of the then outstanding Private Placement Warrants. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The accounting treatment of derivative financial instruments requires that the Company record a derivative liability upon the closing of the IPO. Accordingly, the Company has classified each warrant as a liability at its fair value and the warrants were allocated a portion of the proceeds from the issuance of the Units equal to its fair value determined by a Black Scholes model. This liability is subject tore-measurement at each balance sheet date. With each such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement,</div> the warrant liability will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operations. The Company will reassess the classification at each balance sheet date. If the classification changes as a result of events during the period, the warrants will be reclassified as of the date of the event that causes the reclassification. As such, the Company recorded$24,920,400 of warrant liability upon issuance as of October 22,2021. For the period from April 19,2021(inception) through December 31,2021, the Company recorded a change in the fair value of the warrant liabilities in the amount of $10,944,240 on the statement of operations, resulting in warrant liabilities of $13,976,160 as of December 31,2021 on the balance sheet. For the nine months ended September 30,2022, the Company recorded a change in the fair value of the warrant liabilities in the amount of $11,608,560 on the statement of operations, resulting in warrant liabilities of $2,367,600 as of September 30,2022 on the balance sheet. </div> 27840000 13800000 14040000 11.5 9.2 0.60 9.2 1.15 18 18 1.80 10 10 P30D P5Y P60D P10D 0.361 P10D 18 0.01 P30D 18 P20D P30D 10 0.1 P30D 10 P20D 24920400 -10944240 13976160 -11608560 2367600 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 9 — Recurring Fair Value Measurements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September 30, 2022 and December 31, 2021, investments held in the Trust Account consisted of U.S. Money Market Funds. Fair values of these investments are determined by Level 1 inputs utilizing quoted prices (unadjusted) in active markets for identical assets. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company accounts for the Public Warrants and Private Placement Warrants as liabilities in accordance with the guidance contained in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASC 815-40,</div> Derivatives and Hedging—Contracts in Entity’s Own Equity. Because the Company does not control the occurrence of events, such as a tender offer or exchange, that may trigger cash settlement of the warrants where not all of the shareholders also receive cash, the warrants do not meet the criteria for equity treatment thereunder, as such, the warrants must be recorded as a derivative liability. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Additionally, certain adjustments to the settlement amount of the Private Placement Warrants are based on a variable that is not an input to the fair value of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">“fixed-for-fixed”</div></div> option as defined under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASC815-40,</div> and thus the Private Placement Warrants are not considered indexed to the Company’s own share and not eligible for an exception from derivative accounting. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s Public Warrants are traded on the Nasdaq. As such, the Public Warrant valuation is based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. The fair value of the Public Warrant liability is classified within Level 1 of the fair value hierarchy. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December 31, 2021, the Company’s Private Warrant liability is based on a valuation model utilizing management judgment and pricing inputs from observable and unobservable markets with less volume and transaction frequency than active markets. Significant deviations from these estimates and inputs could result in a material change in fair value. The fair value of the Private Warrant liability is classified within Level 3 of the fair value hierarchy. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September 30, 2021, the Company considers the Private Warrants to be economically equivalent to the Public Warrants. As such, the valuation of the Private Warrants was used to value the Private Warrants. The fair value of the Private Warrant liability is classified within Level 2 of the fair value hierarchy. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables presents fair value information as of September 30, 2022 and December 31, 2021 of the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 52%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">September 30, 2022</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities held in trust account</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">283,154,827</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">283,154,827</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,104,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,104,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,263,600</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,263,600</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,104,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,263,600</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,367,600</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-size: 1pt;"> <td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December 31, 2021</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities held in trust account</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">281,522,137</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">281,522,137</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,076,160</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,076,160</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,076,160</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,976,160</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a summary of the changes in the fair value of the Company’s Level 3 financial instruments that are measured at fair value on a recurring basis: </div><br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 60%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Private<br/>Placement<br/>Warrants</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Public<br/>Warrants</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrant<br/>Liabilities</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant liability – initial measurement</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,776,400</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,144,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,920,400</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of warrant liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,700,240</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,244,000</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,944,240</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transfer to Level 1</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant liabilities at December 31, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,076,160</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,076,160</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of warrant liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,285,360</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,285,360</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant liabilities at March 31, 2022</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,790,800</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,790,800</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of warrant liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(561,600</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(561,600</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant liabilities at June 30, 2022</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,229,200</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,229,200</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of warrant <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">liabilities (1)</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,965,600</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,965,600</td> <td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr> <tr> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Transfer to Level 2<br/></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> (1,263,600</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; width: 8%; padding: 0pt 5pt 0pt 0pt;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">—</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> (1,263,600</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant liabilities at September 30, 2022</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1)</div></td> <td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assumes the Private Placement Warrants were transferred on September 30, 2022. </div></div></div> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transfers to/from Levels 1, 2 and 3 are recognized at the end of the reporting period. The estimated fair value of the Public Warrants transferred from a Level 3 measurement to a Level 1 fair value measurement in September 2021 after the Public Warrants were separately listed and traded. The estimated fair value of the Private Placement Warrants transferred from a Level 3 measurement to a Level 2 fair value measurement in September 2022 due to the use of an observable market quote for a similar asset in an active market. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The estimated fair value of the Private Placement Warrants at December 31, 2021 was determined using a Black Scholes model with assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its ordinary shares based on projected volatility of comparable public companies that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">zero-coupon</div> yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is based on management assumptions regarding the timing and likelihood of completing a business combination. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents quantitative information about the Company’s Level 3 liabilities that are measured at fair value on a recurring basis as of December 31, 2021. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 16%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.50</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share price</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.92</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.32</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term (years)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.81</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables presents fair value information as of September 30, 2022 and December 31, 2021 of the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 52%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">September 30, 2022</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities held in trust account</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">283,154,827</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">283,154,827</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,104,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,104,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,263,600</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,263,600</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,104,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,263,600</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,367,600</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-size: 1pt;"> <td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December 31, 2021</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities held in trust account</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">281,522,137</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">281,522,137</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,076,160</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,076,160</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,076,160</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,976,160</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> 283154827 283154827 1104000 1104000 1263600 0 1263600 1104000 1263600 0 2367600 281522137 281522137 6900000 6900000 7076160 7076160 6900000 7076160 13976160 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a summary of the changes in the fair value of the Company’s Level 3 financial instruments that are measured at fair value on a recurring basis: </div><br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 60%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Private<br/>Placement<br/>Warrants</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Public<br/>Warrants</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrant<br/>Liabilities</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant liability – initial measurement</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,776,400</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,144,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,920,400</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of warrant liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,700,240</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,244,000</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,944,240</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transfer to Level 1</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant liabilities at December 31, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,076,160</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,076,160</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of warrant liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,285,360</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,285,360</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant liabilities at March 31, 2022</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,790,800</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,790,800</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of warrant liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(561,600</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(561,600</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant liabilities at June 30, 2022</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,229,200</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,229,200</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of warrant <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">liabilities (1)</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,965,600</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,965,600</td> <td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr> <tr> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Transfer to Level 2<br/></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> (1,263,600</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; width: 8%; padding: 0pt 5pt 0pt 0pt;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">—</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> (1,263,600</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant liabilities at September 30, 2022</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1)</div></td> <td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assumes the Private Placement Warrants were transferred on September 30, 2022. </div></div></div> </td> </tr> </table> 12776400 12144000 24920400 -5700240 -5244000 -10944240 -6900000 -6900000 7076160 7076160 -3285360 -3285360 3790800 3790800 -561600 -561600 3229200 3229200 -1965600 0 -1965600 -1263600 -1263600 0 0 0 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents quantitative information about the Company’s Level 3 liabilities that are measured at fair value on a recurring basis as of December 31, 2021. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 16%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.50</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share price</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.92</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.32</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term (years)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.81</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> 11.5 9.92 1.32 8.3 5.81 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 10 — Shareholders’ Equity (Deficit) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Preference shares</div></div>—The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of September 30, 2022 and December 31, 2021, there were no preference shares issued or outstanding. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> A ordinary shares</div></div>—The Company is authorized to issue 250,000,000 Class A ordinary shares with a par value of $0.0001 per share. As of September 30, 2022 and December 31, 2021, there were no Class A ordinary shares issued or outstanding other than the 27,600,000 Class A ordinary shares subject to possible redemption that are accounted for outside of the shareholder’s equity (deficit) section of our balance sheets. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> B ordinary shares</div></div>—The Company is authorized to issue 25,000,000 Class B ordinary shares with a par value of $0.0001 per share. Holders are entitled to one vote for each share of Class B ordinary shares. As of September 30, 2022 and December 31, 2021, there were 6,900,000 Class B ordinary shares issued and outstanding. Of the 6,900,000 Class B ordinary shares, up to 900,000 shares were subject to forfeiture to the Company for no consideration to the extent that the underwriters’ over-allotment option was not exercised in full or in part, so that the initial shareholders will collectively own 20% of the Company’s issued and outstanding ordinary shares after the Public Offering. The underwriters exercised their full over-allotment on October 22, 2021. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company’s shareholders except as required by law. Unless specified in the Company’s amended and restated memorandum and articles of association, or as required by applicable provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of the Company’s ordinary shares that are voted is required to approve any such matter voted on by its shareholders. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;">The Class B ordinary shares will automatically convert into Class A ordinary shares (which such Class A ordinary shares delivered upon conversion will not have any redemption rights or be entitled to liquidating distributions from the Trust Account if the Company fails to consummate an initial Business Combination) at the time of the initial Business Combination or earlier at the option of the holders thereof at a ratio such that the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, 20% of the sum of (i) the total number of ordinary shares issued and outstanding upon completion of the Public Offering, plus (ii) the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor, any of its affiliates or any members of the Company’s management team upon conversion of Working Capital Loans. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-to-one.</div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This is different than some other similarly structured blank check companies in which the initial shareholders will only be issued an aggregate of 20% of the total number of shares to be outstanding prior to the initial Business Combination. </div></div> 1000000 0.0001 0 0 0 0 250000000 0.0001 0 0 0 0 27600000 25000000 0.0001 6900000 6900000 6900000 6900000 6900000 900000 0.20 20 0.20 On April 27, 2021, the Sponsor paid $25,000, or approximately $0.004 per share, to cover certain offering costs in consideration for 5,750,000 Class B ordinary shares, par value $0.0001. In September 2021, certain shareholders surrendered, for no consideration, an aggregate of 1,437,500 Class B ordinary shares, leaving 5,750,000 Founder Shares outstanding. In October 2021, a share dividend was issued which resulted in 6,900,000 Founder Shares outstanding; of which 900,000 were subject to surrender if the underwriter had not exercised their full over-allotment option. The underwriters exercised their over-allotment option in full on October 21, 2021. All share values and related amounts have been retroactively restated to reflect the dividend. Assumes the Private Placement Warrants were transferred on September 30, 2022. EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( (N":E4'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "+@FI5> LH1NT K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R'9A,)/FTM%3!X,5-G8SMMJ:Q;&Q-9*^_9RL31G; ^QHZ?>G M3Z#&1&5"PN<4(B9RF.]&W_59F;AF)Z*H +(YH=>Y+HF^- \A>4WEF8X0M?G0 M1P3)^3UX)&TU:9B 55R(K&VL42:AII N>&L6?/Q,W0RS!K!#CSUE$+4 UDX3 MXWGL&K@!)AAA\OF[@'8ASM4_L7,'V"4Y9K>DAF&HA]6<*SL(>'O:O=QO62NYE)40E>![*93DBC^\3ZX__&["/EAW&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ MBX)J59I:)^O"!P /# !@ !X;"]W;W)K5@(^7VW6B4^AL6 MT_24;UD"WZRXB*F$0[$>I5O!:) 'Q='(L:S)**9A,KBZR#];B*L+GLDH3-A" MD#2+8RI>KEG$=Y<#>[#_X$NXWDCUP>CJ8DO7;,GDU^U"P-&H4@G"F"5IR!,B MV.IR,+/?S;VI"LC/^$_(=NG!>Z*L/'+^71W5P&0POB,"E>Z7/9$6T"G#+ >1-@>S4!;AG@YD:+ MEN6VWE-)KRX$WQ&AS@8U]2;OFSP:W(2)NHQ+*>#;$.+DU9P_,4$6<,7(D*0; M*EAZ,9(@K+X>^:7(=2'BU(A,R4>>R$U*;I* !:_C1]"@JE7.OE77#BJX9-M3 MXEHGQ+$.1Y^SY].B6T,?]465+=G>_2+?79Y0!NOY2))S:X^OD?]L3ZQ>3W2&*OW'N5 M>P]3U^X?7K;,Y!0/MZWA9Y,E-*JCI7%E:=S.TN>,"LE$]$*^L"T7TF0/EY(B M,W7*'(WJ:&]2V9NTO&*"0L'-T[7>'ZZUHE%J-(B&=31X5AD\:V=PP43( U5W M")0_8W;B2E6EJ2TU:'Q'G^>5SW.T=3>)#.4+N0TC1NZS^)$)DT-P06?YZ\T]F?E_9V&9ZW,N(-GS M,FTRC V-?-*E/38[QH*Z6 M#QC#;F/Y@3Z3NP!NVW 5^L5#M#ZI&R2GYT-HG@V);?2+!G?UZVB_3AN_LR M]?1D_X;DQ/ I,5]77'(\'4_(T58?L&1K6K)QU/G ?;A>BPU/ M,%QJ$)F>GPTG=DW%Z8.7; U,=BMBFF="*/@MD#Y,UODMF9D'[KCBO:DJS_&@ MCC8=34A.2T*"D5DQS:/@GNY]FVPV*/YAG-68XU%=?6HL!_XX&G\<'%;>>BPG_^I= MXG*?7:/'/MC'U>SCXJ0R X-!83*B:^.Z BY06T_QN*[&-.RX.*1 "8W5U!R, M<5,R(W]]9(K/S2LG1\*4TG)9*RXJ$V I MN?_]!)ZK:JF1?,HDC+&3 'C)V _'740KU,:YFEK??KIRSB:6^GC)YU$SD MXA3S$,J($;XBMO//QW^1)?,S ::-GG"E_0W"!70*%2_EHBP)$S_* J![FI(M M%5+]F-PPDB6A- YN\-_I>M4U/[D-,SR"!OG0]"5^Y)&Q(QH ;#F;&WWU04ZN M)B<7QYW]I07^]33)%"[6F^ M\G \^JK*Y0EAU-\0G\/H-=?N 1WZ"$YZ 9 M $[(3]:I&FJKAS]YHE$&'YD24K" L9@^0EMWM;DYQUO8M2\U$GHX$C;#08. M@H.O1F.][)0ZV"J%TUM[.F@0JJ<#/+"K0\UU'HYE9<%+R8U*WV\;'E5%$$PS MX8=IGGRW7*BE[N+Q03[M2^JK@CJK0AA9B-!G*&S@#?OA:M('1GH:([U)#_7T M2&!8]D ?F.EIS/1PS/R1>HHK52F)CI'*@KO+,[8LC80=9"QPG6N]V' MH@^T1<=L)%$EZ7C3K^]04BS+HND$\$LBV3.C4[ETS7+Q.9R@ ?/'WSA]RMM/AA.QB6]9S.FOY5W$NZ& MVR@ISUFAN"B09,O+P16^F)+$.%06?W*V43O7R%"9"_%@;OY(+P>>0<0RMM F M!(5_CVS*LLQ$ AS_-D$'VV<:Q]WKY^B_5^2!S)PJ-A79=Y[JU>5@-$ I6])U MIK^(S7O6$ I-O(7(5/47;1I;;X 6:Z5%WC@#@IP7]7_ZHUF('0<<'' @C0-Y MJ8/?./@5T1I91>N&:CH92[%!TEA#-'-1K4WE#6QX8=(XTQ*^Y>"G)]//GVYN M/\UN;]#UU8>K3]-;-'M_>_MUAMZB;[,;].N;W\9##<\QUL-%$_.ZCDD.Q)RQ M\ASYWADB'B$6]ZG;_88MP!U7[KCK/@1V6XID2Y%4\?Q#%-=2LD(CJA33ZL+& MIPX0V .8G72A2KI@EP/8*HK)1S:8_/P3CKQW-G8G"M;AZF^Y^J[HDRE5*QO! MVBNJO,S.?IR,$H_$_GCXN N];X9]XB=>:]=!%6Q1!4Y4=Y*5E*>(_8#NHYB" MXEK42;%AK6.%NR#B@(3Q'M:^61AZ@1_8H89;J*$3ZE>A:?:,KBD9&\BP#]*+ M@M#W]E!:[$9QX/NQ'6:TA1F]9D5A00M1.-;4&>VU!1[U.)'(&V$[HWC+*'8R M^DCE ]-TGC&D&##AFD.AK%B6(EZ@KQ):(;I:+,3:3C#N8QKY. Q&9+]N;)8X M) 0?RLEHRV#T@M*Y.E@R(\N# X(3OU?:-DL_("0,0SO$9 LQ>5$KS#B=\ZQ: M8AO2Y)35A' M>\FR& 88!SBRIPKO*#-V0K]9,Z0%S$H9U0"VI%(_69'B/E)X?K+?W"UVI&/6 MQ=G**W8J&O0BD7.EA'R")J1-+SH.F5AZ//:#WMH>M>MB;F42NW6RV^:/;(%'X=>'.[#[1M&7I03MJY+%$/M) M',&V.P"UU4_L%M ;MF2PJBE:%RF3&^CC3*I?4,K5P=Z-^R*91 "Z#_NX81=U M*Z?8K:=U/1Q;WK[P02UZ).H7@D4B Q+X&!\JA58FL5LGIQD,)>@*"9GR @Y> M2*TH-$XXA\W_@:.1Z1BE4(J;7@=I8'EICDLP3,=GL%)GL%;/'E3O&*!'FD&_ M$4OT!GOGQ+/R?[G(6DU!91VY:F46CYPB-C/P5R)+J\*">N,+KJUC/78*]FN% M[%31NK1;Z<9.I30C7[.SJOR=H3?>.:PF-EVVSMX[A$U^.SE>ZY60_#^6OC,3 M(D/0J(WR"8G@3*\TJ"$O[JUKE_0RV-N.+I/N4:W5:W)$K].4FWJ$W7AG!ER8 M_::TY+ [K>>VOO;N@W2:=$&VRDS8^/YHY.\W M#)LI(7Z 27@([<[QUZW/=6]3G5WC0MW7W!HU#GJH+:8&M1<>TA'2*C1YB4+O M=.0S] 6Z%[S<_>;-74.4YVU+U@9]F7ZT"1N-76.XJ05=>(6]>=./A5Y M#@UXIL7BP0K7&>;5;R=.%*U+NAT/2'BBYDV<<\:K:9\H6I=V.U\0]WS1Y%@= MS'%_8.@U,I=)%U8[3) CPT0-JZ[$:_371Y;/F?S;BM 9Z=7I.%&T+N]VA""G M&B'(24>(4T7KTFY'".(>(8Y68=)[_Q%0AE; M@I=W'D,9R_H->WVC15F]I)X+K45>7:X8A?P8 _A^*>!HV=R8]][;WSDF_P-0 M2P,$% @ BX)J51KX\-YP P 80\ !@ !X;"]W;W)K &$W*,A8K <&I?X M8HQ[*B&)^.W!AN]<(V7E@=)'=?-],30L100^.$))$/FQAC'XOE*2'$^9J)&O MJ1)WKU_5OR7FI9D'PF%,_3_>0KA#X]Q "UB2V!=W=',-F:&.TG.HSY/_:)/& M=MH&6F4/41"VK@6S+ MMDO2Q_KT"3@R'2?IN)AN2L.Y:SMW;2=Z[0-Z]Q!$E,G7%DV?8D^\-- \,89N M8\$%"1=>N"HSF:IV$E55(.N1W>M:ZF]@KG?M:)=7I7G!(^+ T)"UQX&MP1A] M^H"[UE>-N59NKJ4U-Y.% (S! LFWQWELH(@PM"9^# UT%@%+-_%SF;]4N+?C MSVI*<_B-N\JP G<[YVX?QYV^;(C$PJ7,^PN+,N3VWI9@JVQ'JN,*T)T=U.I%W^1'/]W%Q?OYOI+J9OVS%] MJ%^O#U6&%:BQM9V)UC'SF*L M'\8GEVZF6UF[U7%%\NU QOJ)?%+Q[H_[.C#E-G?./^KP^9.PE1=RY,-29EK-GI1@Z7DN MO1$T2HY$#U3( U9RZ;]0I*S]5C_X!4$L#!!0 ( (N" M:E7..53L@P< 'HD 8 >&PO=V]R:W-H965T&ULK5I= MD]JX$OTK*C:UM;>*#+;\ 4QFJ)H!7)NJFYE4F.P^;.V#Q@CPC6VQDH#DW]^6 M,#;&0C ;YR%C[.[3W4>M5DOVW8[Q;V)%J43?LS07]YV5E.O;7D_$*YH1<7Q_0(QT\!/-*!!VS],]D+E?WG4$'S>F";%+YA>U^IT5 @<*+62KT M_VA7R#H=%&^$9%FA#!YD2;[_2[X71!PIN-X9!5PHX%.%X(R"5RAXIPK^&06_ M4/"OM1 4"L&U"F&A$&KN]V1IIB=$DM$=9SO$E32@J0L]7%H;"$YRE5DSR>%I M GIR-'Y^FDR?9M,)FKT\O$P_39]>9N@Y0L^?IU\>7CX^/\W0>_1U-D&_O?O/ M74^"1:77BPOT\1X=GT'WT">6RY5 TWQ.YP;]J5T_N*0?V?6'%OT>,%72A0]T MC;$5<$;7-\ASN@@[&!O\F5RO[IKH^#GUZ%\[7R/#*W/'TWC^&;S_TB5)$#&@E)A2I4]6*C!5,';CEP_" :#N][VF$&K355H;\6:Q/2^ Y54 M4+ZEG=&OO[BA\\'$9YM@43. H==W7:<,H,:B7[+H6UG\F(L-)WE,39SM58-C MSCS/<_ )9U8+;^6L3;"H&8 W#()@:.8L*#D+K)P]RQ7E")973F22+U',A#3F M7- PCQUO$)S09S7V5OK:!(N:_KL#R( S](4E?:&5OOV:K!=VF+Q7T!@VW'!. M* R;DSL9$&C!679(!98;LV#0 M,/[>PT/LXS>FJ(=MCAN MDS;!IFV"12V!U<; =:KNT[FP^$D*N+(8" 0E"38XWZ@DKRE%@L8;GLB$"K2B MZ1R$T N'GA@]Q#';Y-+8D#K-DHG]H.^?9JE!\#1%[M!(Y7)%]2Q4\/P@; M=VTO7")'2H[&CN&UG!#0?\8.AZS1QJ M"C98N2@2&41<#_LN#L[%6W7HKKU%?Z+EU/HMA3)OWL,U&UL?A]CI-Y*@*6BJ M[$8Q0VDWR,$X>WWLXS-Q5SVU:V^JQRS+H):,4P)+VP/ZZQ/-7BG_VQA]F_WN MI%6T::MH45MH]3&I>G8W^+D5UVVS=9ZTBC9M%2UJ"ZT^$E7[[]K[_S_U>1LT MOP];Z/=@^7C:J.FAUHW9BH!%]+R10L+F )KF+GHD(HF- ]9LU7$_= QMLD&R M434NBD37V*M34FT17/L>X8V43))T(XTG4F.WV:.?(^7RYN&R2'2-O3HIU;[ MM6\,],"CO%I#8'N A*+#&/@>;'#LZXWKG08]:!3]1M 712*C+2\X$W"U)W"M M[>ZH&-;K0QY>%?+P8) MU]P8A$/32G*MX/1:P>@*P3JEU98$V[O!;L(%@\T6[-<,([6 M))FC=SCH0HYU$=P@ZS5GWY.,2)K^0.^ \>OF -EAF(&$Q/%E$N2Y# M%Y27 M+P?405,,T,F\."A&"P -NOW 42;*-H)QF+V$_]C#BJXZ9B\.I[1-Q[U!'W,T MHVNI^XW"]8-1K;5B*5@12&PXISE4IV0.A>;(%/_(YVA$@1X@-Y.1N ME<0K!!B;5*4HQ!-V89I?,/)!']MIU8/P#F*&\%__1V.I1J9D B4+/KR%?L=T>-M",G5N*\#9+46OE*JO4R1G^^]+("'5 M6; 6A&@Y7:0Z\%5%\XUI5>\=??Z04;[4'ZH(I(^(]^]AR[OEQS"/^A.0D_MC M]W;B&NX_X/!VBD/CDSX\T=_5]"K3^Z]R/A&^3'(!F;8 -YR;/I0%OO_09?]# MLK7^,..52&PO=V]R:W-H965T&ULM9EM;^HV M%,>_BI5-T[T2(P\0*!T@M<35[8L":KC;BVDOW,1 U"3.; -WTC[\[! "@>"2 MRNN+DJ?S._;_'-LY\7!'Z#M;8\S!CR1.V1RF>4\ V28+H/X\X)KN1 M81N'"Z_1:LWE!7,\S- *^YA_S^94G)DE)8P2G+*(I(#BY_RY#D<&99L$8YQP"4"B9\MGN XEB31CK\+J%'ZE(:GQP?Z M4]YYT9DWQ/"$Q']$(5^/C#L#A'B)-C%_);MON.B0*WD!B5G^'^SVS_:$QV## M.$D*8W&>1.G^%_THA#@QL+M7#)S"P+G5H%,8=&XUZ!8&W5L-W,(@[[JY[WLN MG(9"KGUL+O:)4)HK/J;@;"3L^GLRF'ISZT /^XF$!7^!T MX8/9$YC-X>O#XGDV]<&7.:(XY6O,HP#%7\&OX+OO@2\_?QV:7+1 :>VMS#@3"WKWJ'-WBO;[PI M5"^E=TKIG9S7O<9#,09D"7Q.@O<6F! Q^D),43Z 7G& Q0@*@3A>4)0RE ^L M.LGW7GJY%SDO;,?6T-R>JJILAYR*[EF& CPRQ%S#,-UB8_S+3W;/^JU.8YTP MJ E6T;]3ZM]1Z[\6>ZI/MU.W[7. MDUOIN6ERZX1!3;"*XFZIN*M4?$*21$P=^=P"O&@K9I8T9*U"]3J]W0N]>P-+ M_IWIK?3;5&^=,*@)5M&[5^K=NT7O28P8 X_@SQB7T>C?G/V'G&^!V88SCM(P2E=U<5$BF\:E?]MH\FY\#FIJ7$7-NU+- M.Z6:3V23AH=UD2ES6PEJJJ%.F*<3!C7!*M$8E-$8W+B6RD4T$V^-I R-OZ'B M55W$JGY)'5PD6^T,K_3?5'>=,*@)5M'=MHZEDO69<0#^!0UF?[6/ID-$*\W3 M2H.Z:-5HG12VMN;7^P+8/ZVDVF)XV&?C0^VXL>@Z:;"@#<[ZT"V[4%7S6*O: MZF+U>NX?IJ!FHT!G%3G12O.TTJ N6C5NQQK7_J#(U?21P;XL5QWW M NQJ%6Q?EL&N_.APF>E:ZV"M-*B+5E7]6 K;ZEKX,U][U,C&"T+O(HI=M]_I M6?VS\DNK6ZB+5M7]6/3:_T/5:U]6H%<27F=][&FE05VTO?#FR7:*W"U[0705 MI0S$>"GP5KLOQ*+[#:C]"2=9OL/R1C@G27ZXQDC,._(!<7])"#^(X72R8>]&ZO5VB!IYA]67VF M_*ZW0YG%*<[RF&2 XOE-9VQ?W<.18"@H_A7C;;YW#<147@GY)FX>9C<=2XP( M)SAB @+Q?QL\P4DBD/@X_JQ .SN9@G'_^@T]+";/)_.*=(8= M,,-SM$[8,]E^Q-6$/($7D20O_H)M16MU0+3.&4DK9CZ"-,[*_^A[I8@]!MMI M88 5 SQ@4; $5U!Q-7!3V+;BY1>),N.*44?YKS/G8[>3IT0\>IX$/IB_C ME^!3\/@R!4\AF'P'819V""5C'' E\_X?05T_\J0'T]Z#-F?.'B&0@0S>)LD>NP CW6A*0I7V:3 M!.4Y&.^ 0/5\RDCT30'$I1%&" &V!*# M5[R(,Z$B\6"\HI? 'G8!M*"M\H 2NE] BWUQYM]@RNH7,<^H/)E MJ@.*X"A%*%/T1S5-0S_.3C_.S^GG/??,?(DHSC^= M'-,-[MS^_6]VW_I=M89,@ODFP8(2S-,82:;@1K(DM[G7V^6KK?-^=V==MT!Q M6E >LHC'^!SSG0^75Q] 7*VR)4EFF.:_@>#/=JE7WG MFC2Q23#?)%A@$BPT!-:POK>SOJ?UH4>>#<991%)N_X3DN3+*>9*[7MB>,W(. M-CFMI'/-=9K,P*3,T!!8PQ#]G2'ZYVRR.)N)RRE>70+':M]2^Y*:1GUK<& 8 MF4@5?60JI<;[1T.03-$:@@8[[0S.UHUB_,P"IA MAJQL%,TWBA8810M-H36=8*]/8?_U1*S":&Y3^_M+932MJ+.-=I+0P*C0T!1: MTQIU1\ ^JR5P:C96H1Y)QQ14JI"D(%,F9/;QIH""I#4JV75;P#ZK+_ S29E> MPMF;E=&>@%&TP#[>%5"0J,/2$;L"!W7 M\OK2=B632FNA!;A&FF:KZV^[_RNS,&VU?[;M3*+Y1M$"HVBA*;2F M$]1M!EM?U8XC;OKB#)', :&S.$/T1[EH0;Y^_1^.^*(F8,43M/@UP8#B&4Y7 M@D'I!'*IS3,GQQU"*24PVE X66Y04>[O@$K"T-0 FW:IVP2VOD]P6G:L:@CT MG0%TX:&ZM=+.5O>I<@.C=#;0EY9KZL5)Y>PKEAQ2B:;Q0M MJ-!.2 D4E-J4 -8U.=37Y*=V)]6F4I7-GN.Y[D Z'99)I:/A%C3//DRG@XKT M( $>62-K" ]5)Y.V^_G>UW.0^<7)L#0:&5O%,TWBA8810M-H36=H*[YH;[F-YL 0T79;D/7&TBA7C^L MLPU\JMP RBT )6%H:H!-N]1-!6C@G![*Q;$+^]"2 X[17L"I8@.C8D-3:$V+ MU/T"^%_"M*V]%=!VIX6U+4U-'F&KU:>T4-\ MHVB^4;0 RB5\6T)P_#R_:3!1=#>?U"4?/'KB^92)]_SB!,!!V;GL%M:&ZV&_B:TX*J2'![G*.7>B7ELZQ;B,M(<0Q>@#*#%@N(% MGY:(E';7=09=3S>@!*.-F%8]]I"LA10P+2@ 6;. MQ1L^#KYVMH@K)\_7F%\NXVC)0W&^3AB_Y?/I=[D+'!'RNQAXR?I&O,7-,+_3 M!(CGA9D+K"V-&7^T1#.N&0;P=TRC..>".45,P7S-4T-AT@N4)(2E.&. %"G" M)7AI8N02LY)/S*A$W=-*U3B_!&/^0ZF;PMXY-\Z,*R-!0AUFB]5L:*W]SYZBNFB^-0@YS["196O MU>Z>EI\SA/;5??'6_\'S,1Q>W?,%J?IE]/8%1*\647X_\0E17E'EW*/F7)QU M.>!KGY:?))0WC*R*-^)?"6,D+2Z7&'&M"P+^^YP0]G8C!.P^#+G]/U!+ P04 M " "+@FI5QYW:L8L$ S' & 'AL+W=OS:E YZ9,WC*,53"M@Z M21#]YQ['9-,W;&-WX3E:++F\8 YZ*[3 /N8OJRD59V:!$D8)3EE$4D#QO&\, M[3MH=Z5!]L3O$=ZP@V,@I_)*R)L\&85]PY(CPC$.N(1 XN<=NSB.)9(8Q]<< MU"A\2L/#XQWZ0S9Y,9E7Q+!+XC^BD"_[QHT!0CQ'ZY@_D\TCSB?4EG@!B5GV M'VSR9RT#!&O&29(;BQ$D4;K]1=]R(@X,[-89 R9"QGUD+OJ)4)HK/J;@;"3L^<"=C#XY] MZ %_-IS!)SB>^6#R -S'X?@7Z(/1&/B/PV?X./G5@\\_^N"+!Q]&[FAV!>!O M+Z/9G^ +F"**4[[$/ I0#*[ 3^#%]\"7[Z]Z)A=#E([,(!_._78XSIGA#%?T M&CC=!G LQZXP=]7F/EY=@Z:5F3L5YI[:W,.!,+?/>H<7>*\>O"G"4L3&*6+C M9'BM.ID7 MV3C>!U;/?#]D53D.V:ONV H%N&^(9L0P?+A84+Q#'8+Q.7@7%DSG(Z9]L4AQ6D;U%;!_RTVIVV]9Q%O)N$N21+2.K+< +WH7G24-62-GO8KO]@G?G5M+_AWQK?1; MEV^=8% 36(GO3L%WYQ*^W1@Q!N[!7T]8YOG?540K@>IV$9U@GDXPJ FL%(UN M$8WNQ=F_R_D&F*PYXR@-HW11%1;I!(.:P$K1N"VB<7OA6BH7T95X:R1%:/PU%>_J(E;5 M2^KM2;)5=GBE_[J\ZP2#FL!*O-O67DM9GZD#\"^HT?W5/NJ6B%8T3RL:U(56 MCM:!\K4UO][G@-U#)74MRL,^J@^UX]JDZT2#.=KMT1Q:Q13*;.ZUJJT6J^=S M?]>"ZE6!3A7I:D7SM*)!76CEN.TUKOV!R-7TD<$^E:M.^W3I4(^F=B2T"F!= M:.5(["6PK=; G^A'K0]J.>=RELJ[7P9[[VJ"%K+PB=DRBVVMUFQ^H>R2^M M;J$NM#+O>]%K_P^JUSY5H&<27J<^]K2B05UH6^+-@_T6N9WVA.@B2AF(\5S M6]==01;=[E!M3SA995LPKX1SDF2'2XQ$WY$/B/MS0OCN1.[J%/N$@_\ 4$L# M!!0 ( (N":E7&1I$&F@8 ! G 8 >&PO=V]R:W-H965T&ULK5I=<]HX%/TK&G9GIYUIBRT; ]F$&8+Q-#-MDBGI]F%G'X01P:TM M>24Y)/]^)=LQ8(0"K%X2?^@>R??HZNH>=+FF[!=?82S L0S++[G]TS>=1N419)APA-* M ,/+J\[8O8A@:5"V^"O!:[YU#=2GS"G]I6YN%E<=1XT(IS@6"@+)?T]X@M-4 M('V]2MZ5'Z\_)@YXGA"TQ_)0JRN.H,.6. E*E+QC:X_X_J# M>@HOIBDO_X)UW=;I@+C@@F:UL1Q!EI#J/WJN';%E(''T!K V@&T#_X"!5QMX MQ_;@UP;^L0:]VJ!WK$%0&P2E[RMGE9X.D4"C2T;7@*G6$DU=E'25UM+!"5$S M:R:8?)M(.S&:W-V&T]O9- 2SA_'#].OT]F$&[B(P&<\^@^C+W8\9^ B^ST+P M[O?WEUTA>U1VW;A&OZ[0X0%T#WRE1*PXF)(%7FCL0[-][RW[J=E^\)9]9+8? M&NR[TM.-N^&KNZ^A$7"&\T_ '-7Y\[_9SXUFXI91S[4)4000EA$JG3R,?!M#I.Y?=IVV^]MM]=(-AJU6H:]7S MAMYNLZEQW*>Z>+]/UPV\/O1AT^N.^WJ-^WK&.!DO?LH\(G<#@@-!P3<<4Q(G M*0;*KS>U7[\HOZK7953=,_J4R!4/S%_ N^]<7B3DO3; P-_C.1=,;A#^T;'2 MLQEJ-L%"FV!3FV"1);"=N1(T[?L-=W\C=#1%8H@J $2,R9!6)*IA7.%7Q M"QZ87 9DZ,:T($+'9'_/7Q]=Z/?Z?J^UANXW;*^?QI'J_0!T@74&SF%R=-\7 M>'![]=]Q_*!Q_,#H^,D*D4>L7+Q$"0-/*"TPH$NP1HPA(D":H'F2ELNESNV# M_6%YGM\+G';JVF_8=KMQG">X?:!)?\[0]Z'?ZC'2#%X&F3.0P]<[==@X=6C, M6C(QR4J9R]0DMYWEU7OEX4T.FJ \$2A](P$-;:Y.-L%"FV!3FV"1); =VEUG M4Y ZQFBZ9[C,.HAS++0!8P8XE52K:.$Y:-H0M#JLJ$;;CE-?5F&]@3Y(W2WY MP#6R)=,)*V2RP<\Y)ER_P)DA3N;+)EI8HVT[QNNW5]ZIU3XC39]!?^#" RNF M"S=D0",9H>@Z3FTJF'4:#N;%=_S M N\0BQN!PGU;H8B;7:#B4TN93;E@8A4M/ =-3YE53:1&.YZRC2CB&NOH4CW\ M .;X,2%$19O">S9U7,. =-SYXEH*@&VBF^/>@-'>\ M<1N%PC5+%!5QF"R.H"S8JV,&0P?V6Q+ Q-SC\5\=V@*::D;>=E_MYWV1H_6) MNV[>B ENWUA_S8H\3[%2#66-M4AXG%)>L+*NC5^%=[G8+5\%(ZW2[MJLWR=6 MT4*K:%.K:)$MM%WN-WJ&>ZR@T6@9DU368U478T#9(B&(O0"^0K)_P(OY3QP+ MM??,*>?)/,5R$[K 6:YFAG9BG*%4&":&3;3P'#1]$-L<5N3N2RUNX/D#V#\0 MZANEQ356]*,0+S%C2C%YBS5/><%(G%[?ERWYX=V E@5 M9JRBA37:MJ=AS]DO"JV*+N>@ 4.TPXW@ LV"R['T%V2!695Q&E\ZLLP8-7QJ^I& MT+P\+C2G0M"LO%QA)$-?-9#OEU2&?'VC.F@.P8W^ U!+ P04 " "+@FI5 M(.!I/YP5 I10 & 'AL+W=O?GGZZ9Z!7F]L_ZPB]S6Z]4@Z_UXMRM:ZT*?FA5GD_'X^?G*V6JH[>O^=J7^NUK MVS:EJ?27.G/M:J7J[3M=VLV;H\E1N/"S62P;NG#^]O5:+?2-;GY9?ZGQ[3R. M4IB5KIRQ55;K^9NCJ\EW[Y[1_7S#/XW>N.1S1BN96?N-OGPLWAR-22!=ZKRA M$13^N=77NBQI((CQ+S_F49R2'DP_A]$_\-JQEIER^MJ6OYJB6;XYNCS*"CU7 M;=G\;#<_:+^>"QHOMZ7C_\\V_M[Q49:WKK$K_S D6)E*_E5W7@^/>6#J'YBR MW#(12_F]:M3;U[7=9#7=C='H R^5GX9PIB*CW#0U?C5XKGG[N5ZHROQ;B8JJ M(GO7.MSB7/9YK6N^_/J\P41T^WGN!WTG@TX/#/HR^]%6S=)E[ZM"%_WGSR%@ ME'(:I'PWO7? &[T^RYZ.1]ET/)W>,][3N.JG/-[31ZQZE%W;RMG2%)T2OM3: MZ:J1"W:>?3"5JG*CRNP&%S6LW M1VN:J[[51V___K?)\_&K>Y;W+"[OV7VC_U&CWCOHL,@_V49GD^SO?[N<3J:O MLD=,G+V_^Z'F5NJ6J-V?*EJA9Z!%D<(%1U MRPJW8!S&:5< MGL21Y#Q57EI'0T.!]!4/BM:<5G!3U@*,6%NWUIPOHVQ#+GK )Q:Z(B7K5.&8 MLM:WNFJAEQ86A^;GC1:5DV%+'>S-7N$G'?)'A%K#CT'B$OX_Y)E1@LI63SH) MO@Y8PZT)_>&MSB/3IT_7F"+['D;<4/P&]RZ-FIF27"4@2QIX-S),/];(U2E% M\-)P&,*?89!!MFP+FJ;BWWD4^*AX(SQ;%R):W^EO^.GHW;#]\61\!KE@ M51XC.]D 5I;=^#3&O(47(!74N1$(IXLMV$B]J6'-VGFE9_96UT]46=J&36,E MO+$B&1/&, XTS(GQKAUJN3!)\]&XV>B+;A,K:H=A7VIS2UYXY<2Z9/G M^=7?%M>E%:;S JL9AH460^;@)'!=(L-D5SMJ%7U,SBY$'WR- X2"V.0LW?$D MJ.N@'+0V?H)_7L>?O2F]<^,S1B8$T00I*Q!?56G;NG(K'D#W[F 5 @$3."4< M/+<.JE$K"PB0C'$\>3Z:/+T!& MV?'+T?/G\3X0EA/10WYC@L"8:G(Q M>C:]'$T0?12HL XR$Z^#-;^T)2:-\0Q93 X'Y1E?3"#CI3Q'_I8KKP%26O0: MNE7?H>*"BONXMD(N#4BI>[3@/K!T2(.W3%Q@X,4"@$0&GBN#9U7]#5GU5I4M MNPE,6VJ%22['_Q$BIB)*0\0&X^@RAN[7FH2YRG-22W:B9*E52#FGV0EX$8*1 M)J;['V>41MT!)M9JR_YO*Y\:$:T >4)[FL .2' :,D*#NY]>CS+?K ;Y*^ZCYZ<;*)1'AH$PB-2C*@6W+)Y,GA7 M2"\0TZ,0U.^I0>)F($&;*H K"T+?*7\3?X)?7) =O8]X>Z(J1QJJV#"WEJW@ M=-[60B3]39YN24[DZ-@0B%)FKS4/S7XKR0VA0PY-?.X69F+]A@6PM85F=#\& MU5TA4Z08.7Q++Y^2KQ-I)9=L$2],:;SI>Q8!*0T8&HVCADWBVCS'-;C+I\?3RTG$JA-*3],N/9T*E0S1!&J5:XTZ!15GC"=F89*_ M:+YXCY\XI!F&UX.I9.2Y QR+^0I#>L-QHD*D>EWWHJ=+K8A!\2-RTYGV)I6A M:"GXQ.6O"S9;4/:L6(K.C0(QH+CRZUMI57E%WOBHFYZHTY/)\].HW&$/">@% MM&IH_"VGV\N+K%!;KH)*,BBY:@5'K_0VP-J\I6)PI;5 C:X;)6%?&,%%< M@^%W1/"$WP7F%)90<.%4D)@-JV>E@2BXTJZD6J-ZKQ3T0%S:W 26GG*GI!1I M9[\E+-$CBG14, 1(MY]N@2)21F*GA(5N42QV$1^C),;7#O78HVGWQ\\]"DVK MW:C0..U.-IR<[NAZY N>_5+GH80Q(D8NNQG*M@*>(@!0[.!\T>!?#S:=0@NMSQWZ4I9 G\#\4YF MI]YM"FKSA!8!'#K533)A0QY<"X;M+D6E0E(^Y(S!3O]GW3\[N6*KK6QAYEOQ MPG9&N3=GX@:FDF26W4*PPPJ.4^_Y,>W[APZ: .JA7C0]"_QD7F+J\+.H?5@A M#Q.8NK-<-AEW1+&O?=-;5E98[4(K1I+Q0S5^2!Z3"T)UZB2?M)5 ?>0C^J[Q MYDD=Q<=OZ&"T3KHQG-)M2+9)3N[E>.([L??2;T1&R;YP?R@F30K0=Z=[2,Z= M#T9PMI[?PN@+PD9B\ONQ>M:KW&?$RT M@-IG 7Y[@;]91G<1+SSDM8\+SYZ=\U*U\ ."A&AUG>M"6"U2*<4:ANBPFUNF MI<"/)-$#(-ZN?:JEH$6&"JRV0U)FO/='2FF0VORFPB.L\="(]QAEU_L8@ ]I MVMF( 0.=LP VAVJ.B!-VO;9U0\VA;8()I&QI(>+'SC=A^+YW1@7_OOR4:<-! M=6).'_:82/X@E&]/KVEY^K#C4S0;C#W;,F=UOO_,.42@0516Z%QB6G&7=[/4 M+-9>(>*T_M:3223 ZGA@RE+<3#DD#/'5-F]V9(A%SDK!4K-MGVR@L-"2NLF& M1,%JW>7V\.B,.0RM(+M5M='"K.<*Q0VLS ZD7"BJDU35)-T<'B]9.LCKR@W= MN+%M602JMTM##^M(B'@?9GC7I+'YM[CU@CASOK\1?Z=B'XNR BS^8^JAY M!^[RQ.\>41=O%+LBY/3*+4<9UHH!?";I.CO2J0H,+E2#PZP6<4$;-7XCC=:S ML5V;GPLLS"XI7];AP>K19+(K:0^T<1ZJ9,C#"" ,)U:'F[5[8E!:O>Z23OLLHJ][-,I,V$P&^KM M('GC;O+&)OU-&I3D"3E%FID;<=@&-X")8VB*>P3K/3EEIS(<<7,DI^F8D'/L M=WO\WE:T\!OR"57#2=]9_!,9>NBD?+BZ>1>YX.!SUU0!A.W-\-C5S75\ZJM= M0[1GE^/ -K\7/&N-6])0G_R^$W7HF*Z\Y^6>A3[+QTK@.N<]YGWK2)D<$N0@ MY RQ$PT; 5X-H8YO :=-XN,+ZG;AOXGH743808@#T_&6T\BC!OEU, M_ZN2[/^I')B=L .W:]EX&\=-LRB9'Z"S#<^./ -2V0H!E\TI=WIO/GTPITH+ M-^M+:.7Z7.ZD4WJO&T+E(6T%S=N:26M:H<5D*KN* MHK'35U)SFT=NO;8Q%I(3#4 @*/5::*H!961M+PMCEE(][OY+:S MI49@6(U.C':KNYF]=^5* E#*9^>#+ZQR=.C42M*_]L1\Y^ 5D?.D6T4ACRF, M5 2H00K#Y"0T97<;O](MV>TI$"B'W6?>&Z5M\I5.70TRJ(7?KM9J);"MV:,I MHK@9DVS^19X?"R: DFN5[':+7^+GK8S#SW&<$<1ME(GMM,1WO1<.'(+ ?1^L M:$O.,7BL^_,#L39V.CZ/[G#Z,ICT0BW.=*M_U^Q_N@=*#6&I__Z_%_H_U M] M+'4X@8@"]M-)>!;B; )S">7][D;IT%&O_Z5.YXZQ#]FQ ^%>Y,BPF"0".>;L M ?FA!M_0*G8"3$" =VG[)IPK4[H=7I8T[PZ>Y1QLWO4ACMA:@!P*'-/$A@T= M/Y,M[5063E.1![!9&UZ,AUXD9T6-;20+.IDIQQSI["X(#_F_WQRQ;#UJ-?F- MZ9UI3JQO\JAJT&[@"WI-@U5-/!>@(SZIKBZ:FWIU.LKV3AGZ,P=1=VR?",8] M-MMM*C+(>V9E>;,[Z4T%P!_Y"M?OZ) @[L"VJ?7;E%SETSE;SC$$_,F1LS2Z M@U]*1QXS$UWT['#OWGL87HP'SM[^;;X\$&/X@GTG\AI#+-UD,)M2<6'0T(T]-5? M6=^(-<,"=L<(AJ)E527E;-HV.03F:@$^2$? _%&&LFL+I$5&9#SANN\A9&M9<# P$_$*<06!TYOA=I8 MN6^^*HX''2EB^!6';EAOM=C+Z?EQY<&[A\T=*,(Y,+NTKM*.>8K[KIW3<4$^ M(,PE(3DAQG?S4-%%KTFH>*#385(@F-&WR3$)UQU,%CY5(#\D4HX M*.JNTO%1Y\W1PYNTZN"Z-+B8B0>0N?U'F(7J-.GECI+'X-Y%*%7N@10-X:\_ M__/C]T\F+RDT?N03]-/Q="SZ^M764,(/6I7(9;TW8^C<*+(%/.+?WO$@S P% MY;=X\!+\O,SH[+AA],]MC5KSU@"!4-!!(/9#ZB&'%RBD#17D&3&M@&5KWKJD M35!=+0@@-%B+70%9
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end
XML 52 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 141 207 1 true 30 0 false 9 false false R1.htm 1001 - Document - Cover Page Sheet http://www.esgen-spac.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - CONDENSED BALANCE SHEETS Sheet http://www.esgen-spac.com/role/CondensedBalanceSheets CONDENSED BALANCE SHEETS Statements 2 false false R3.htm 1003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) Sheet http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical CONDENSED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - CONDENSED STATEMENTS OF OPERATIONS Sheet http://www.esgen-spac.com/role/CondensedStatementsOfOperations CONDENSED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1005 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Parenthetical) Sheet http://www.esgen-spac.com/role/CondensedStatementsOfOperationsParenthetical CONDENSED STATEMENTS OF OPERATIONS (Parenthetical) Statements 5 false false R6.htm 1006 - Statement - CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDER'S (DEFICIT) EQUITY Sheet http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquity CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDER'S (DEFICIT) EQUITY Statements 6 false false R7.htm 1007 - Statement - CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDER'S (DEFICIT) EQUITY ( Parenthetical ) Sheet http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquityParenthetical CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDER'S (DEFICIT) EQUITY ( Parenthetical ) Statements 7 false false R8.htm 1008 - Statement - CONDENSED STATEMENTS OF CASH FLOWS Sheet http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows CONDENSED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 1009 - Disclosure - Organization and Business Operation Sheet http://www.esgen-spac.com/role/OrganizationAndBusinessOperation Organization and Business Operation Notes 9 false false R10.htm 1010 - Disclosure - Significant Accounting Policies Sheet http://www.esgen-spac.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 10 false false R11.htm 1011 - Disclosure - Public Offering Sheet http://www.esgen-spac.com/role/PublicOffering Public Offering Notes 11 false false R12.htm 1012 - Disclosure - Private Placement Sheet http://www.esgen-spac.com/role/PrivatePlacement Private Placement Notes 12 false false R13.htm 1013 - Disclosure - Related Party Transactions Sheet http://www.esgen-spac.com/role/RelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 1014 - Disclosure - Prepaid Expenses Sheet http://www.esgen-spac.com/role/PrepaidExpenses Prepaid Expenses Notes 14 false false R15.htm 1015 - Disclosure - Commitments & Contingencies Sheet http://www.esgen-spac.com/role/CommitmentsContingencies Commitments & Contingencies Notes 15 false false R16.htm 1016 - Disclosure - Warrant Liabilities Sheet http://www.esgen-spac.com/role/WarrantLiabilities Warrant Liabilities Notes 16 false false R17.htm 1017 - Disclosure - Recurring Fair Value Measurements Sheet http://www.esgen-spac.com/role/RecurringFairValueMeasurements Recurring Fair Value Measurements Notes 17 false false R18.htm 1018 - Disclosure - Shareholder's Equity (Deficit) Sheet http://www.esgen-spac.com/role/ShareholderSEquityDeficit Shareholder's Equity (Deficit) Notes 18 false false R19.htm 1019 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.esgen-spac.com/role/SignificantAccountingPolicies 19 false false R20.htm 1020 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.esgen-spac.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://www.esgen-spac.com/role/SignificantAccountingPolicies 20 false false R21.htm 1021 - Disclosure - Public Offering (Tables) Sheet http://www.esgen-spac.com/role/PublicOfferingTables Public Offering (Tables) Tables http://www.esgen-spac.com/role/PublicOffering 21 false false R22.htm 1022 - Disclosure - Prepaid Expenses (Tables) Sheet http://www.esgen-spac.com/role/PrepaidExpensesTables Prepaid Expenses (Tables) Tables http://www.esgen-spac.com/role/PrepaidExpenses 22 false false R23.htm 1023 - Disclosure - Recurring Fair Value Measurements (Tables) Sheet http://www.esgen-spac.com/role/RecurringFairValueMeasurementsTables Recurring Fair Value Measurements (Tables) Tables http://www.esgen-spac.com/role/RecurringFairValueMeasurements 23 false false R24.htm 1024 - Disclosure - Organization and Business Operation (Details) Sheet http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails Organization and Business Operation (Details) Details http://www.esgen-spac.com/role/OrganizationAndBusinessOperation 24 false false R25.htm 1025 - Disclosure - Significant Accounting Policies (Details) Sheet http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Details http://www.esgen-spac.com/role/SignificantAccountingPoliciesTables 25 false false R26.htm 1026 - Disclosure - Significant Accounting Policies - Reconciliation of Net Loss per Common Share (Details) Sheet http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails Significant Accounting Policies - Reconciliation of Net Loss per Common Share (Details) Details 26 false false R27.htm 1027 - Disclosure - Public Offering (Details) Sheet http://www.esgen-spac.com/role/PublicOfferingDetails Public Offering (Details) Details http://www.esgen-spac.com/role/PublicOfferingTables 27 false false R28.htm 1028 - Disclosure - Public Offering - Summary of Ordinary Shares Reflected on Balance Sheet (Details) Sheet http://www.esgen-spac.com/role/PublicOfferingSummaryOfOrdinarySharesReflectedOnBalanceSheetDetails Public Offering - Summary of Ordinary Shares Reflected on Balance Sheet (Details) Details 28 false false R29.htm 1029 - Disclosure - Private Placement (Details) Sheet http://www.esgen-spac.com/role/PrivatePlacementDetails Private Placement (Details) Details http://www.esgen-spac.com/role/PrivatePlacement 29 false false R30.htm 1030 - Disclosure - Related Party Transactions - Founder Shares (Details) Sheet http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails Related Party Transactions - Founder Shares (Details) Details 30 false false R31.htm 1031 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 31 false false R32.htm 1032 - Disclosure - Prepaid Expenses (Details) Sheet http://www.esgen-spac.com/role/PrepaidExpensesDetails Prepaid Expenses (Details) Details http://www.esgen-spac.com/role/PrepaidExpensesTables 32 false false R33.htm 1033 - Disclosure - Commitments & Contingencies (Details) Sheet http://www.esgen-spac.com/role/CommitmentsContingenciesDetails Commitments & Contingencies (Details) Details http://www.esgen-spac.com/role/CommitmentsContingencies 33 false false R34.htm 1034 - Disclosure - Warrant Liabilities (Details) Sheet http://www.esgen-spac.com/role/WarrantLiabilitiesDetails Warrant Liabilities (Details) Details http://www.esgen-spac.com/role/WarrantLiabilities 34 false false R35.htm 1035 - Disclosure - Recurring Fair Value Measurements - Fair value hierarchy for liabilities measured at fair value on recurring basis (Details) Sheet http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails Recurring Fair Value Measurements - Fair value hierarchy for liabilities measured at fair value on recurring basis (Details) Details 35 false false R36.htm 1036 - Disclosure - Recurring Fair Value Measurements - changes in the fair value (Details) Sheet http://www.esgen-spac.com/role/RecurringFairValueMeasurementsChangesInTheFairValueDetails Recurring Fair Value Measurements - changes in the fair value (Details) Details 36 false false R37.htm 1037 - Disclosure - Recurring Fair Value Measurements - Companys Level 3 liabilities that are measured at fair value on a recurring basis (Details) Sheet http://www.esgen-spac.com/role/RecurringFairValueMeasurementsCompanysLevel3LiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetails Recurring Fair Value Measurements - Companys Level 3 liabilities that are measured at fair value on a recurring basis (Details) Details 37 false false R38.htm 1038 - Disclosure - Shareholder's Equity - Preferred Stock Shares (Details) Sheet http://www.esgen-spac.com/role/ShareholdersEquityPreferredStockSharesDetails Shareholder's Equity - Preferred Stock Shares (Details) Details 38 false false R39.htm 1039 - Disclosure - Shareholder's Equity-Common Stock Shares (Details) Sheet http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails Shareholder's Equity-Common Stock Shares (Details) Details 39 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:DocumentTransitionReport, esac:NumberOfWarrantsIssuedPerUnit - d374880d10q.htm 9, 253 d374880d10q.htm d374880dex311.htm d374880dex312.htm d374880dex321.htm d374880dex322.htm esac-20220930.xsd esac-20220930_cal.xml esac-20220930_def.xml esac-20220930_lab.xml esac-20220930_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 57 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d374880d10q.htm": { "axisCustom": 0, "axisStandard": 9, "contextCount": 141, "dts": { "calculationLink": { "local": [ "esac-20220930_cal.xml" ] }, "definitionLink": { "local": [ "esac-20220930_def.xml" ] }, "inline": { "local": [ "d374880d10q.htm" ] }, "labelLink": { "local": [ "esac-20220930_lab.xml" ] }, "presentationLink": { "local": [ "esac-20220930_pre.xml" ] }, "schema": { "local": [ "esac-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 298, "entityCount": 1, "hidden": { "http://www.esgen-spac.com/20220930": 1, "http://xbrl.sec.gov/dei/2022": 5, "total": 6 }, "keyCustom": 77, "keyStandard": 130, "memberCustom": 12, "memberStandard": 17, "nsprefix": "esac", "nsuri": "http://www.esgen-spac.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "1001 - Document - Cover Page", "role": "http://www.esgen-spac.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1010 - Disclosure - Significant Accounting Policies", "role": "http://www.esgen-spac.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "esac:InitialPublicOfferingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1011 - Disclosure - Public Offering", "role": "http://www.esgen-spac.com/role/PublicOffering", "shortName": "Public Offering", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "esac:InitialPublicOfferingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "esac:PrivatePlacementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1012 - Disclosure - Private Placement", "role": "http://www.esgen-spac.com/role/PrivatePlacement", "shortName": "Private Placement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "esac:PrivatePlacementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1013 - Disclosure - Related Party Transactions", "role": "http://www.esgen-spac.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "esac:PrepaidExpensesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1014 - Disclosure - Prepaid Expenses", "role": "http://www.esgen-spac.com/role/PrepaidExpenses", "shortName": "Prepaid Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "esac:PrepaidExpensesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1015 - Disclosure - Commitments & Contingencies", "role": "http://www.esgen-spac.com/role/CommitmentsContingencies", "shortName": "Commitments & Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "esac:WarrantLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1016 - Disclosure - Warrant Liabilities", "role": "http://www.esgen-spac.com/role/WarrantLiabilities", "shortName": "Warrant Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "esac:WarrantLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativesAndFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1017 - Disclosure - Recurring Fair Value Measurements", "role": "http://www.esgen-spac.com/role/RecurringFairValueMeasurements", "shortName": "Recurring Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativesAndFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1018 - Disclosure - Shareholder's Equity (Deficit)", "role": "http://www.esgen-spac.com/role/ShareholderSEquityDeficit", "shortName": "Shareholder's Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1019 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002 - Statement - CONDENSED BALANCE SHEETS", "role": "http://www.esgen-spac.com/role/CondensedBalanceSheets", "shortName": "CONDENSED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "0", "lang": null, "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1020 - Disclosure - Significant Accounting Policies (Tables)", "role": "http://www.esgen-spac.com/role/SignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "esac:InitialPublicOfferingTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1021 - Disclosure - Public Offering (Tables)", "role": "http://www.esgen-spac.com/role/PublicOfferingTables", "shortName": "Public Offering (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "esac:InitialPublicOfferingTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "esac:PrepaidExpensesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "esac:ScheduleOfPrepaidExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1022 - Disclosure - Prepaid Expenses (Tables)", "role": "http://www.esgen-spac.com/role/PrepaidExpensesTables", "shortName": "Prepaid Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "esac:PrepaidExpensesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "esac:ScheduleOfPrepaidExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:DerivativesAndFairValueTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1023 - Disclosure - Recurring Fair Value Measurements (Tables)", "role": "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsTables", "shortName": "Recurring Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DerivativesAndFairValueTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1024 - Disclosure - Organization and Business Operation (Details)", "role": "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "shortName": "Organization and Business Operation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:NatureOfOperations", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "0", "lang": null, "name": "esac:TransactionCosts", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1025 - Disclosure - Significant Accounting Policies (Details)", "role": "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails", "shortName": "Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:IncomeTaxPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn12_31_2021", "decimals": "0", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P07_01_2022To09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1026 - Disclosure - Significant Accounting Policies - Reconciliation of Net Loss per Common Share (Details)", "role": "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails", "shortName": "Significant Accounting Policies - Reconciliation of Net Loss per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P07_01_2022To09_30_2022", "decimals": "0", "lang": null, "name": "esac:AccretionOfTemporaryEquityToRedemptionValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1027 - Disclosure - Public Offering (Details)", "role": "http://www.esgen-spac.com/role/PublicOfferingDetails", "shortName": "Public Offering (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "esac:InitialPublicOfferingTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P10_22_2021To10_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis", "decimals": "0", "lang": null, "name": "esac:NumberOfSharesIssuedPerUnit", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:TemporaryEquityTableTextBlock", "esac:InitialPublicOfferingTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P04_19_2021To12_31_2021", "decimals": "0", "first": true, "lang": null, "name": "esac:ProceedsFromIssuanceOfTemporaryEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1028 - Disclosure - Public Offering - Summary of Ordinary Shares Reflected on Balance Sheet (Details)", "role": "http://www.esgen-spac.com/role/PublicOfferingSummaryOfOrdinarySharesReflectedOnBalanceSheetDetails", "shortName": "Public Offering - Summary of Ordinary Shares Reflected on Balance Sheet (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:TemporaryEquityTableTextBlock", "esac:InitialPublicOfferingTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P04_19_2021To12_31_2021", "decimals": "0", "first": true, "lang": null, "name": "esac:ProceedsFromIssuanceOfTemporaryEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "div", "esac:PrivatePlacementTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn09_30_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis", "decimals": "2", "first": true, "lang": null, "name": "esac:ClassOfWarrantOrRightPriceOfWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1029 - Disclosure - Private Placement (Details)", "role": "http://www.esgen-spac.com/role/PrivatePlacementDetails", "shortName": "Private Placement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "esac:PrivatePlacementTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn09_30_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis", "decimals": "2", "first": true, "lang": null, "name": "esac:ClassOfWarrantOrRightPriceOfWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesOutstanding", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)", "role": "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P04_27_2021To04_27_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1030 - Disclosure - Related Party Transactions - Founder Shares (Details)", "role": "http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails", "shortName": "Related Party Transactions - Founder Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022_FounderSharesMemberusgaapRelatedPartyTransactionAxis", "decimals": "2", "lang": null, "name": "esac:PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn04_27_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1031 - Disclosure - Related Party Transactions - Additional Information (Details)", "role": "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related Party Transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn04_27_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "esac:ScheduleOfPrepaidExpensesTableTextBlock", "esac:PrepaidExpensesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1032 - Disclosure - Prepaid Expenses (Details)", "role": "http://www.esgen-spac.com/role/PrepaidExpensesDetails", "shortName": "Prepaid Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "esac:ScheduleOfPrepaidExpensesTableTextBlock", "esac:PrepaidExpensesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "esac:ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1033 - Disclosure - Commitments & Contingencies (Details)", "role": "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "shortName": "Commitments & Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "0", "lang": null, "name": "esac:MaximumNumberOfDemandsForRegistrationOfSecurities", "reportCount": 1, "unique": true, "unitRef": "Unit_Day", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "esac:WarrantLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn10_22_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1034 - Disclosure - Warrant Liabilities (Details)", "role": "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails", "shortName": "Warrant Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "esac:WarrantLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn10_22_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsHeldInTrustNoncurrent", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1035 - Disclosure - Recurring Fair Value Measurements - Fair value hierarchy for liabilities measured at fair value on recurring basis (Details)", "role": "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "Recurring Fair Value Measurements - Fair value hierarchy for liabilities measured at fair value on recurring basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "us-gaap:DerivativesAndFairValueTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn09_30_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "decimals": "0", "lang": null, "name": "us-gaap:AssetsHeldInTrustNoncurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn06_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1036 - Disclosure - Recurring Fair Value Measurements - changes in the fair value (Details)", "role": "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsChangesInTheFairValueDetails", "shortName": "Recurring Fair Value Measurements - changes in the fair value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn04_18_2021", "decimals": "0", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn12_31_2021_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Unit_D", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1037 - Disclosure - Recurring Fair Value Measurements - Companys Level 3 liabilities that are measured at fair value on a recurring basis (Details)", "role": "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsCompanysLevel3LiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetails", "shortName": "Recurring Fair Value Measurements - Companys Level 3 liabilities that are measured at fair value on a recurring basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn12_31_2021_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Unit_D", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1038 - Disclosure - Shareholder's Equity - Preferred Stock Shares (Details)", "role": "http://www.esgen-spac.com/role/ShareholdersEquityPreferredStockSharesDetails", "shortName": "Shareholder's Equity - Preferred Stock Shares (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R39": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesOutstanding", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1039 - Disclosure - Shareholder's Equity-Common Stock Shares (Details)", "role": "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails", "shortName": "Shareholder's Equity-Common Stock Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": "2", "lang": null, "name": "esac:AggregatePercentageOfOutstandingSharesIssuedToInitialShareholdersPriorToBusinessCombination", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P07_01_2022To09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "esac:LegalAndProfessionalFees", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004 - Statement - CONDENSED STATEMENTS OF OPERATIONS", "role": "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "shortName": "CONDENSED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P07_01_2022To09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "esac:LegalAndProfessionalFees", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P04_27_2021To04_27_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Parenthetical)", "role": "http://www.esgen-spac.com/role/CondensedStatementsOfOperationsParenthetical", "shortName": "CONDENSED STATEMENTS OF OPERATIONS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn04_18_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006 - Statement - CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDER'S (DEFICIT) EQUITY", "role": "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquity", "shortName": "CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDER'S (DEFICIT) EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "PAsOn04_18_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P04_27_2021To04_27_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007 - Statement - CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDER'S (DEFICIT) EQUITY ( Parenthetical )", "role": "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquityParenthetical", "shortName": "CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDER'S (DEFICIT) EQUITY ( Parenthetical )", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P07_01_2022To09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1008 - Statement - CONDENSED STATEMENTS OF CASH FLOWS", "role": "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows", "shortName": "CONDENSED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P04_19_2021To09_30_2021", "decimals": "0", "lang": null, "name": "esac:FormationCostsPaidBySponsor", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1009 - Disclosure - Organization and Business Operation", "role": "http://www.esgen-spac.com/role/OrganizationAndBusinessOperation", "shortName": "Organization and Business Operation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d374880d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 30, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "esac_AccretionOfTemporaryEquityToRedemptionValue": { "auth_ref": [], "calculation": { "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_TemporaryEquityNetIncome", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accretion of temporary equity to redemption value.", "label": "Accretion of temporary equity to redemption value", "negatedTerseLabel": "Accretion of temporary equity to redemption value" } } }, "localname": "AccretionOfTemporaryEquityToRedemptionValue", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "esac_AccruedExpensesPaidBySponsorUnderPromissoryNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued expenses paid by sponsor under promissory note.", "label": "Accrued Expenses Paid By Sponsor Under Promissory Note", "terseLabel": "Deferred offering costs paid by Sponsor under the promissory note" } } }, "localname": "AccruedExpensesPaidBySponsorUnderPromissoryNote", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "esac_AccruedOfferingCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of offering costs accrued but not yet paid as of the period date.", "label": "Accrued Offering Costs", "verboseLabel": "Accrued Offering Costs And Expenses" } } }, "localname": "AccruedOfferingCosts", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "xbrltype": "monetaryItemType" }, "esac_AdditionalAmountOwedToRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional amount owed to related party [Member]", "terseLabel": "Additional amount owed to related party [Member]" } } }, "localname": "AdditionalAmountOwedToRelatedPartyMember", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "xbrltype": "domainItemType" }, "esac_AggregateNumberOfSharesOwned": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares owned by the founders after the impact of the stock dividend.", "label": "Aggregate Number Of Shares Owned", "terseLabel": "Aggregate number of shares owned" } } }, "localname": "AggregateNumberOfSharesOwned", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquityParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfOperationsParenthetical", "http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "sharesItemType" }, "esac_AggregateOfSponsorSharesSurrendered": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of common stock shares subject aggregate of sponsor surrendered.", "label": "Aggregate Of Sponsor Shares Surrendered", "terseLabel": "Number of shares surrender" } } }, "localname": "AggregateOfSponsorSharesSurrendered", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquityParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfOperationsParenthetical", "http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "sharesItemType" }, "esac_AggregatePercentageOfOutstandingSharesIssuedToInitialShareholdersPriorToBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Aggregate Percentage of Outstanding Shares Issued to Initial Shareholders Prior to Business Combination.", "label": "Aggregate Percentage of Outstanding Shares Issued to Initial Shareholders Prior to Business Combination" } } }, "localname": "AggregatePercentageOfOutstandingSharesIssuedToInitialShareholdersPriorToBusinessCombination", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails" ], "xbrltype": "percentItemType" }, "esac_AllocatedToWarrantsAndExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents allocated to the warrants and expense.", "label": "Allocated To The Warrants And Expense", "terseLabel": "Allocated to the warrants and expense" } } }, "localname": "AllocatedToWarrantsAndExpense", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "esac_AssetsHeldInTrustAccountPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of accounting policy for assets held in trust.", "label": "Assets Held In Trust Account, Policy [Policy Text Block]", "terseLabel": "Marketable Securities Held in Trust Account" } } }, "localname": "AssetsHeldInTrustAccountPolicyPolicyTextBlock", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "esac_ChangeInValuationOfClassAOdinarySharesSubjectToPossibleRedemption": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in valuation of class a odinary shares subject to possible redemption.", "label": "Change In Valuation Of Class A Odinary Shares Subject To Possible Redemption", "terseLabel": "Change in value of Class\u00a0A ordinary shares subject to possible redemption" } } }, "localname": "ChangeInValuationOfClassAOdinarySharesSubjectToPossibleRedemption", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "esac_ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of Warrant or Right, Adjustment of Exercise Price of Warrants or Rights, Percent, Based On Market Value", "label": "Class Of Warrant Or Right Adjustment Of Exercise Price Of Warrants Or Rights Percent Based On Market Value", "terseLabel": "Adjustment of exercise price of warrants based on market value (as a percent)" } } }, "localname": "ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValue", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "esac_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of adjustment of redemption price of stock based on market value.", "label": "Class Of Warrant Or Right Adjustment Of Redemption Price Of Warrants Or Rights Percent Based On Market Value" } } }, "localname": "ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValue", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "esac_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of adjustment of redemption price of stock based on market value and newly issued price.", "label": "Class of Warrant or Right, Adjustment of Redemption Price of Warrants or Rights, Percent, Based On Market Value And Newly Issued Price 1", "terseLabel": "Adjustment one of redemption price of stock based on market value and newly issued price (as a percent)" } } }, "localname": "ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails" ], "xbrltype": "percentItemType" }, "esac_ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum threshold period during which a written notice is required for redemption of warrants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Class Of Warrant Or Right, Minimum Threshold Written Notice Period For Redemption Of Warrants", "terseLabel": "Minimum threshold written notice period for redemption of public warrants" } } }, "localname": "ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrants", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "esac_ClassOfWarrantOrRightPriceOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Price of Warrants or Rights", "terseLabel": "Price of warrant", "verboseLabel": "Price of warrants" } } }, "localname": "ClassOfWarrantOrRightPriceOfWarrantsOrRights", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/PrivatePlacementDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "esac_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of the entity's common stock which would be required to be attained to trigger the redemption of warrants.", "label": "Class Of Warrant Or Right Redemption Of Warrants Or Rights Reference Price", "terseLabel": "Stock price trigger for redemption of public warrants" } } }, "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "perShareItemType" }, "esac_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days for stock price trigger considered for redemption of warrants.", "label": "Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Trading Days", "terseLabel": "Threshold trading days for redemption of public warrants" } } }, "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "esac_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redemption price per share or per unit of warrants or rights outstanding.", "label": "Class Of Warrant Or Right, Redemption Price Of Warrants Or Rights", "terseLabel": "Redemption price per public warrant (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "perShareItemType" }, "esac_CommonStockSubjectToPossibleRedemptionPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the accounting policy on common stock subject to possible redemption.", "label": "Common Stock Subject to Possible Redemption [Policy Text Block]", "terseLabel": "Class A Ordinary Shares Subject to Possible Redemption" } } }, "localname": "CommonStockSubjectToPossibleRedemptionPolicyTextBlock", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "esac_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The threshold net tangible assets which the reporting entity must maintain in order to proceed with a business combination utilizing the proceeds of the offering.", "label": "Condition for future business combination threshold Net Tangible Assets" } } }, "localname": "ConditionForFutureBusinessCombinationThresholdNetTangibleAssets", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "xbrltype": "monetaryItemType" }, "esac_ConditionForFutureBusinessCombinationThresholdPercentageOwnership": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The threshold percentage of voting interest to be acquired in a future business combination as specified for the use of proceeds from the offering.", "label": "Condition for future business combination threshold Percentage Ownership" } } }, "localname": "ConditionForFutureBusinessCombinationThresholdPercentageOwnership", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "xbrltype": "pureItemType" }, "esac_ConvertibleStockConversionRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The ratio to be applied to the stock in a conversion of convertible stock.", "label": "ConvertibleStockConversionRatio", "terseLabel": "Ratio to be applied to the stock in the conversion" } } }, "localname": "ConvertibleStockConversionRatio", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails" ], "xbrltype": "pureItemType" }, "esac_DeferredOfferingCostsNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.", "label": "Deferred Offering Cost Non-Current" } } }, "localname": "DeferredOfferingCostsNoncurrent", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "xbrltype": "monetaryItemType" }, "esac_DeferredOfferingCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred offering costs paid by sponsor in exchange for issuance of ordinary shares.", "label": "Deferred Offering Costs Paid By Sponsor In Exchange For Issuance Of Ordinary Shares", "terseLabel": "Deferred offering costs paid by Sponsor in exchange for issuance of Class\u00a0B ordinary shares" } } }, "localname": "DeferredOfferingCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "esac_DeferredUnderwriterSDiscountNoncurrent": { "auth_ref": [], "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of balance sheet date of deferred underwriting discount, classified as noncurrent.", "label": "Deferred Underwriter's Discount, Noncurrent", "terseLabel": "Deferred underwriters' discount" } } }, "localname": "DeferredUnderwriterSDiscountNoncurrent", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "esac_DeferredUnderwritingDiscount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents deferred underwriting discount .", "label": "Deferred Underwriting Discount" } } }, "localname": "DeferredUnderwritingDiscount", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "xbrltype": "percentItemType" }, "esac_DerivativeFinancialInstrumentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of Derivative Financial Instruments", "label": "Derivative Financial Instruments [Policy Text Block]", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativeFinancialInstrumentsPolicyTextBlock", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "esac_EmergingGrowthCompanyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the accounting policy on Emerging Growth Company.", "label": "Emerging Growth Company [Policy Text Block]", "terseLabel": "Emerging Growth Company Status" } } }, "localname": "EmergingGrowthCompanyPolicyTextBlock", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "esac_FairMarketValuePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of Fair Market Value", "label": "Fair Market Value Price" } } }, "localname": "FairMarketValuePrice", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "perShareItemType" }, "esac_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3ToLevel2": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 to level 2.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 to Level 2", "terseLabel": "Transfer to Level 2" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3ToLevel2", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsChangesInTheFairValueDetails" ], "xbrltype": "monetaryItemType" }, "esac_FormationCostsPaidBySponsor": { "auth_ref": [], "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of formation costs paid by sponsor.", "label": "Formation Costs Paid By Sponsor", "verboseLabel": "Formation costs paid by Sponsor" } } }, "localname": "FormationCostsPaidBySponsor", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "esac_FounderSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The member represents founder shares.", "label": "Founder Shares [Member]" } } }, "localname": "FounderSharesMember", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquityParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfOperationsParenthetical", "http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "domainItemType" }, "esac_InitialPublicOfferingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Public Offering" } } }, "localname": "InitialPublicOfferingAbstract", "nsuri": "http://www.esgen-spac.com/20220930", "xbrltype": "stringItemType" }, "esac_InitialPublicOfferingTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure on information about initial public offering.", "label": "Initial Public Offering [Text Block]", "terseLabel": "Public Offering" } } }, "localname": "InitialPublicOfferingTextBlock", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/PublicOffering" ], "xbrltype": "textBlockItemType" }, "esac_LegalAndProfessionalFees": { "auth_ref": [], "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Legal and professional fees.", "label": "Legal And Professional Fees", "terseLabel": "Legal and professional fees" } } }, "localname": "LegalAndProfessionalFees", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "esac_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of maximum borrowing capacity of related party promissory note.", "label": "Maximum Borrowing Capacity of Related Party Promissory Note", "terseLabel": "Maximum borrowing capacity of related party promissory note" } } }, "localname": "MaximumBorrowingCapacityOfRelatedPartyPromissoryNote", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "esac_MaximumCommonStockSharesSubjectToForfeiture": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the maximum number of common stock shares subject to forfeiture.", "label": "Maximum Common Stock Shares Subject To Forfeiture", "terseLabel": "Maximum shares subject to forfeiture" } } }, "localname": "MaximumCommonStockSharesSubjectToForfeiture", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails" ], "xbrltype": "sharesItemType" }, "esac_MaximumLoansConvertibleIntoWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The maximum amount which a potential loan could have repaid through issuance of warrants.", "label": "maximum Loans Convertible Into Warrants", "terseLabel": "Loan conversion agreement warrant" } } }, "localname": "MaximumLoansConvertibleIntoWarrants", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "esac_MaximumNumberOfDemandsForRegistrationOfSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the maximum number of demands for registration of securities.", "label": "Maximum Number Of Demands For Registration Of Securities", "terseLabel": "Maximum number of demands for registration of securities" } } }, "localname": "MaximumNumberOfDemandsForRegistrationOfSecurities", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "xbrltype": "integerItemType" }, "esac_MonthToCompleteAcquisition": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This elements represents months to complete acquisition.", "label": "Month To Complete Acquisition" } } }, "localname": "MonthToCompleteAcquisition", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "esac_NetTangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This elements represents net tangible assets.", "label": "Net Tangible Assets", "terseLabel": "Net tangible assets" } } }, "localname": "NetTangibleAssets", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "xbrltype": "monetaryItemType" }, "esac_NumberOfSharesIssuedPerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of shares in a unit.", "label": "Number of Shares Issued Per Unit", "terseLabel": "Number of shares in a unit" } } }, "localname": "NumberOfSharesIssuedPerUnit", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/PublicOfferingDetails" ], "xbrltype": "sharesItemType" }, "esac_NumberOfWarrantsIssuedPerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of warrants in a unit.", "label": "Number of Warrants Issued Per Unit", "terseLabel": "Number of warrants in a unit" } } }, "localname": "NumberOfWarrantsIssuedPerUnit", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/PublicOfferingDetails" ], "xbrltype": "sharesItemType" }, "esac_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of offering costs associated with the initial public offering.", "label": "Offering Costs Associated With The Initial Public Offering [Policy Text Block]", "terseLabel": "Offering Costs Associated with Initial Public Offering" } } }, "localname": "OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "esac_OfferingCostsIncludedInAccountsPayableAccruedExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Offering costs included in accounts payable accrued expenses.", "label": "Offering Costs Included In Accounts Payable Accrued Expenses", "terseLabel": "Deferred offering costs included in accrued offerings costs" } } }, "localname": "OfferingCostsIncludedInAccountsPayableAccruedExpenses", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "esac_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of shares which the reporting entity is obligated to redeem if a business combination is not consummated using the offering proceeds within a specified period.", "label": "Percentage Obligation To Redeem Public Shares If Entity Does Not Complete A Business Combination", "terseLabel": "Obligation to redeem Public Shares if entity does not complete a Business Combination (as a percent)" } } }, "localname": "PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "esac_PercentageOfBusinessCombinationsAggregateFairMarketValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This elements represents percentage of business combinations aggregate fair market value.", "label": "Percentage Of Business Combinations Aggregate Fair Market Value", "terseLabel": "Percentage of business combinations aggregate fair market value" } } }, "localname": "PercentageOfBusinessCombinationsAggregateFairMarketValue", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "xbrltype": "percentItemType" }, "esac_PercentageOfGrossProceedsOnTotalEquityProceeds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of gross proceeds on total equity proceeds.", "label": "Percentage Of Gross Proceeds On Total Equity Proceeds" } } }, "localname": "PercentageOfGrossProceedsOnTotalEquityProceeds", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "esac_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The expected ownership percentage by the founders after completion of the proposed public offering.", "label": "Percentage Of Issued And Outstanding Shares After The Initial Public Offering Collectively Held By Initial Stockholders", "terseLabel": "Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders" } } }, "localname": "PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "percentItemType" }, "esac_PrepaidExpensesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents prepaid expenses text block.", "label": "Prepaid Expenses [Text Block]", "terseLabel": "Prepaid Expenses" } } }, "localname": "PrepaidExpensesTextBlock", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/PrepaidExpenses" ], "xbrltype": "textBlockItemType" }, "esac_PrepaidInsuranceNoncurrent": { "auth_ref": [], "calculation": { "http://www.esgen-spac.com/role/PrepaidExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits.", "label": "Prepaid Insurance, Noncurrent", "terseLabel": "Prepaid Insurance, Non Current" } } }, "localname": "PrepaidInsuranceNoncurrent", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/PrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "esac_PrivatePlacementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Private Placement." } } }, "localname": "PrivatePlacementAbstract", "nsuri": "http://www.esgen-spac.com/20220930", "xbrltype": "stringItemType" }, "esac_PrivatePlacementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure on information about private placement.", "label": "Private Placement [Text Block]", "terseLabel": "Private Placement" } } }, "localname": "PrivatePlacementTextBlock", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/PrivatePlacement" ], "xbrltype": "textBlockItemType" }, "esac_PrivatePlacementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents a redeemable warrant (Private Placement Warrant) that entitles the holder to purchase shares of common stock if the underwriter's option is exercised in full.", "label": "Private Placement Warrants", "terseLabel": "Private Placement Warrants", "verboseLabel": "Private Warrants" } } }, "localname": "PrivatePlacementWarrantsMember", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/PrivatePlacementDetails", "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsChangesInTheFairValueDetails", "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "esac_PrivateWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to private warrants.", "label": "Private Warrants", "terseLabel": "Private Warrants" } } }, "localname": "PrivateWarrantsMember", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "esac_ProceedsFromIssuanceOfTemporaryEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash inflow from issuance of temporary equity.", "label": "Proceeds from Issuance of Temporary Equity", "terseLabel": "Gross proceeds" } } }, "localname": "ProceedsFromIssuanceOfTemporaryEquity", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/PublicOfferingSummaryOfOrdinarySharesReflectedOnBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "esac_ProceedsFromSaleOfUnits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents Proceeds From Sale Of Units.", "label": "Proceeds From Sale Of Units", "terseLabel": "Gross proceeds" } } }, "localname": "ProceedsFromSaleOfUnits", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/PublicOfferingDetails" ], "xbrltype": "monetaryItemType" }, "esac_PromissoryNoteWithRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for promissory note with related party.", "label": "Promissory Note with Related Party" } } }, "localname": "PromissoryNoteWithRelatedPartyMember", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "esac_PublicWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents a redeemable warrant (Public Warrant) that entitles the holder to purchase shares of common stock subject to adjustment.", "label": "Public Warrants", "terseLabel": "Public Warrants" } } }, "localname": "PublicWarrantsMember", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/PublicOfferingDetails", "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsChangesInTheFairValueDetails", "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "esac_RedemptionOfSharesCalculatedBasedOnNumberOfBusinessDaysPriorToConsummationOfBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the redemption of shares calculated based on number of business days prior to consummation of business combination.", "label": "Redemption of Shares Calculated Based On Number Of Business Days Prior To Consummation Of Business Combination", "terseLabel": "Redemption of shares calculated based on business days prior to consummation of business combination" } } }, "localname": "RedemptionOfSharesCalculatedBasedOnNumberOfBusinessDaysPriorToConsummationOfBusinessCombination", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "xbrltype": "durationItemType" }, "esac_RedemptionOfWarrantPricePerShareEqualsOrExceeds10.00Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Redemption Of Warrant Price Per Share Equals Or Exceeds10.00.", "label": "Redemption Of Warrant Price Per Share Equals Or Exceeds10.00 [Member]", "terseLabel": "Redemption Of Warrant Price Per Share Equals Or Exceeds10.00 [Member]" } } }, "localname": "RedemptionOfWarrantPricePerShareEqualsOrExceeds10.00Member", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "esac_RedemptionOfWarrantPricePerShareEqualsOrExceeds18.00Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Redemption Of Warrant Price Per Share Equals Or Exceeds18.00.", "label": "Redemption Of Warrant Price Per Share Equals Or Exceeds18.00 [Member]", "terseLabel": "Redemption Of Warrant Price Per Share Equals Or Exceeds18.00 [Member]" } } }, "localname": "RedemptionOfWarrantPricePerShareEqualsOrExceeds18.00Member", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "esac_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of time after completion of a business combination during which the shares or warrant may not be transferred.", "label": "Restrictions On Transfer Period Of Time After Business Combination Completion", "terseLabel": "Restrictions on transfer period of time after business combination completion" } } }, "localname": "RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "durationItemType" }, "esac_SaleOfStockConsiderationReceivedOnTransactionShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of stock consideration received on transaction shares.", "label": "Sale Of Stock Consideration Received On Transaction Shares", "terseLabel": "Consideration received, shares" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransactionShares", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquityParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfOperationsParenthetical", "http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "sharesItemType" }, "esac_SaleOfStockOtherOfferingCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of other offering costs incurred.", "label": "Sale of Stock, Other Offering Costs", "terseLabel": "Other offering costs", "verboseLabel": "Offering Cost" } } }, "localname": "SaleOfStockOtherOfferingCosts", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "esac_SaleOfStockUnderwritingFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of offering fees incurred and paid for underwriters.", "label": "Sale of Stock, Underwriting fees", "terseLabel": "Underwriting fees" } } }, "localname": "SaleOfStockUnderwritingFees", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "xbrltype": "monetaryItemType" }, "esac_ScheduleOfPrepaidExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of Prepaid Expenses. This disclosure includes other current and other noncurrent expenses.", "label": "Summary of Prepaid expenses" } } }, "localname": "ScheduleOfPrepaidExpensesTableTextBlock", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/PrepaidExpensesTables" ], "xbrltype": "textBlockItemType" }, "esac_ShareholdersDeficit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents for Shareholder's deficit.", "label": "Shareholders Deficit", "terseLabel": "Shareholders deficit" } } }, "localname": "ShareholdersDeficit", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "esac_SponsorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for sponsor.", "label": "Sponsor", "terseLabel": "Sponsor" } } }, "localname": "SponsorMember", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquityParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfOperationsParenthetical", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/PrivatePlacementDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "domainItemType" }, "esac_TemporaryEquityIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of issuance costs related to temporary equity.", "label": "Temporary Equity, Issuance Costs", "terseLabel": "Class A ordinary share issuance costs" } } }, "localname": "TemporaryEquityIssuanceCosts", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/PublicOfferingSummaryOfOrdinarySharesReflectedOnBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "esac_TemporaryEquityProceedsAllocatedToWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of gross proceeds allocated from temporary equity to warrants.", "label": "Temporary Equity , Proceeds Allocated To Warrants", "terseLabel": "Proceeds allocated to Public Warrants" } } }, "localname": "TemporaryEquityProceedsAllocatedToWarrants", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/PublicOfferingSummaryOfOrdinarySharesReflectedOnBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "esac_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of time after a business combination which must elapse before consideration of the share price condition for transfer of shares.", "label": "Threshold Period After Business Combination In Which Specified Trading Days Within Any Specified Trading Day Period Commences", "terseLabel": "Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences" } } }, "localname": "ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "xbrltype": "durationItemType" }, "esac_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of time which must elapse after completion of a business combination before the Sponsor can transfer, assign or sell any Founder Shares unless other specified conditions are met.", "label": "Threshold Period For Not To Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination", "terseLabel": "Threshold period for not to transfer, assign or sell any of their shares or warrants after the completion of the initial business combination" } } }, "localname": "ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "esac_ThresholdPeriodForRegistrationStatementToBeEffectiveAfterWhichWarrantsCanBeExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period for registration statement to be effective after which warrants can be exercised on a cashless basis.", "label": "Threshold Period For Registration Statement To Be Effective After Which Warrants Can Be Exercised" } } }, "localname": "ThresholdPeriodForRegistrationStatementToBeEffectiveAfterWhichWarrantsCanBeExercised", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "esac_TradingDayPriorToDateOnWhichNoticeOfExercise": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Trading Day Prior To The Date On Which The Notice Of Exercise", "label": "Trading Day Prior To The Date On Which The Notice Of Exercise" } } }, "localname": "TradingDayPriorToDateOnWhichNoticeOfExercise", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "esac_TransactionCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of transaction costs incurred.", "label": "Transaction Costs", "terseLabel": "Transaction Costs" } } }, "localname": "TransactionCosts", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "xbrltype": "monetaryItemType" }, "esac_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The share price threshold that must be achieved in order to waive the restriction on transfer of shares during a restricted period after a business combination.", "label": "Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Stock Price Trigger", "terseLabel": "Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)" } } }, "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "xbrltype": "perShareItemType" }, "esac_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "When determining the condition for transfer of shares without restriction after a business combination, the number of consecutive trading days used to observe the share price.", "label": "Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Consecutive Trading Days", "terseLabel": "Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination" } } }, "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "xbrltype": "integerItemType" }, "esac_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "When determining the condition for transfer of shares without restriction after a business combination, the number of days in which the share price must exceed the specified amount.", "label": "Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Trading Days", "terseLabel": "Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination" } } }, "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "integerItemType" }, "esac_UnderwriterCashDiscount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the cash underwriting discount per unit.", "label": "Underwriter cash discount" } } }, "localname": "UnderwriterCashDiscount", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "esac_UnderwritingDiscountEarnedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents underwriting discount percentage.", "label": "Underwriting Discount Earned Percentage" } } }, "localname": "UnderwritingDiscountEarnedPercentage", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "xbrltype": "percentItemType" }, "esac_UnitsEachConsistingOfOneShareOfClassCommonStockAndOneHalfOfOneWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Units Each Consisting Of One Share Of Class Common Stock And One Half Of One Warrant .", "label": "Units Each Consisting Of One Share Of Class Common Stock And One Half Of One Warrant [Member]", "terseLabel": "Units, each consisting of one share of Class A Common Stock and one-half of one Warrant" } } }, "localname": "UnitsEachConsistingOfOneShareOfClassCommonStockAndOneHalfOfOneWarrantMember", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "esac_UnitsIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new units issued during the period.", "label": "Units Issued During Period, Shares, New Issues", "terseLabel": "Sale of Units, net of underwriting discounts (in shares)", "verboseLabel": "Number of units sold" } } }, "localname": "UnitsIssuedDuringPeriodSharesNewIssues", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/PublicOfferingDetails" ], "xbrltype": "sharesItemType" }, "esac_WarrantLiabilitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Warrant Liabilities" } } }, "localname": "WarrantLiabilitiesDisclosureAbstract", "nsuri": "http://www.esgen-spac.com/20220930", "xbrltype": "stringItemType" }, "esac_WarrantLiabilitiesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for Warrant Liabilities", "label": "Warrant Liabilities Disclosure [Text Block]", "terseLabel": "Warrant Liabilities" } } }, "localname": "WarrantLiabilitiesDisclosureTextBlock", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilities" ], "xbrltype": "textBlockItemType" }, "esac_WarrantLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of Warrant Liabilities as on the balance sheet date.", "label": "Warrant Liabilities, Fair Value Disclosure", "terseLabel": "Total warrant liabilities" } } }, "localname": "WarrantLiabilitiesFairValueDisclosure", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "esac_WarrantLiabilitiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of warrant liabilities", "label": "Warrant Liabilities [Policy Text Block]", "terseLabel": "Warrant Liability" } } }, "localname": "WarrantLiabilitiesPolicyTextBlock", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "esac_Warrantliabilities": { "auth_ref": [], "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "no definition available", "label": "WarrantLiabilities", "terseLabel": "Warrant Liabilities" } } }, "localname": "Warrantliabilities", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "esac_WarrantsAndRightsOutstandingExercisableTermAfterBusinessCombinations": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Warrants And Rights Outstanding Exercisable Term After Business Combination.", "label": "Warrants And Rights Outstanding Exercisable Term After Business Combinations" } } }, "localname": "WarrantsAndRightsOutstandingExercisableTermAfterBusinessCombinations", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "xbrltype": "durationItemType" }, "esac_WarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants Each Whole Warrant Exercisable For One Share Of Class Common Stock At Exercise Price.", "label": "Warrants Each Whole Warrant Exercisable For One Share Of Class Common Stock At Exercise Price [Member]" } } }, "localname": "WarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceMember", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "esac_WorkingCapitalLoan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of working capital loans.", "label": "Working Capital Loan", "terseLabel": "Working Capital Loan" } } }, "localname": "WorkingCapitalLoan", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "esac_WorkingCapitalLoansWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Working capital loans warrant.", "label": "Working capital loans warrant" } } }, "localname": "WorkingCapitalLoansWarrantMember", "nsuri": "http://www.esgen-spac.com/20220930", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r23" ], "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r14", "r232" ], "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r56", "r57", "r58", "r174", "r175", "r176", "r193" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Anti-dilutive securities attributable to warrants (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r10", "r53", "r98", "r100", "r104", "r107", "r116", "r117", "r118", "r120", "r121", "r122", "r123", "r124", "r125", "r127", "r128", "r188", "r190", "r210", "r230", "r232", "r249", "r253" ], "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r20", "r53", "r107", "r116", "r117", "r118", "r120", "r121", "r122", "r123", "r124", "r125", "r127", "r128", "r188", "r190", "r210", "r230", "r232" ], "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldInTrust": { "auth_ref": [ "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.", "label": "Assets Held-in-trust", "terseLabel": "Cash held outside of the Trust Account" } } }, "localname": "AssetsHeldInTrust", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsHeldInTrustNoncurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.", "label": "Assets Held-in-trust, Noncurrent", "terseLabel": "Marketable securities held in trust account", "verboseLabel": "Marketable securities held in Trust Account" } } }, "localname": "AssetsHeldInTrustNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets", "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r8", "r47" ], "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r42", "r47", "r49" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, end of the period", "periodStartLabel": "Cash, beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r42", "r211" ], "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r11", "r12", "r13", "r51", "r53", "r72", "r73", "r74", "r77", "r79", "r85", "r86", "r87", "r107", "r116", "r121", "r122", "r123", "r127", "r128", "r138", "r139", "r143", "r147", "r154", "r210", "r270" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/CondensedBalanceSheets", "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquity", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquityParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "http://www.esgen-spac.com/role/CondensedStatementsOfOperationsParenthetical", "http://www.esgen-spac.com/role/CoverPage", "http://www.esgen-spac.com/role/PrivatePlacementDetails", "http://www.esgen-spac.com/role/PublicOfferingDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails", "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r162", "r173" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/PrivatePlacementDetails", "http://www.esgen-spac.com/role/PublicOfferingDetails", "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsChangesInTheFairValueDetails", "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/PrivatePlacementDetails", "http://www.esgen-spac.com/role/PublicOfferingDetails", "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsChangesInTheFairValueDetails", "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrants", "verboseLabel": "Exercise price of warrant" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/PrivatePlacementDetails", "http://www.esgen-spac.com/role/PublicOfferingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of shares issuable per warrant", "verboseLabel": "Number of shares per warrant" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/PrivatePlacementDetails", "http://www.esgen-spac.com/role/PublicOfferingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Sale of Private Placement Warrants (in shares)", "verboseLabel": "Number of warrants to purchase shares issued" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/PrivatePlacementDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r112", "r113", "r114", "r115", "r264" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments & Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Class A Common Stock" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/CondensedBalanceSheets", "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquity", "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "http://www.esgen-spac.com/role/CoverPage", "http://www.esgen-spac.com/role/PrivatePlacementDetails", "http://www.esgen-spac.com/role/PublicOfferingDetails", "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "terseLabel": "Class B Common Stock" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets", "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquity", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquityParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "http://www.esgen-spac.com/role/CondensedStatementsOfOperationsParenthetical", "http://www.esgen-spac.com/role/CoverPage", "http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails", "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockDividendsShares": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits.", "label": "Common Stock Dividends, Shares", "terseLabel": "Share dividend" } } }, "localname": "CommonStockDividendsShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquityParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfOperationsParenthetical", "http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r56", "r57", "r193" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common shares, par value, (per share)", "verboseLabel": "Common shares, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common shares, shares authorized", "verboseLabel": "Common shares, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common shares, shares issued", "verboseLabel": "Common shares, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r13", "r154" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common shares, shares outstanding", "verboseLabel": "Common shares, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquityParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfOperationsParenthetical", "http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails", "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r13", "r232" ], "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesRelatedParty": { "auth_ref": [ "r35" ], "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties.", "label": "Costs and Expenses, Related Party", "terseLabel": "Operating cost\u2014related party" } } }, "localname": "CostsAndExpensesRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r129", "r131", "r132", "r218", "r219", "r220" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Borrowed amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentDetailAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instrument Detail [Abstract]", "terseLabel": "Recurring Fair Value Measurements" } } }, "localname": "DerivativeInstrumentDetailAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilityMeasurementInput": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure derivative liability.", "label": "Derivative Liability, Measurement Input", "terseLabel": "Derivative liability, Measurement input" } } }, "localname": "DerivativeLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsCompanysLevel3LiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_DerivativesAndFairValueTextBlock": { "auth_ref": [ "r196", "r208" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities.", "label": "Derivatives and Fair Value [Text Block]", "terseLabel": "Recurring Fair Value Measurements" } } }, "localname": "DerivativesAndFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_DueToOtherRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r22", "r54", "r225" ], "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount payable to related parties classified as other, due within one year or the normal operating cycle, if longer.", "label": "Due to Other Related Parties, Current", "terseLabel": "Due to related party" } } }, "localname": "DueToOtherRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r22", "r54", "r119", "r121", "r122", "r126", "r127", "r128", "r225" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Due to related party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r34", "r61", "r62", "r63", "r64", "r65", "r69", "r72", "r77", "r78", "r79", "r82", "r83", "r194", "r195", "r252", "r258" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net income per share", "verboseLabel": "Basic net income (loss) per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r34", "r61", "r62", "r63", "r64", "r65", "r72", "r77", "r78", "r79", "r82", "r83", "r194", "r195", "r252", "r258" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net income per share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r80", "r81" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income (Loss) Per Ordinary Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r30", "r31", "r32", "r56", "r57", "r58", "r60", "r66", "r68", "r84", "r108", "r154", "r161", "r174", "r175", "r176", "r186", "r187", "r193", "r212", "r213", "r214", "r215", "r216", "r217", "r221", "r259", "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquity", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r45", "r133" ], "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.esgen-spac.com/role/CondensedStatementsOfOperations": { "order": 9.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of warrant liabilities", "terseLabel": "Change in fair value of warrant liabilities" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows", "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r197", "r198", "r205" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsCompanysLevel3LiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsCompanysLevel3LiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of quantitative information regarding Level 3 fair value measurements inputs" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r130", "r131", "r132", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r172", "r198", "r233", "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r197", "r198", "r200", "r201", "r206" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r130", "r164", "r165", "r170", "r172", "r198", "r233" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r130", "r131", "r132", "r164", "r165", "r170", "r172", "r198", "r234" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r130", "r131", "r132", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r172", "r198", "r235" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r197", "r198" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of fair value hierarchy for liabilities measured at fair value on recurring basis" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsChangesInTheFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsChangesInTheFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r202", "r205" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsChangesInTheFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r202", "r205" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of change in the fair value of the warrant liabilities" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r203" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value of warrant liabilities" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsChangesInTheFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net", "terseLabel": "Transfer to Level 1" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsChangesInTheFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r202" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Warrant liabilities at end of the period", "periodStartLabel": "Warrant liability - initial measurement" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsChangesInTheFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r130", "r131", "r132", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r172", "r233", "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r204", "r206" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r207", "r209" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralInsuranceExpense": { "auth_ref": [ "r37" ], "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).", "label": "General Insurance Expense", "terseLabel": "Insurance" } } }, "localname": "GeneralInsuranceExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "Initial Public Offering" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/PublicOfferingDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "verboseLabel": "STATEMENT OF OPERATIONS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r29", "r178", "r179", "r182", "r183", "r184", "r185" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r44" ], "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Due to Related Parties, Current", "terseLabel": "Due to related party" } } }, "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r44" ], "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquity" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r38", "r97" ], "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.esgen-spac.com/role/CondensedStatementsOfOperations": { "order": 8.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "negatedLabel": "Interest earned on cash held in Trust Account", "terseLabel": "Interest income on marketable securities held in Trust Account" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows", "http://www.esgen-spac.com/role/CondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r24", "r53", "r101", "r107", "r116", "r117", "r118", "r121", "r122", "r123", "r124", "r125", "r127", "r128", "r189", "r190", "r191", "r210", "r230", "r231" ], "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r18", "r53", "r107", "r210", "r232", "r250", "r255" ], "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities, Redeemable Ordinary Shares and Shareholders' Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities, Redeemable Ordinary Shares and Shareholders' Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r6", "r25", "r53", "r107", "r116", "r117", "r118", "r121", "r122", "r123", "r124", "r125", "r127", "r128", "r189", "r190", "r191", "r210", "r230", "r231", "r232" ], "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price [Member]", "terseLabel": "Exercise price" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsCompanysLevel3LiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Term (years)" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsCompanysLevel3LiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Expected volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsCompanysLevel3LiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk-free rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsCompanysLevel3LiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]", "terseLabel": "Share price" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsCompanysLevel3LiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsCompanysLevel3LiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsCompanysLevel3LiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r88", "r96" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Organization and Business Operation" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperation" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r42", "r43", "r46" ], "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r27", "r28", "r32", "r33", "r46", "r53", "r59", "r61", "r62", "r63", "r64", "r67", "r68", "r75", "r98", "r99", "r102", "r103", "r105", "r107", "r116", "r117", "r118", "r121", "r122", "r123", "r124", "r125", "r127", "r128", "r195", "r210", "r251", "r257" ], "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.esgen-spac.com/role/CondensedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_TemporaryEquityNetIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquity", "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r61", "r62", "r63", "r64", "r69", "r70", "r76", "r79", "r98", "r99", "r102", "r103", "r105" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "verboseLabel": "Allocation of income (loss)" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r39" ], "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesAndLoansPayableCurrent": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer.", "label": "Notes and Loans Payable, Current", "terseLabel": "Outstanding amount" } } }, "localname": "NotesAndLoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r21", "r54", "r226" ], "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Notes Payable, Related Parties, Current", "terseLabel": "Promissory note - related party" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r54", "r225", "r256" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties.", "label": "Notes Payable, Related Parties", "terseLabel": "Outstanding balance of related party note" } } }, "localname": "NotesPayableRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingCostsAndExpenses": { "auth_ref": [], "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.", "label": "Operating Costs and Expenses", "terseLabel": "Formation and operating costs" } } }, "localname": "OperatingCostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r98", "r99", "r102", "r103", "r105" ], "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherCostAndExpenseOperating": { "auth_ref": [ "r36" ], "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.", "label": "Other Cost and Expense, Operating", "terseLabel": "Other operating costs" } } }, "localname": "OtherCostAndExpenseOperating", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r19", "r111" ], "calculation": { "http://www.esgen-spac.com/role/PrepaidExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "terseLabel": "Other Prepaid Items, Current" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/PrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/PrivatePlacementDetails", "http://www.esgen-spac.com/role/PublicOfferingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r12", "r138" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value, (per share)", "verboseLabel": "Preferred stock, par value, (per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/ShareholdersEquityPreferredStockSharesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "verboseLabel": "Preferred shares, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/ShareholdersEquityPreferredStockSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r12", "r138" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "verboseLabel": "Preferred shares, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/ShareholdersEquityPreferredStockSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "verboseLabel": "Preferred shares, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/ShareholdersEquityPreferredStockSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r12", "r232" ], "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred share, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r3", "r19", "r110", "r111" ], "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.esgen-spac.com/role/PrepaidExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses - current", "totalLabel": "Prepaid Expense, Current, Total" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets", "http://www.esgen-spac.com/role/PrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expense, Current [Abstract]" } } }, "localname": "PrepaidExpenseCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseNoncurrent": { "auth_ref": [ "r9" ], "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.esgen-spac.com/role/PrepaidExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.", "label": "Prepaid Expense, Noncurrent", "terseLabel": "Prepaid expense - noncurrent", "totalLabel": "Total Prepaid Expenses, Non Current" } } }, "localname": "PrepaidExpenseNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets", "http://www.esgen-spac.com/role/PrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r4", "r109", "r111" ], "calculation": { "http://www.esgen-spac.com/role/PrepaidExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid Insurance, Current" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/PrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/PrivatePlacementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r40" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r40" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "verboseLabel": "Aggregate purchase price" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/PrivatePlacementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r41" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from Related Party Debt" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r171", "r224", "r225" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquityParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfOperationsParenthetical", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/PrivatePlacementDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r171", "r224", "r225", "r227" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquityParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfOperationsParenthetical", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquityParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfOperationsParenthetical", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r224" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "verboseLabel": "Expenses incurred and paid" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r171", "r224", "r227", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquityParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfOperationsParenthetical", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/PrivatePlacementDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r222", "r223", "r225", "r228", "r229" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r15", "r161", "r232", "r254", "r262", "r263" ], "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r56", "r57", "r58", "r60", "r66", "r68", "r108", "r174", "r175", "r176", "r186", "r187", "r193", "r259", "r261" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquity", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Consideration received", "verboseLabel": "Sale of Stock, Consideration Received on Transaction" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquityParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfOperationsParenthetical", "http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/PrivatePlacementDetails", "http://www.esgen-spac.com/role/PublicOfferingDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of compute basic and diluted net income per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r11", "r12", "r13", "r51", "r85", "r86", "r134", "r136", "r137", "r138", "r139", "r140", "r141", "r143", "r147", "r152", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance at the end (in shares)", "periodStartLabel": "Balance at the beginning (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquityParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfOperationsParenthetical", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/PublicOfferingDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r11", "r12", "r13", "r51", "r53", "r72", "r73", "r74", "r77", "r79", "r85", "r86", "r87", "r107", "r116", "r121", "r122", "r123", "r127", "r128", "r138", "r139", "r143", "r147", "r154", "r210", "r270" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/CondensedBalanceSheets", "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquity", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquityParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "http://www.esgen-spac.com/role/CondensedStatementsOfOperationsParenthetical", "http://www.esgen-spac.com/role/CoverPage", "http://www.esgen-spac.com/role/PrivatePlacementDetails", "http://www.esgen-spac.com/role/PublicOfferingDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails", "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r26", "r30", "r31", "r32", "r56", "r57", "r58", "r60", "r66", "r68", "r84", "r108", "r154", "r161", "r174", "r175", "r176", "r186", "r187", "r193", "r212", "r213", "r214", "r215", "r216", "r217", "r221", "r259", "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquity", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets", "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquity", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquityParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "http://www.esgen-spac.com/role/CondensedStatementsOfOperationsParenthetical", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r56", "r57", "r58", "r84", "r236" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets", "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquity", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquityParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "http://www.esgen-spac.com/role/CondensedStatementsOfOperationsParenthetical", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r12", "r13", "r154", "r161" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Number of shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r12", "r13", "r154", "r161" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Aggregate purchase price" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r13", "r16", "r17", "r53", "r106", "r107", "r210", "r232" ], "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "totalLabel": "Total shareholders' deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders' Deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r52", "r139", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r153", "r161", "r163", "r192" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholder's Equity (Deficit)" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/ShareholderSEquityDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/PrivatePlacementDetails", "http://www.esgen-spac.com/role/PublicOfferingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/PrivatePlacementDetails", "http://www.esgen-spac.com/role/PublicOfferingDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/PrivatePlacementDetails", "http://www.esgen-spac.com/role/PublicOfferingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of accretion of temporary equity to its redemption value during the period.", "label": "Temporary Equity, Accretion to Redemption Value", "terseLabel": "Accretion of carrying value to redemption value" } } }, "localname": "TemporaryEquityAccretionToRedemptionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/PublicOfferingSummaryOfOrdinarySharesReflectedOnBalanceSheetDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.", "label": "Temporary Equity, Accretion to Redemption Value, Adjustment", "negatedLabel": "Accretion of ordinary share subject to possible redemption" } } }, "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInShareholderSDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r116", "r121", "r122", "r123", "r127", "r128" ], "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "terseLabel": "Class A ordinary shares subject to possible redemption, 27,600,000 shares at redemption value of $10.20", "verboseLabel": "Class A ordinary shares subject to possible redemption" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets", "http://www.esgen-spac.com/role/PublicOfferingSummaryOfOrdinarySharesReflectedOnBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityNetIncome": { "auth_ref": [], "calculation": { "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of net income or loss attributable to temporary equity interest.", "label": "Temporary Equity, Net Income", "totalLabel": "Net income (loss) including accretion of temporary equity to redemption value" } } }, "localname": "TemporaryEquityNetIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "terseLabel": "Class A common stock subject to possible redemption, outstanding (in shares)" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquityTableTextBlock": { "auth_ref": [ "r7", "r135" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity [Table Text Block]", "terseLabel": "Summary of ordinary shares reflected on the balance sheet" } } }, "localname": "TemporaryEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/PublicOfferingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r177", "r181" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r180" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized tax benefits accrued for interest and penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r89", "r90", "r91", "r92", "r93", "r94", "r95" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Public Warrants expiration term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r71", "r79" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares outstanding, diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r69", "r79" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares outstanding, basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r114": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r163": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r196": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org/topic&trid=2229140" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r208": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "https://asc.fasb.org/topic&trid=2155941" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r229": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r265": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r266": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r267": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r268": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r269": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r270": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r271": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r272": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(b))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r55": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r96": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" } }, "version": "2.1" } ZIP 58 0001193125-22-282645-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-282645-xbrl.zip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end